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ABSTRACT 
Background 
South Africa has the largest HIV epidemic globally, with a prevalence among 
pregnant women estimated at 30.8% in 2015. Consequent to this high HIV 
prevalence rate, which has plateaued around 30% over the past decade, South 
Africa was identified as one of the priority countries for elimination of mother-to-child 
transmission of HIV (eMTCT) and decreasing HIV-related maternal deaths. The aim 
of this thesis was to evaluate the evolution of the Soweto PMTCT and antiretroviral 
therapy (ART) programme, in Johannesburg, one of the largest and oldest in the 
country with data spanning almost two decades. The evaluation is on the impact of 
the programme on MTCT rates and HIV-related maternal mortality, in a high HIV 
prevalence urban setting. 
 
Methods 
This thesis includes six studies that chronicle progress and challenges in eMTCT and 
decreasing HIV-related maternal mortality. The studies address three objectives: (i) 
to describe progress made in implementation of efficacious PMTCT interventions and 
ART coverage in HIV-infected pregnant women; (ii) to identify patient-related risk 
factors for MTCT; and (iii) to assess the impact of evolving HIV management 
guidelines and increased availability of ART on maternal mortality in HIV-infected 
women. Three studies address the first objective and include two secondary 
analyses of routinely collected PMTCT data, and a cross-sectional study to assess 
quality of care in the Soweto PMTCT programme. The second objective is addressed 
by two studies, one a case-control study and the other a cross-sectional survey, both 
identifying patient-related risk factors for MTCT. The third objective is addressed by a 
19-year record review assessing trends in maternal deaths in HIV-infected women. 
 
Results 
Findings from this thesis show how successful implementation of evolving PMTCT 
and ART guidelines, in a high HIV prevalence setting, have led to a significant 
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decrease in the MTCT rate to levels below 2% at early infant diagnosis. There is also 
a decrease in the maternal mortality ratio (MMR) among HIV-infected women, 
coinciding with the expansion of the South African ART programme. While reporting 
on these are public health successes, this thesis also identifies remaining challenges. 
Through evaluating aspects of the continuum of care along the PMTCT cascade in 
the studies that make up this thesis, three overarching themes emerge. These are 
delayed or lack of access to antenatal care, delayed HIV diagnosis and ART initiation 
among pregnant women, and suboptimal quality of care in PMTCT and ART 
programmes as reflected in the healthcare workers’ and patients’ knowledge of 
PMTCT interventions. 
 
Conclusion 
The findings have important implications for policy and practice. Challenges identified 
in accessing antenatal care, HIV diagnosis and ART initiation among pregnant 
women and quality of HIV care all intersect and increase the risk of MTCT and 
maternal mortality in HIV-infected women. These are both patient-related and health 
system-related. Targeted interventions are needed to build on the gains made. 
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THESIS OVERVIEW AND STRUCTURE  
 
This thesis was done through the route of thesis with publications and 
comprises of two parts: (i) an integrating narrative which provides the background, 
rationale, methodology and findings of the research and (ii) the research papers that 
form part of this PhD. The research is made up of six related studies, five which 
address various aspects of prevention of mother-to-child transmission of HIV 
(PMTCT) and one on HIV-related maternal mortality. The integrating narrative is 
divided into five chapters:  
 
Chapter one is the background and literature review and is divided into two sections. 
The first section is on the evolution of PMTCT and antiretroviral treatment (ART) 
guidelines in resource-constrained settings, including in South Africa. It will also 
discuss progress made towards elimination of mother-to-child transmission of HIV 
(eMTCT) and challenges that still exist within PMTCT programmes. The second 
section of the literature review is on global trends, and trends in South Africa, on 
maternal deaths. The literature review will focus on maternal deaths in HIV-infected 
women and how the evolving PMTCT and ART guidelines have impacted on 
mortality in this group of women.  
 
Chapter two outlines the rationale for the research and the overall aims and 
objectives of this PhD. 
  
Chapter three gives an overview of the methodology used in the six studies that 
make up this PhD with a detailed description of the study setting and a summary of 
the data collection and analysis. Detailed description of the methodology for each 
study is described in the appended Papers 1-6.  
 
Chapter four provides a synthesis of the key findings from the six studies and how 
they address the research objectives.  
 
Chapter five discusses the key cross-cutting themes that emerged from the 
synthesis of all the data from the six studies. The discussion section also highlights 
the contribution of the research to existing literature, and also the implications of the 
6 
 
research on eMTCT and decreasing HIV-related maternal mortality. Lastly it outlines 
the research limitations and makes recommendations for future research. 
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CHAPTER 1: BACKGROUND AND LITERATURE REVIEW 
 
1.1 PMTCT BACKGROUND AND LITERATURE REVIEW 
This section will discuss progress made towards elimination of mother-to-child 
transmission of HIV (eMTCT), in the context of evolving prevention of MTCT 
(PMTCT) and antiretroviral therapy (ART) guidelines. It will also discuss rationale 
behind the guideline changes and challenges that still exist within PMTCT 
programmes in resource-limited settings. 
 
1.1.1 The road to elimination of mother-to-child transmission of HIV  
In 2011, UNAIDS, the Joint United Nations Programme on HIV/AIDS, 
launched the Global Plan for elimination of mother-to-child transmission of HIV 
(eMTCT) by 2015, and keeping HIV-infected mothers alive.1 The first goal of the 
Global Plan was for a 90% reduction in new paediatric HIV infections by 2015, and 
the target was to reduce the MTCT rate to 5% or less among breastfeeding women, 
and to 2% or less among non-breastfeeding women.1 The second goal was to 
decrease HIV-related maternal deaths by 50%, by 2015. There were 22• priority 
countries identified in the Global Plan and together accounted for 90% of the global 
number of women living with HIV in 2009. The priority countries included 21 countries 
in sub-Saharan Africa, and India.  
Since the launch of the Global Plan, great strides have been made towards 
eMTCT, including in South Africa.2 According to the 2016 UNAIDS report on the 21 
priority countries in sub-Saharan Africa, 1.2 million new paediatric HIV infections 
were averted between 2009 and 2015.2 This translates to a 60% reduction in 
paediatric infections, and although this falls short of the 90% target, it has been 
hailed as ‘one of the greatest public health achievements of recent times’.2 Data were 
not available for India hence the UNAIDS report is on 21 countries. South Africa is 
one of seven priority countries that reduced new paediatric HIV infections by more 
than 70%, with an estimated 84% reduction between 2009 and 2015. The other 
                                                          
• Angola, Botswana, Burundi, Cameroon, Chad, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, 
Ghana, India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, South Africa, Uganda, United 
Republic of Tanzania, Swaziland, Zambia and Zimbabwe 
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countries that had a more than 70% reduction in new infections were Uganda (86%), 
Burundi (84%), Swaziland (80%), Namibia (79%), Mozambique (75%) and Malawi 
(71%). Four of these countries – South Africa, Uganda, Swaziland and Namibia – 
achieved the Global Plan milestone of an MTCT rate of less than 5%.2   
These significant gains in PMTCT have been largely due to the increased 
availability of efficacious antiretrovirals and scale-up of antiretroviral therapy (ART) 
programmes.2 In the 21 priority countries, the proportion of HIV-infected pregnant 
women who received antiretrovirals for PMTCT increased from 36% in 2009 to 80% 
in 2015, with 93% of the women receiving lifelong ART in 2015. PMTCT and ART 
guidelines in resource-limited settings have been guided by the World Health 
Organization (WHO) recommendations and guidelines which have evolved 
significantly over the past decade – Table 1.1.   
 
1.1.2 Evolution of the World Health Organization PMTCT and ART 
recommendations and guidelines for resource-limited settings  
 The first WHO document on interventions for PMTCT in low resource settings 
were the technical notes published in 2001, following a meeting in 2000 organised on 
behalf of the United Nations Interagency Task Team on mother-to-child transmission 
of HIV infection.3 The document provided evidence and recommendations on various 
antiretroviral regimens for PMTCT started either early or late in pregnancy, or given 
intrapartum. The regimens for preventing perinatal transmission were zidovudine 
either alone or in combination with lamivudine, or intrapartum single-dose nevirapine 
– Table 1.1.3 In the early years the main determinant for the choice of antiretrovirals 
for PMTCT in resource-limited settings was cost, as the cost of providing complex 
antiretroviral regimens was prohibitive at the time. While the efficacy of more complex 
regimens with antepartum, intrapartum and postpartum components was recognised 
to be higher, single-dose nevirapine was more practical for low resource settings. At 
the time, complex antenatal and intrapartum regimens, and combination 
antiretrovirals were already in use for PMTCT in resource-rich settings. In the 2001 
technical notes, a recommendation was also made for a three-pronged strategy for 
PMTCT and it comprised the following: “primary prevention of HIV among parents-to-
be; prevention of unwanted pregnancies among HIV-infected women; and prevention 
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of HIV transmission from HIV-infected women to their infants through the provision of 
antiretroviral drugs to HIV-infected pregnant women and their infants, safe delivery 
practices, and counselling and support for safer infant feeding practices”.3 The 
strategy would further be developed into the four prongs of PMTCT, and these will be 
discussed in detail in Section 1.1.4. 
The subsequent WHO guideline, published in 2004, reiterated the efficacy or 
more complex antiretroviral regimens (Table 1.1), but acknowledged that where 
these were not feasible or acceptable maternal and infant single-dose nevirapine 
remained an alternative.4 Cost and weak health systems that were seen to be unable 
to manage implementation of more complex antiretroviral regimens for PMTCT 
necessitated that simpler regimens were used in low resource settings. The 2004 
guideline acknowledged the importance of lifelong antiretroviral treatment for 
maternal health. In the previous year, 2003, WHO released guidelines for life-long 
antiretroviral treatment for children, adolescents and adults living with HIV in 
resource-limited settings.5 The eligibility criteria were based on the WHO clinical 
stage and a CD4 count where available – Table 1.1.   
As the guidelines evolved and there was more experience with implementation 
of PMTCT programmes programmatic evidence showed that it was possible to 
implement effective large-scale programmes even in resource-limited setting. The 
2006 WHO guidelines called for a public health approach for increasing access to 
PMTCT services.6 In the document, it was said that “the main purpose of adopting a 
public health approach is to ensure access to high-quality services at the population 
level, while striking a balance between the best proven standard of care and what is 
feasible on a large scale in resource-constrained settings”.6 In order to optimise the 
effectiveness of PMTCT programmes, all four components of the WHO 
comprehensive strategic approach to the prevention of HIV infection in infants and 
young children, first introduced in 2001, had to be implemented.   The strategic 
approach would also make headway towards elimination of HIV infection in infants 
and young children. A fourth component, care, treatment and support for mothers 
living with HIV, their children and families, was added to the original strategic 
approach.6   
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Table 1.1: WHO PMTCT and ART recommendations for resource-limited settings, 2001-2016 3–10 
 2001 
 
2004 2006 2010 2013 2016 
PMTCT  
Maternal 
antiretroviral 
regimens 
 
Long-course (from 14 
weeks gestation) or 
short-course (from 28-
36 weeks) ZDV as 
monotherapy or with 
3TC and intrapartum 
single-dose NVP; or 
single-dose NVP 
  
Antenatal (from 28 
weeks) and 
intrapartum ZDV with 
or without 3TC and 
intrapartum single-
dose NVP; or ZDV and 
3TC from 36 weeks, 
continued intrapartum 
and 1 week 
postpartum   
ZDV starting at 28 
weeks gestation and 
intrapartum single-
dose NVP.  
Intrapartum ZDV and 
3TC, and 7 days of ZDV 
and 3TC if the mother 
receives intrapartum 
single-dose NVP   
ARV prophylaxis 
starting at 14 weeks: 
Option A: antenatal 
ZDV, with intrapartum 
NVP, ZDV and 3TC, and 
ZDV and 3TC for 7 days 
postpartum. Option B: 
triple therapy during 
pregnancy and 
breastfeeding 
Option B 
Option B+: Lifelong 
triple antiretrovirals 
for all pregnant and 
breastfeeding women, 
regardless of WHO 
stage and CD4 count 
Lifelong ART for all 
pregnant and 
breastfeeding women 
Infant antiretrovirals 
 
ZDV for 3 days to 6 
weeks; or ZDV and 3TC 
for 1 week; or single-
dose NVP 
Single-dose NVP and 
ZDV for 1 week; or ZDV 
alone or with 3TC for 1 
week; or single-dose 
NVP 
ZDV for 1 week or 4 
weeks if the mother 
received less than 4 
weeks of ZDV during 
pregnancy 
**Daily NVP or twice-
daily ZDV for 4-6 
weeks, irrespective of 
infant feeding method 
6 weeks NVP if 
breastfed. With 
replacement feeding, 
4-6 weeks of NVP or 
ZDV  
Same as in 2013. 
#Infants at high risk for 
MTCT: ZDV and NVP 
for 6 weeks, extended 
to 12 weeks if 
breastfed 
ART eligibility (lifelong 
treatment)    
 
_______ *WHO stage 4 
irrespective of CD4 
count; or WHO stage 3 
with CD4 <250; or 
WHO stage 1 and 2 
with CD4 <200 
Same as in the 2004 
guidelines 
CD4 counts ≤350 
irrespective of WHO 
stage;  
WHO 3 or 4, 
irrespective of CD4 
count 
CD4 count ≤500 or 
WHO stage 3 or 4 
disease 
Regardless of CD4 
count or WHO stage 
ZDV=zidovudine; 3TC=lamivudine; NVP=nevirapine; ARV=antiretroviral  
*The eligibility criteria were based on the 2003 WHO treatment guidelines; ** Extended NVP prophylaxis for breastfed infants and mothers not eligible for ART 
#Infants at high risk for MTCT: less than 4 weeks of maternal ART; viral load >1000 in the 4 weeks before delivery; incident HIV infection during pregnancy and breastfeeding   
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Up until 2010, antenatal zidovudine and intrapartum single-dose nevirapine 
remained the recommendation for PMTCT in women who did not need treatment for 
their own health, in resource-limited settings. In 2010 there were major changes in 
the WHO guidelines starting with the introduction of two options for prophylaxis in 
women who did not need treatment for their own health, and an increase in the CD4 
threshold for ART initiation in pregnant women.7 For the first time, there was also a 
recommendation for antiretroviral prophylaxis during the breastfeeding period, 
acknowledging the risk of MTCT during this period. The two options for PMTCT were 
Options A and B, and the CD4 threshold for ART initiation was increased to ≤350 
cells/µl irrespective of WHO stage.7 Option A is antenatal and intrapartum 
zidovudine, with intrapartum single-dose nevirapine and seven days of postpartum 
zidovudine and lamivudine, and extended infant nevirapine prophylaxis for the 
duration of breastfeeding period. Option B is the provision of combination triple 
therapy for all HIV-infected pregnant women, with withdrawal of treatment 
postpartum if not breastfeeding, or after cessation of breastfeeding. In both Options, 
women who were eligible for lifelong ART were started on treatment for their own 
health and for PMTCT. The decrease in cost of antiretrovirals made it possible to 
recommend combination regimens for PMTCT even in resource-limited settings. At 
the time of the release of the 2010 guidelines there was no scientific or programmatic 
evidence to show that one PMTCT strategy, either Option A or B, was more 
efficacious than the other. Countries were encouraged to choose a PMTCT option 
based on local resources and feasibility of implementing either option.   
In 2012 WHO released a programmatic update with a recommendation for a 
single antiretroviral regimen for PMTCT and treatment for HIV-infected pregnant 
women.8 While Options A and B were judged at the time to be equally efficacious for 
prophylaxis, there were concerns that the two options might be confusing and there 
were challenges with implementation of Option A. The challenges with Option A 
included the fact that different antiretrovirals had to be used in the antenatal, 
intrapartum and postpartum periods, and also the need for CD4 count testing which 
was not always readily available in most resource-limited settings. The 2012 update 
also introduced a third option, Option B+, which is lifelong ART for all HIV-infected 
pregnant and postpartum women regardless of the level of immune suppression. The 
subsequent 2013 guidelines made a recommendation for Option B+ for all HIV-
infected pregnant and postpartum women, especially for countries with generalised 
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epidemics as the option provided a simplified and efficacious regimen with 
programmatic and operational advantages.9 Option B+ will be discussed in more 
detail in Section 1.1.7. The last WHO guideline update was in 2016 and the 
recommendation is for lifelong ART for all pregnant and breastfeeding women.10   
 
1.1.3 Evolution of the South African PMTCT and ART guidelines         
The evolution of the South African PMTCT and ART guidelines (Table 1.2) 
mirrors the evolution of the WHO guidelines.11–16 The biggest changes in the South 
African PMTCT guidelines were in the period 2010 to 2015, starting in 2010 with the 
increase in the CD4 count threshold for ART initiation in pregnant women to ≤350 
cells/µl, and the introduction of nurse-initiated and managed ART (NIMART).14–16 The 
period also saw withdrawal of free infant formula which was available for HIV-infected 
women who elected not to breastfeed. As part of the PMTCT programme, a six 
months’ supply of free formula was available until 2011 when South Africa adopted a 
single policy of supporting breastfeeding for all HIV-infected women.17 In 2013, 
Option B was introduced and lastly in 2015 Option B+ was adopted.  
Introduction of NIMART in 2010 was part of task-shifting and decentralisation 
of services where professional nurses, including midwives, could initiate and manage 
patients on ART.18 This was an attempt to address delays and limitations with the 
number of patients started on ART with physician-led programmes. Introduction of 
NIMART within antenatal clinics became necessary as the proportion of ART-eligible 
pregnant women increased with guideline changes in 2010 increasing the CD4 
threshold for eligibility. Results from the STRETCH (Streamlining Tasks and Roles to 
Expand Treatment and Care for HIV) trial, a large cluster-randomised trial conducted 
in South Africa with over 8 000 patients, provided evidence that primary care nurses 
could safely initiate and manage patients on ART.19 In the trial, there was no 
difference in risk of mortality and the proportion of patients that were virally 
suppressed at 12 months between patients managed by physicians and those 
managed by nurses. The trial provided no detail on NIMART among pregnant 
women. 
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Table 1.2: Evolution of the South African recommendations for PMTCT and treatment for HIV-infected women 11–16 
 2002 2004 2008 2010 2012 2013 2015 
 
PMTCT  
Maternal 
antiretroviral 
regimens  
Intrapartum 
single-dose NVP 
Same as in 2002 
 
Option A – ZDV 
monotherapy 
from 28 weeks 
gestation for 
pregnant women 
not eligible for 
lifelong 
treatment.  
 
Zidovudine 
monotherapy 
from 14 weeks. 
 
Integration of ART 
initiation within 
antenatal clinics 
(*NIMART) 
Withdrawal of 
free infant 
formula for HIV-
infected women 
who elected not 
to breastfeed 
Option B – triple 
therapy for all 
HIV-infected 
pregnant women, 
with postpartum 
withdrawal of 
therapy in those 
not eligible for 
lifelong treatment 
 
Option B+ –   
lifelong ART for all 
HIV-infected 
pregnant, 
regardless of level 
of immune 
suppression  
Infant 
antiretrovirals  
Immediate 
postpartum 
single-dose NVP 
 
 1 or 4 weeks of 
ZDV if mother had 
less than 4 weeks 
of ZDV  
Same as in 2008 ------- Daily NVP for 6 
weeks  
Daily NVP for 6 
weeks, extended 
for 12 weeks if 
high risk for MTCT 
ART eligibility 
(lifelong 
treatment)   
 
 
 
------- 
Antiretroviral 
therapy (ART) 
Eligibility criteria: 
CD4 <200, or 
WHO stage 4  
Eligibility criteria 
for ART remains 
the same  
ART eligibility 
criteria for 
pregnant women: 
CD4 ≤350, or 
WHO stage 3 or 4 
  
 
 
------- 
CD4 ≤350, or 
WHO stage 3 or 4  
 
 
Regardless of CD4 
count or WHO 
stage   
ZDV=zidovudine; 3TC=lamivudine; NVP=nevirapine; ARV=antiretroviral  
*NIMART= nurse initiated and managed antiretroviral therapy 
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Challenges with introduction of NIMART within antenatal clinics were 
highlighted in a review of a donor-funded PMTCT programme in Cape Town, South 
Africa.20 Referral of pregnant women to separate ART clinics was associated with 
failure of linkage to care and delays in starting treatment. In an attempt to address 
these challenges, a model to integrate ART initiation within midwives’ obstetric units 
was introduced in the Cape Town PMTCT programme. The challenges associated 
with introduction of NIMART were that ART initiation within the obstetric units was 
seen as an additional task to perform by overworked staff and midwives were also 
not skilled to manage both pregnancy and HIV infection. Despite effective ART 
services led by nurses in nearby ART clinics, it took six years to establish a NIMART 
programme within the midwives’ obstetric units.20 When the South African guidelines 
changed in 2010, increasing the proportion of ART-eligible pregnant women with the 
increase in the CD4 threshold, task shifting and the ability of midwives to prescribe 
ART became necessary. Midwives were trained in NIMART and a mentorship 
programme was established. The authors of the paper acknowledge that dedicated 
staff, government policies, and partnerships between the department of health, 
academic institutions and non-governmental institutions were all important for the 
success of the NIMART programme.20   
The evolution of the WHO and the South African guidelines illustrate the 
important developments that have occurred in the field of PMTCT. While the greatest 
achievements have been through the provision of antiretrovirals, the Global Plan 
goals and targets were built on the WHO four prongs of PMTCT, Figure 1.1.6 In the 
first WHO PMTCT recommendations published in 2001, it was recognised that in 
order to significantly decrease perinatal HIV transmission interventions will have to 
address various aspects of HIV prevention.3 These were later developed into the four 
prongs of PMTCT.6     
 
1.1.4 THE FOUR PRONGS OF PMTCT  
Prong 1 – Primary prevention of HIV infection:  
Primary prevention of HIV infection has seen the least progress with only a 5% 
decrease in new HIV infections among women of reproductive age between 2009 
17 
 
and 2015, falling far short of the Global Plan target of a 50% reduction.2  
 
Figure 1.1: The World Health Organization four prongs of prevention of mother-to-
child transmission of HIV 6   
 
According to the 2016 UNAIDS report, South Africa has had the largest 
number of new HIV infections, with approximately 1.2 million new infections among 
women of reproductive age between 2009 and 2015.2 Estimates from the 2012 South 
African National HIV Prevalence, Incidence and Behaviour Survey (the most recent 
national incidence survey) are that there was almost double the number of new HIV 
infections among women of reproductive age, 15-49 years, compared to men in the 
same age group.21 The gender-related disparity in HIV incidence was even higher in 
the 15-24 age group with a four-times greater incidence in women than in men. Age-
disparate relationships where the sexual partner is five years older or more, and 
often associated with transactional sex, is said to be the key driver of the high HIV 
incidence in girls and women aged 15-24 years.  
School attendance has been identified as a protective factor in decreasing HIV 
incidence in young women.22 In a large randomized controlled trial done in South 
Africa with 2 533 participants, young women who attended school less than 80% of 
Prong 1:  
Primary 
prevention of HIV 
infection among 
women of 
childbearing age 
Prong 2: 
Preventing 
unintended 
pregnancies 
among women 
living with HIV 
Prong 3: 
Preventing HIV 
transmission from 
a woman living 
with HIV to her 
infant 
Prong 4: 
Providing 
appropriate 
treatment, care 
and support to 
mothers living with 
HIV and their 
children and 
families 
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the expected time had an increased risk of HIV acquisition, relative risk 1.88 (95% CI: 
1.08, 3.27, p=0.03).  Although not statistically significant, dropping out of school was 
also associated with an increased risk of HIV acquisition, relative risk 1.77 (95% CI 
0.95, 3.28, p=0.07). Several prevention strategies targeting adolescents and young 
women and encouraging them to stay at school and avoid age-disparate 
relationships have been advocated, but they have yet to show results in South Africa.         
 
Prong 2 – Preventing unintended pregnancies among women living with HIV 
With prevention of unplanned and unintended pregnancies, indications are 
that there remains a large unmet need for family planning among all women of 
reproductive age, including HIV-infected women.2 Data on unmet need for family 
planning are however often outdated, based on contraceptive needs of married 
women and not disaggregated by HIV status.2 The contraceptive prevalence rate 
(CPR), which is defined as the proportion of women aged 15 to 49 years who are 
currently using a contraceptive method, is used to report on contraception use. For 
South Africa, nationally representative data on contraception use are from the 2003 
and 2016 South Africa Demographic and Health Surveys, and the 2012 South 
African National HIV Prevalence, Incidence and Behaviour survey.21,23,24 The CPR 
among married women in South Africa remained unchanged in 2016 at 54% 
compared to 55% in 1998.24 Among sexually active unmarried women the CPR 
declined from 68% in 2003 to 64% in 2016.24   
Regarding the unmet need for family planning the 2016 Survey defines this as 
“the proportion of women who are currently fecund and not pregnant who want to 
postpone or stop childbearing but are not using a contraceptive method, together 
with the women who report that their current pregnancy or birth in the last 2 years 
was mistimed or unwanted”.24 The figure was 17% in 1998 and 15% in 2016.24 In 
their analysis of the 2012 South African National HIV Prevalence, Incidence and 
Behaviour Survey, Chersich et al report on a high rate of unwanted and unintended 
pregnancies.25 They found that two-thirds of all pregnancies were unintended, and 
among women who were pregnant at the time of the survey 49% had an unwanted 
pregnancy.         
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Another index used for family planning is the couple year protection (CYP) 
rate, which reflects distribution of contraceptives and is the estimated protection 
provided by family planning services in a 12-month period. In the 2015 Millennium 
Development Goal Report, the estimated CYP rate for South Africa increased from 
27.6% in 2010 to 52.7% in 2014.26 While this shows an increase in the distribution of 
contraceptives, data from national surveys discussed above reflect a high unmet 
need for contraceptives and also a high rate of unintended pregnancies. The 
limitation with the national surveys however is that they are cross-sectional and do 
not reflect on trends.  
 
Prong 3 – Prevention of HIV transmission from mothers living with HIV to their 
infants:  
Prevention of HIV transmission from women living with HIV to their infants has 
largely been the focus of PMTCT programmes and is the area where the greatest 
success has been achieved, and has been discussed in detail in Section 1.1.1.  
 
Prong 4 – Care, treatment and support for mothers living with HIV, their 
children and families:  
Postpartum retention in care which is part of prong 4 is an area where efforts 
still need to be intensified.2 The UNAIDS estimate is that over 50% of new paediatric 
HIV infections are due to breastfeeding transmission as a result of HIV-infected 
women not being retained in care and on treatment postpartum.2 Postpartum 
retention in care and breastfeeding transmission will be discussed in more detail in 
Sections 1.1.10 and 1.1.11.  
As we celebrate the successes and the enormous gains made in PMTCT 
programmes in the priority countries including South Africa, it is important to take 
stock of the gaps that still exist in prevention of HIV transmission to infants.  
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1.1.5 Challenges that still exist in prevention of mother-to-child transmission of 
HIV programmes 
Availability of antiretrovirals alone does not guarantee a successful PMTCT 
programme.27 Several methods have been used in evaluating effectiveness of 
PMTCT programmes and these include assessing coverage at various steps of the 
PMTCT cascade; facility- and community-based case finding of HIV-infected infants; 
prospective cohorts and community-based surveys assessing HIV-free survival.28 
While more representative, community-based case finding and surveys are more 
complex and expensive to conduct.28 Hence coverage along the PMTCT cascade 
(Figure 1.2) and facility-based case finding are often used to assess successes and 
challenges that still exist in PMTCT programmes.27,28 While these are convenient and 
less complex, they rely on accuracy and completeness of routinely collected data.  
 
(PCR=polymerase chain reaction) 
Figure 1.2:  PMTCT cascade (Adapted from Stringer et al. 2008 and Barker et al. 
2011 27,28)  
Routine HIV testing 
during pregnancy  
HIV-infected: initiation of 
ART 
Prophylaxis for the  
HIV-exposed baby 
Early infant (PCR)* testing 
PCR 
negative 
Not breastfed 
(BF),  
repeat testing  
at 18 months 
Breastfed, repeat 
testing 
 post BF 
cessation,  
and again at 18 
months 
PCR 
positive 
Initiation  
of lifelong ART 
HIV-uninfected: risk reduction 
counselling; antenatal and 
postnatal repeat testing  
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Several factors influence the risk of MTCT, among them timing of maternal 
HIV infection, maternal viral load and extent of immunosuppression, initiation of ART 
and antiretroviral prophylaxis (when prophylaxis was still part of PMTCT guidelines), 
and infant feeding practices.29,30 Attrition at any step of the cascade translates to the 
HIV-infected pregnant woman and HIV-exposed infant not receiving the appropriate 
care, and hence increasing the risk of HIV transmission.27   
In a study assessing factors associated with completion of the PMTCT 
cascade in four countries (Cameroon, Cote d’Ivoire, South Africa and Zambia), just 
over a third, 36.4%, of HIV-infected women completed the cascade.31 This was a 
community-based study where 7 985 mother-infant pairs were enrolled, and women 
who reported a delivery in the past 24 months were included in the study. Data were 
collected on details of the last pregnancy and mother-infant pairs were tested for HIV 
and for HIV-infected women the PMTCT cascade was recreated using information 
collected during the interviews. A total of 1 014 mothers tested HIV positive and 
complete data were available for 976 HIV-infected women. Completion of the 
cascade was defined as attendance of an antenatal clinic at least once, HIV test and 
receipt of results, and initiation of maternal and infant antiretroviral prophylaxis. Infant 
testing was not included in the cascade and the MTCT rate was not reported on, both 
important omissions as the success of any PMTCT programme is based on the 
MTCT rate. In the study, the biggest fall-off was at receipt of HIV test results – of the 
976 women identified as HIV-infected, 87.0% were tested for HIV in the last 
pregnancy, and only 47.0% received their results. No details were given on whether 
HIV testing was done using rapid or laboratory-based testing, an important factor in 
delivery of results.  
Factors that were associated with completion of the PMTCT cascade were 
HIV diagnosis prior to pregnancy, awareness of partner’s HIV status, having an HIV-
infected partner, and ever use of long-acting contraception, the last factor likely to be 
a proxy for health-seeking behaviour and access to healthcare.31 The study has 
limitations in that it was done in an earlier period of PMTCT interventions, 2007-2009, 
a factor acknowledged by the authors. The study also does not give details on why 
there were fall-offs at the various stages of the PMTCT cascade.  
In a South African study done in a later time period, 2012 to 2013, where 
pregnant women who were newly diagnosed as HIV-infected at the first antenatal 
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visit were followed up for 60 days, there were high rates of loss to follow-up and 
failure to initiate antiretroviral prophylaxis and treatment.32 Of the 158 pregnant 
women diagnosed as HIV-infected, 46.0% were eligible for ART. Only 3.0% of the 
pregnant ART-eligible women were started on treatment within 30 days of the first 
antenatal visit, and 21.0% were initiated within 60 days. A third of the women did not 
return for follow-up within 60 days of the first antenatal visit. The high rate of loss to 
follow-up and the delays in ART initiation were despite interventions to fast-track ART 
initiation in pregnant women, including implementation of NIMART and integration of 
antenatal and ART services. Health system factors – stock-out of HIV test kits, drug 
stock-outs and staff shortages – contributed to the delays in starting treatment. The 
study does have limitations in that routine data, which are prone to being incomplete, 
were used, and the study sample was small at only 158 participants. Patients could 
have also initiated treatment at other facilities. The authors acknowledge that the 
study was not designed to identify causes of failure to initiate and adhere to 
treatment, but rather to assess steps within the PMTCT cascade.32 Both papers 
highlight the attrition that occurs at various steps of the PMTCT cascade. The next 
section of the literature review will discuss the various steps of the PMTCT cascade 
and factors that contribute to fall-offs at different stages.           
 
1.1.6 HIV diagnosis and initiation of antiretrovirals in pregnant women  
Routine HIV testing of all pregnant women at the first antenatal visit, through 
provider-initiated counselling and testing (PICT), is standard practice and provides an 
entry point for engagement in care. Pregnant women need to access antenatal care 
early, and once diagnosed as HIV-infected started on antiretrovirals. For pregnant 
women to be identified as HIV-infected and started on treatment, they need to access 
antenatal care. Several factors result in pregnant women not accessing any antenatal 
care, presenting for care late in pregnancy, or being lost to follow-up. In a meta-
synthesis of why pregnant women in low- and middle-income countries do not utilise 
antenatal services, with four of the studies done in South Africa, the barriers to 
accessing antenatal care were universal.33 The main reasons for not accessing any 
antenatal care or presenting late for care were cultural beliefs, financial 
considerations, and poor quality of services at antenatal clinics.33 Cultural beliefs 
meant that pregnant women delayed pregnancy disclosure, and hence antenatal 
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clinic attendance, until the pregnancies were advanced because of fears of losing the 
pregnancies. Cost of transport to the antenatal facilities and fear of losing their 
employment if they took time off work were also found to be important factors. Even 
when pregnant women made the effort and managed to access antenatal care, the 
disappointment with the quality of services offered at the facilities prevented them 
from continued utilisation of the services. Accessing antenatal care is not only 
important for HIV diagnosis and ART initiation for PMTCT, but is also an important 
factor in maternal mortality in HIV-infected women. An in-depth discussion of the role 
of antenatal care in PMTCT and maternal mortality in HIV-infected women will be 
included in the discussion, integrating the available literature and findings from the 
studies that make up this PhD.  
Once pregnant women have accessed antenatal care and been found to be 
HIV-infected, they need to start antiretrovirals for PMTCT and also for their own 
health. Health system and patient-related factors have both been identified as 
barriers to accessing care and initiating antiretrovirals among HIV-infected pregnant 
women. One of the major health system-related barriers to ART initiation among 
pregnant women was the vertical nature of services, where antenatal care and HIV 
management were provided at different sites, often in different facilities. This led to 
fragmentation of care and delays in ART initiation. Integration of antenatal and ART 
services has been an important intervention in increasing the proportion of pregnant 
women started on ART.34,35 In one of the early studies to report on integration of 
antenatal care and ART initiation, Killam et al found that integration of services 
doubled the proportion of ART-eligible pregnant women that were started on 
treatment prior to delivery, AOR 2.01; 95% CI: 1.37, 2.95.34 This study, done in 
Zambia in the period 2007-2008, was a stepped-wedge evaluation of integration of 
ART initiation and antenatal care and involved 1 562 ART-eligible pregnant women.34 
However, even with the integrated model, the overall proportion of pregnant women 
started on ART was low at 33%. There was no difference in time-to-initiation and 
gestational age at ART initiation among women started on ART within antenatal 
clinics, compared to those referred for treatment to ART sites.34 While the authors 
provide no explanation on why the percentage initiated on ART was low and the fact 
that there was no decrease in time-to-initiation in the integrated model, it is likely 
related to the fact that ART services were only offered once or twice a week in the 
antenatal clinics that were part of the study.34   
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Similar to the Zambian study, a South African study also done in 2008, found 
a higher proportion of pregnant women started on ART with integrated services.35 In 
the study, there were three models of care for ART initiation: model 1 (‘integrated’) 
where ART initiation was done within the antenatal clinic once a week; model 2 
(‘proximal’) where pregnant women were referred for ART initiation to a separate site, 
but within the same facility; and model 3 (‘distal’) where the referral was to a separate 
healthcare facility.35 There was a significant difference in the percentage of pregnant 
women initiated in the three models at 55%, 38% and 45% respectively, p=0.003. 
With referral to separate ART sites, there were delays with ART initiation during 
pregnancy even if the site was within the same facility and proximal to the antenatal 
clinic. The other barrier to ART initiation during pregnancy identified in the study was 
the gestational age at the first antenatal visit. Pregnant women who were started on 
ART accessed antenatal care at an earlier median gestation compared to those who 
were not started, 23 weeks vs. 29 weeks, p<0.001.35 While the results of the study 
suggest that an integrated model is associated with a higher proportion of pregnant 
women started on ART, the overall ART initiation rate was low at 46%. The main 
limitation of the study is that it was a retrospective review of patient records, and data 
may be incomplete, a fact the authors acknowledge.35    
There have been various models of integrating PMTCT services into other 
health services in an attempt to increase the uptake of PMTCT interventions.36 These 
models have included integration with maternal, newborn, child health, sexual and 
reproductive health services and have had mixed results in terms of uptake, 
effectiveness and efficiency of services.36 Integration of ART management into 
maternal and child health services, and task shifting enabling midwives to initiate and 
manage pregnant women on ART has had the biggest impact in increasing the 
proportion of pregnant women started on treatment.36    
Prior to introduction of Option B+, HIV-infected pregnant women were 
assessed for ART eligibility based on a CD4 count threshold and WHO HIV disease 
stage, and once found to be eligible underwent a lengthy counselling process in 
preparation for ART initiation. Several studies from South Africa reported on lengthy 
delays between assessment for eligibility and initiation of ART among pregnant 
women, with delays of more than 30 days reported in some studies.32,37–39 Given that 
the majority of pregnant women presented for antenatal care late in the second 
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trimester, or even in the third trimester, a proportion of women delivered without 
being started on ART. In their study evaluating adherence to recommended PMTCT 
services, Schnippel et al found that of 72 ART-eligible pregnant women, only two 
initiated ART within 30 days of their first antenatal visit and 15 within 60 days of the 
first visit.32 The median period between the first antenatal visit and ART initiation was 
47 days. These delays were despite fast-tracking of pregnant women, availability of 
NIMART and integration of antenatal care and ART services at the study sites. While 
the study was not designed to identify causes for the delay in starting ART, the 
authors mention that there were staff shortages, shortage of HIV test kits and 
antiretrovirals at the sites, at various points during the study period.32 The results 
from this study highlight the fact that despite the best policies programmes are likely 
to fail if there are inadequate resources to support them. 
In a study done in Cape Town, lengthy adherence counselling sessions while 
delaying starting ART did not improve maternal outcomes.38 In their study, where the 
median time between assessment at the ART clinic and starting treatment was 21 
days, Myer et al found that the duration of the systemic delays before starting 
treatment were not associated with improved maternal outcomes. The outcomes of 
interest were retention in care and virologic suppression up to 12 months after ART 
initiation. There was no difference in these outcomes among pregnant women who 
started ART less than 14 days after screening compared to those initiated on 
treatment after 14 days. In the study, no details are given on why some pregnant 
women were started on treatment earlier. Also, there are no details on the number of 
counselling sessions received and how patient readiness to start ART was 
assessed.38                                  
While integration of antenatal and ART services and Option B+ have 
increased the proportion of pregnant women initiated on ART and eliminated the 
need for assessment for ART eligibility, timeous initiation of ART still depends on 
pregnant women presenting early for antenatal care and agreeing to start treatment. 
The risk of MTCT has been associated with the duration of antenatal ART.40 In a 
Zambian study with 1 813 mother-infant pairs, four weeks or less of antenatal ART 
was associated with a 5.2-fold increased odds of MTCT compared with at least 13 
weeks of antenatal ART.40 In women who had less than 13 weeks of antenatal ART, 
the risk of MTCT was reduced by 14% with each additional week of ART. There was 
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no data on maternal viral loads, an important determinant of MTCT risk, and the 
authors acknowledged this limitation and explain that viral load monitoring was not 
routinely available in Zambia at the time of the study.40 Data from resource-rich 
settings, which have longer experience with using combination ART for PMTCT, also 
show a significant association between duration of antenatal ART and risk of 
MTCT.41 Results from population-based surveillance data from the United Kingdom 
and Ireland, with over 12 000 singleton pregnancies in HIV-infected women, show 
that in women starting ART in pregnancy there is a rapid decline in MTCT risk with 
each additional week of ART, up to 15 weeks of treatment when the risk less than 
0.5%.41 The findings on the association between duration of antenatal ART and risk 
of MTCT underpin the recommendation for same day initiation of ART in pregnant 
women diagnosed as HIV-infected.         
Early antenatal care also provides an opportunity for pregnant women who 
initially test negative to be retested for HIV during the course of the pregnancy. The 
WHO guidelines recommend retesting in the third trimester and again during labour, 
for all pregnant women who initially test HIV negative.10 The South African guideline 
recommendation is for retesting every three months during pregnancy and 
breastfeeding, and a repeat HIV test intrapartum.16 The rationale for retesting during 
pregnancy is that primary HIV infection during pregnancy is associated with high 
rates of MTCT due to the high viraemia associated with acute HIV infection.30 High 
primary HIV infection rates during pregnancy have been reported in high HIV 
incidence settings, and may contribute to a significant proportion of MTCT, especially 
where PMTCT programmes are effective in reducing transmission in women with 
known HIV infection.42,43 Results from a national PMTCT evaluation study conducted 
in South Africa between 2011 and 2012 indicate that HIV seroconversion in 
pregnancy contributes significantly to early MTCT cases diagnosed between four and 
eight weeks postpartum.44 In the study involving 9 802 mother/caregiver-infant pairs, 
there was a 3.3% seroconversion rate during pregnancy and although this group 
represented 6.7% of all HIV-infected pregnant women, they accounted for 26% of 
early MTCT cases in the study.44 The early MTCT risk was also higher for the cases 
of seroconversion during pregnancy at 10.7% compared to 2.2% for women who 
were known to be HIV-infected during pregnancy. The women who seroconverted 
reported fewer antenatal visits and received their last HIV test result at a mean 
gestational age of 25 weeks. The authors estimated that 50% of the seroconversions 
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occurred after 32 weeks gestation. The findings from this South African study 
highlight the contribution of HIV seroconversion during pregnancy to MTCT, in a high 
HIV prevalence setting. The authors however caution that they could have 
overestimated the seroconversion rate as they were only able to verify 46% of the 
cases of self-reported antenatal HIV negative test results with clinic records.44 
However, the 3.3% seroconversion rate reported in the South African PMTCT 
evaluation study is similar to that reported in an earlier study done in South Africa.42 
In a study done from 2006 to 2007 in three provinces in South Africa, where pregnant 
women who initially tested HIV negative in early pregnancy were retested at 36 to 40 
weeks, the seroconversion rate was 3.0%, similar to the figure from the national 
evaluation study.42    
 
1.1.7 The rationale for Option B+   
 In 2012, WHO introduced Option B+ as the third option for management of 
HIV-infected women in resource-limited settings. This was seen as a public health 
approach as all HIV-infected pregnant and postpartum women would receive the 
same antiretroviral treatment, regardless of the level of immune suppression.8  
Having all pregnant and postpartum HIV-infected women receive the same 
antiretroviral regimen meant simplification of the interventions, and hence a public 
health approach. At the time of introduction of Option B+, the other two options for 
resource-limited settings were Option A and Option B.8   
The idea for Option B+ was initiated in the context of the PMTCT programme 
in Malawi, where health system weaknesses and limitations with technology were a 
major barrier in CD4 testing to assess for ART eligibility in pregnant women.45 The 
other argument for Option B+ was that women in Malawi have high fertility rates and 
short birth intervals, and that starting treatment for life in all HIV-infected pregnant 
women would benefit future pregnancies and also protect HIV-uninfected partners.45 
Lifelong treatment would also eliminate the need for starting and stopping treatment 
associated with PMTCT interventions, and also decrease the risk of disease 
progression.45   
When Option B+ was introduced in 2011 in Malawi, no robust data were 
available to show superiority of triple therapy for PMTCT at high CD4 counts, and 
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also no data showing benefits of starting lifelong ART at high CD4 counts. Data 
subsequently became available to support both. Results from PROMISE, a large 
multinational trial that randomised 3 490 HIV-infected pregnant women with CD4 
counts ≥350 cells/µl to receive either zidovudine monotherapy or triple therapy for 
PMTCT, showed benefits of ART in decreasing MTCT risk even at high CD4 
counts.46 The median CD4 in the participants was 530 cells/µl, and the transmission 
rate in the ART group was 0.5% compared to 1.8% in the zidovudine monotherapy 
group, -1.3% points, CI: −2.1 to −0.4.46 Hence the PROMISE data provides evidence 
of the benefit of   triple therapy for PMTCT even for pregnant women with high CD4 
counts.           
With regards to starting ART for PMTCT during pregnancy and stopping 
postpartum, published studies found that treatment interruption was associated with 
a risk of HIV disease progression.47,48 Results from a study done in Brazil, where 
triple therapy started during pregnancy and discontinued postpartum has been 
standard of care since 2006, found that 24.2% (29/120) of women who had received 
ART for PMTCT had to be restarted on ART after a mean of 1.5 years postpartum.47 
Of the 29 women restarted on ART, 10 had evidence of HIV disease progression, 
and in 9/10 the diagnosis of disease progression was based on a drop in CD4 count. 
A baseline CD4 count <500 cells/µl during pregnancy was the only significant 
predictor of postpartum HIV disease progression. A total of 19/29 women were 
restarted on ART for PMTCT for a subsequent pregnancy.47 Data from a multi-
country HIV care programme also showed that an antenatal CD4 count <500 cells/µl 
was associated with an increased risk of postpartum HIV disease progression in 
women who discontinued ART for PMTCT after delivery.49    
An observational study done in Malawi also highlights the issue of a need to 
restart treatment within a short period postpartum.48 In the study where HIV-infected 
women with baseline CD4 counts >350 cells/µl stopped ART six months postpartum, 
one in five reached a CD4 count threshold of <350 cells/µl by 18 months of stopping 
ART. A CD4 count of <350 cells/µl was criteria for lifelong treatment at the time of the 
study. Overall, 30% of women had to restart ART by 18 months, either due to a low 
CD4 count or a new pregnancy.   
The other argument for Option B+ is that even pregnant women with high CD4 
counts will be started on treatment early instead of waiting for CD4 counts to drop to 
29 
 
treatment eligibility levels which may occur within a short interval postpartum. Results 
from a multinational study with sites in Zimbabwe, South Africa, Uganda, and 
Tanzania showed high rates of postpartum HIV disease progression in women with 
high CD4 counts that were not started on ART during pregnancy, in accordance with 
guidelines and standard of care at the time.50 In 37% of women who had baseline 
CD4 counts between 400 and 549 cells/µl during pregnancy, and hence not started 
on treatment, the CD4 count dropped to <350 cells/µl at one year.50 Evidence from 
studies involving non-pregnant populations show benefits of starting ART early, at 
higher CD4 counts. Data from two randomized controlled studies published in 2015, 
TEMPRANO and START, showed benefits of starting ART early, at CD4 counts >500 
cells/µl.51,52 In both studies, there was a decrease in AIDS- and non-AIDS-related 
morbidity and mortality in patients started on ART at CD4 counts >500 cells/µl.51,52 
The 2016 WHO guidelines now recommend lifelong ART for all HIV-infected 
individuals, regardless of level of immune suppression, and South Africa adopted the 
‘test and treat’ guidelines in September 2016.10,53   
While there has been a significant increase in the proportion of HIV-infected 
pregnant women initiated on ART through Option B+ with 93% of the women on 
antiretrovirals in the 21 priority countries on ART in 2015 compared to 73% in 2014, 
there remain challenges with postpartum follow-up and retention in care.54  
 
1.1.8 Postpartum care       
 Postpartum follow-up is an important component of PMTCT programmes and 
has received less attention than antenatal care, beyond provision of infant 
prophylaxis and testing of the HIV-exposed infant.54 Postpartum care encompasses 
early infant HIV diagnosis, provision of infant prophylaxis for all HIV-exposed infants, 
immediate ART initiation in HIV-infected infants, ongoing counselling on safe infant 
feeding practices, retention in care and adherence to treatment in all HIV-infected 
mothers on ART, infant testing after cessation of breastfeeding, and retesting and 
risk reduction counselling for HIV-uninfected mothers. It is also in the postpartum 
period that HIV-infected mothers and their infants are transitioned into general ART 
programmes for lifelong care. Infant diagnosis, safe infant feeding practices and 
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postpartum retention in care will be discussed in turn in the next three sections. ART 
initiation in HIV-infected infants is beyond the focus and scope of this PhD. 
 
1.1.9 Infant diagnosis  
Early infant diagnosis of all HIV-exposed infants ensures prompt diagnosis 
and initiation of ART in infants found to be HIV-infected. In the CHER (Children with 
HIV Early Antiretroviral Therapy) trial done in Soweto, South Africa, early HIV 
diagnosis and early initiation of ART in HIV-infected infants was associated with a 
76% decrease in mortality and 75% decrease in HIV disease progression.55 The 
CHER trial was a randomized, open label trial where HIV-infected infants at 6-12 
weeks of age were assigned to early antiretroviral therapy initiated soon after 
diagnosis, or deferred treatment until clinical or laboratory criteria for ART were met, 
according to guidelines at the time.55 The findings from the CHER trial led to WHO 
recommendations for immediate ART initiation in HIV-infected infants and children 
less than two years of age.   
Infant testing needs to be at multiple points during the postpartum MTCT risk 
period in order to identify HIV-infected infants that may be missed by a single test, 
and to be able to have a final HIV diagnosis.56 In settings where a single test is done, 
the 2016 WHO recommendation is for all HIV-exposed infants to have a virological 
(polymerase chain reaction, PCR) HIV test at 4-6 weeks of age, or soon thereafter.10 
While acknowledging the benefits of doing a birth PCR, and the prompt initiation of 
infants found to be HIV-infected, in decreasing morbidity and early mortality 
associated with in utero transmission, the recommendation is for testing at birth to be 
in addition to testing at 4-6 weeks of age.10 Testing around 6 weeks of age will 
identify infants infected in utero and some infected during the intrapartum and 
immediate postpartum periods.56 While the 6-week test appears well-timed, 
coinciding with routine postnatal visits, loss to follow-up occurs in the period between 
birth and six weeks and cases of in utero transmission may be missed.56 It may 
however be early to detect all cases of intrapartum and early breastfeeding 
transmission in infants receiving antiretroviral prophylaxis who may have low HIV 
viral loads, hence the recommendation for multiple tests during the at risk postpartum 
period.56       
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The South African guidelines introduced routine testing at birth in 2015 and 
recommend testing of HIV-exposed infants at the following intervals: birth, 10 weeks 
(all HIV-exposed infants), 18 weeks (all infants who receive extended (12 weeks) 
nevirapine prophylaxis), 6 weeks post cessation of breastfeeding, and the final test at 
18 months of age.16 The reason for the shift in the timing of early infant diagnosis 
from 4-6 weeks to 10 or 18 weeks is the possibility of false negative or indeterminate 
results associated with infant nevirapine prophylaxis decreasing the viral load in the 
HIV-infected infant.16 A large South African study with over 6 000 neonates tested at 
birth, and a testing coverage rate of 99%, showed that it is feasible to implement 
universal screening at birth with early ART initiation in those found to be HIV-
infected.57 A total of 99 out of 6 377 neonates tested were found to be HIV-infected 
and 95/99 were initiated on ART at a median age of eight days.57 The authors though 
acknowledge that their findings may not be generalizable to a routine PMTCT 
programme setting as their birth testing programme was within a study with additional 
resources for counselling and tracking of neonates with positive results.57 The 
importance of tracking is illustrated by the fact that in the study only 52% of neonates 
with negative results returned for results.                  
Coverage of early infant diagnosis at four to eight weeks of life remains low.2 
In 2015, the UNAIDS estimate is that only 51% of the estimated 1.2 million HIV-
exposed infants in the 21 priority countries were tested in the first eight weeks of life.2 
Missed opportunities for early infant diagnosis occur throughout the continuum of 
care, from HIV-infected pregnant women being lost to follow-up during the antenatal 
period, to failure to identify and test HIV-exposed infants, and failure to deliver results 
in tested infants.58 South Africa is one of the few countries that have achieved almost 
universal coverage of early infant diagnosis, with an estimated 95% of HIV-exposed 
infants tested in 2015.2 The other two countries with infant testing coverage rates 
above 80% are Swaziland (81%) and Lesotho (93%).    
There has been less emphasis on infant testing after cessation of 
breastfeeding, and indications are that late postnatal transmission rates are higher 
than at early infant diagnosis.2 While the MTCT rate at early infant diagnosis was 
estimated to be 4.7% in the 21 priority countries, the transmission rate after cessation 
of breastfeeding was higher at 8.9%, and the difference was even larger for some 
countries.2 In three countries – Cameroon, Democratic Republic of Congo and 
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Ghana – the transmission rate at the end of breastfeeding is more than double that in 
the first eight weeks of life.2   
For South Africa the estimated transmission rate at early infant diagnosis is 
1.4% while that at the end of breastfeeding is 2%.2 Data from South Africa also 
indicate that while MTCT rates at early infant diagnosis have declined significantly, 
late postnatal transmission rates are higher than at early infant diagnosis.59 In the 
South African PMTCT evaluation study, the cumulative MTCT rate at 18 months in 
the national cohort was 4.3% compared with the 2.6% transmission rate in infants 
aged four to eight weeks.59 The South African data were not disaggregated according 
to infant feeding option, and the study was done during the transition period from 
Option A to Option B.59 Infant feeding practices are the major determinant of late 
postnatal transmission rates, and it is important to determine the contribution of 
breastfeeding to MTCT rates.   
 
1.1.10 Infant feeding practices  
 Safe infant feeding practices are an integral part of PMTCT, and an important 
part of postpartum care and follow-up. There are several challenges to promoting 
safe infant feeding practices, with low exclusive breastfeeding rates and mixed 
feeding the norm in most sub-Saharan countries, including South Africa.60 In 2010, 
WHO made a recommendation for a public health approach to infant feeding, with 
each country advised to promote and support one infant feeding practice for HIV-
infected women.61 Following the recommendation, South Africa in 2011 made a 
declaration to promote and support breastfeeding for HIV-infected women.17 Free 
infant formula which had been available for HIV-infected women who elected not to 
breastfeed was withdrawn following the declaration.17 The current South African 
PMTCT guidelines recommendation is for HIV-infected women to exclusively 
breastfeed for six months, with introduction of complementary food at six months and 
continued breastfeeding for 12 months.16 ART taken by the mother provides 
prophylaxis for the breastfed infant.  The South African guidelines are in line with the 
2010 WHO guidelines which stated that 12 months presented the best time for 
cessation of breastfeeding as the survival benefit associated with breastfeeding 
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decreases with age, especially after 12 months of life, while the risk of HIV 
transmission continues with ongoing breastfeeding.61          
Despite low quality of evidence based on observational studies, WHO in 2016 
updated its infant feeding guidelines in the context of HIV infection to recommend 
that breastfeeding may continue for up to 24 months or longer, with adherence 
support for lifelong ART for breastfeeding women.62 The WHO guideline goes on to 
say that “the recommendation is intended mainly for countries with high HIV 
prevalence and settings in which diarrhoea, pneumonia and undernutrition are 
common causes of infant and child mortality”.62 While acknowledging that 
“breastfeeding has less protective effect against serious morbidity and mortality in the 
second year of life than in the first 12 months”, breastfeeding has nutritional benefits 
for infants in food insecure countries.62 There is acknowledgement in the guideline 
that no comparative data exist on breastfeeding for 24 months, compared to 12 
months, in mothers on ART. Data are available from observational studies assessing 
HIV-free survival at 12 and 18 months, and the pooled estimates were marginally 
higher for infants whose mothers were receiving lifelong ART compared to those who 
stopped ART at six months postpartum.62 Not enough data were available for women 
on lifelong ART to be able to estimate HIV-free survival at 24 months.62     
There are several health system challenges with extending breastfeeding 
duration in HIV-exposed infants to 24 months – follow-up of the mother-infant pair for 
more than 24 months; provision of co-trimoxazole prophylaxis for 24 months as 
recommended for all HIV-exposed breastfed infants; ensuring maternal ART 
adherence and viral suppression throughout the period of breastfeeding; infant HIV 
retesting after cessation of breastfeeding; and initiation of ART in infants found to be 
HIV-infected. There are also concerns about extended infant exposure to 
antiretrovirals through breast milk, but available evidence suggests that extended 
exposure is not associated with an increased risk of adverse events.63   
 
1.1.11 Postpartum retention in care   
Postpartum retention in care of mother-infant pairs has been one of the major 
challenges in PMTCT programmes, and reports from Malawi, the first country to 
adopt Option B+, highlight high rates of lost-to-follow-up postpartum.64,65 Estimates 
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are that 25% to 50% of women on ART at delivery are lost to follow-up postpartum.66 
Similar factors identified as barriers to ART initiation and retention in care during 
pregnancy also contribute to postpartum loss to follow-up.67,68 While introduction of 
Option B+ has led to an increase in the number of HIV-infected pregnant women 
initiated on ART, and decrease in time-to-initiation, available data show high rates of 
attrition postpartum.64,65 In a review of the first three years of Malawi’s Option B+ 
programme, with analysis of facility- and patient-level data of almost 30 000 women, 
patients who were started on ART under Option B+ had higher rates of loss to follow-
up than women who were not pregnant and initiated ART because of a CD4 count 
<350 cells/µl, or WHO stage 3 or 4 disease.65 Loss to follow-up was highest in the 
first year of treatment. Poor adherence, defined as a cumulative medication 
adherence of less than 85%, younger age, and initiation of ART during breastfeeding 
were all associated with an increased risk of being lost from care.65   
In another study done in Malawi comparing service uptake and outcomes 
along the PMTCT cascade before and after the introduction of Option B+, 
significantly more pregnant women were enrolled in the PMTCT programme with 
Option B+ compared to before, 68% vs. 93%, p<0.001.64 There was however a 
higher rate of withdrawal from PMTCT services during the antenatal period with 
Option B+; 5% withdrew with Option B+ compared to 3% prior to the introduction of 
the programme, p=0.02.64 There was also a higher rate of loss to follow-up at six 
months after initiating ART under Option B+, 6% vs. 11%, p=0.02. While a proportion 
of the cases of loss-to-follow-up occurred in the postnatal period as a third of the 
women were started on ART in the third trimester, this is not specified in the paper. 
The rate of loss-to-follow-up was high despite the fact that the women were initiated 
on treatment within a programme that had facility- and community-based healthcare 
worker support for HIV-infected women during pregnancy and postpartum.64     
Results from a qualitative study on barriers and facilitators to uptake and 
adherence to ART in a Option B+ programme in Malawi show that various factors 
influence uptake of treatment and retention in care, and may be more salient in 
women initiating ART in the context of Option B+ than in other ART programmes.69 
The need for more time to decide on starting ART, including consulting with their 
partners, and feeling healthy were the main reasons pregnant and postpartum 
women gave for refusing to start ART.69 Among women who stopped taking ART, 
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lack of partner support and side effects were the main reasons women defaulted 
treatment, with side effects cited as the main reason by 50% of the women. 
Community health worker support, declining health and resolution of side effects led 
some women who had initially declined or defaulted treatment to start ART. While the 
study findings cannot be generalised to all settings because of the small sample size, 
as is the nature of qualitative studies, they provide insight and important lessons for 
interventions to improve retention in care, as Malawi has the longest experience with 
Option B+.  
Results from an implementation science study describing early experiences 
with Option B+ in 11 African countries, highlight the importance of counselling and 
support to increase acceptance of lifelong ART among pregnant women, and hence 
improve postpartum retention in care.70 Pregnant women felt overwhelmed by being 
told that they were HIV-infected and on the same day having to commit to lifelong 
treatment.70 There was also the issue of disclosure to partners and families they also 
had to deal with.70 While postpartum loss to follow-up is not new or unique to Option 
B+ programmes, expedited ART initiation and committing to lifelong treatment, 
especially among women who do not need treatment for their own health, appear to 
be the major barriers to retention in care.69,70     
Several interventions have been tried in an attempt to increase postpartum 
retention in care, but a recent systematic review on interventions to increase 
postpartum retention in care identified only four studies that were judged to be of high 
or moderate quality evidence.66 Of the interventions evaluated, only telephone-based 
interventions (calls and text messages), appear to improve retention in care in the 
first three months postpartum.66 The authors concluded that due to the small number 
and poor quality of the studies included in the systematic review, they could make no 
meaningful conclusions for policy implications.66 Factors that impact on postpartum 
retention in care are complex, and need multiple interventions throughout the 
continuum of care, starting in the antenatal period.66   
WHO recommends periodic retesting of HIV-uninfected women throughout the 
breastfeeding period, however there is no guidance on the retesting intervals.10 The 
South African guidelines are explicit in their recommendations with retesting 
recommended at the 6-weeks postnatal visit and every three months during 
breastfeeding.16    
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While great strides have been made towards eMTCT, primarily through scale-
up of efficacious antiretroviral regimens for HIV-infected pregnant women, there are 
many lessons to be learnt from programmatic experience in implementation of 
PMTCT programmes. This PhD makes an important contribution to the existing 
literature on PMTCT as it chronicles the evolution of one of the oldest and largest 
PMTCT programmes in South Africa, starting in the period when only single-dose 
nevirapine was available for PMTCT, to adoption of Option B+ in 2015. It provides 
information on performance of the Soweto PMTCT programme through evaluation of 
14 years of routinely collected data and original research conducted in the 
programme. The evaluation chronicles evolution of the PMTCT programme through 
various steps of the PMTCT cascade, from diagnosis of HIV infection in pregnancy 
through to postpartum infant testing. The original research highlights important 
patient-related risk factors for MTCT, and also infant feeding practices among HIV-
infected and HIV-uninfected women following changes in South African infant feeding 
guidelines.  
The second part of the background and literature review addresses the 
second goal of the Global Plan, that of decreasing HIV-related maternal deaths. In 
the next section I will provide an in-depth discussion of the maternal mortality trends 
in sub-Saharan Africa and also discuss causes of maternal deaths in HIV-infected 
women and what the impact of ART has been.     
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1.2 KEEPING MOTHERS ALIVE: TRENDS IN MATERNAL MORTALITY AMONG 
HIV-INFECTED WOMEN 
In 2015, approximately 830 women died every day from complications related 
to pregnancy and childbirth, and an estimated 10.7 million maternal deaths occurred 
globally from 1990 to 2015.71,72 Maternal mortality is a health indicator that highlights 
the disparities in access to health, with two-thirds of global maternal deaths occurring 
in sub-Saharan Africa alone.71 Maternal deaths are a public health concern and 
reducing maternal mortality remains a global priority.  
This section of the literature review will discuss classification of, and trends in 
maternal mortality, globally and in South Africa. There will also be an in-depth 
discussion of maternal mortality in HIV-infected women, including causes of death 
and the role of ART.    
 
1.2.1 Definition and classification of maternal deaths 
The WHO classification of maternal deaths is the most widely used 
classification system, and it allows for standardisation in reporting of maternal 
mortality.73 A maternal death is defined as ‘the death of a woman while pregnant or 
within 42 days of termination of pregnancy, irrespective of the duration and site of the 
pregnancy, from any cause related to, or aggravated by the pregnancy or its 
management, but not from accidental or incidental causes’.73 Deaths that occur more 
than 42 days, but less than one year after termination of pregnancy are defined as 
late maternal deaths. Maternal deaths may be either direct or indirect, and direct 
maternal deaths are those resulting from obstetric complications, and may occur 
either antenatally, intrapartum, or postpartum. Direct maternal deaths include 
complications related to hypertensive disorders, obstetric haemorrhage, pregnancy-
related infections, early pregnancy losses (abortion, miscarriages and ectopic 
pregnancies) and other obstetric complications. Indirect maternal deaths refer to 
deaths due to non-pregnancy related diseases that are either pre-existing or develop 
during pregnancy, and are aggravated by the physiologic effects of pregnancy. 
Complications due to diseases and conditions related to the various organ systems 
that lead to death, including infections and neoplasms that are not a direct result of 
pregnancy, are classified as causes of indirect maternal deaths. Incidental causes of 
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death, which are not classified as maternal deaths, are due to external causes such 
as accidents and assault.73        
The classification of maternal deaths in HIV-infected women is more complex. 
According to the WHO classification, direct maternal deaths in HIV-infected women 
are those that are due to obstetric causes, similar to HIV-uninfected women.73 AIDS-
related indirect maternal deaths are defined as deaths in HIV-infected women that 
are ‘the result of the aggravating effect of pregnancy on HIV’ infection, and include 
infectious and non-infectious causes of death. Deaths that are due to fatal 
complications of HIV/AIDS are however classified as HIV-related deaths and are not 
considered maternal deaths as the causes are considered incidental. Conditions 
listed under this category include HIV wasting syndrome, infectious and parasitic 
diseases and malignant neoplasms due to HIV/AIDS. In the WHO ICD-10 
classification, these are termed ‘HIV-related deaths to women during pregnancy, 
delivery or puerperium’.73   
While the ICD-10 list of non-obstetric causes of indirect maternal deaths is the 
same for HIV-infected and –uninfected women, the terminology on the aggravating 
effect of pregnancy on HIV infection can be confusing and lead to 
misclassifications.74,75 It is difficult to determine the aggravating effect of pregnancy 
on HIV infection and its complications, and there have been several debates on 
whether pregnancy is associated with HIV disease progression, especially with 
increased availability of ART.74,75 The debate on pregnancy and HIV disease 
progression will be discussed further in the section on mortality in HIV-infected 
pregnant and postpartum women.  
Given the complexities in classification of maternal deaths in HIV-infected 
women, Rosen et al and Calvert et al have suggested that the focus be on 
pregnancy-related HIV deaths, which would include all deaths in HIV-infected women 
during pregnancy, or within 42 days of termination of pregnancy, irrespective of the 
cause.73–75 Using the classification of pregnancy-related HIV deaths will include direct 
obstetric deaths, indirect maternal deaths and also deaths from HIV disease that 
were incidental to the pregnancy.74,75 The rationale for using the classification of 
pregnancy-related HIV deaths is that no distinction needs to be made on whether 
HIV infection was a cause of an indirect maternal death aggravated by the 
39 
 
pregnancy, or whether it was incidental to the pregnancy, what the ICD-10 
classification terms HIV-related deaths.74,75   
In the following section of the literature review, the classification systems used 
in the various publications for global, regional and country estimates and the 
contribution of HIV infection to maternal mortality will be discussed. Global and 
regional trends in maternal mortality, with a focus on sub-Saharan Africa, will be 
discussed first, followed by a discussion on maternal mortality trends in South Africa.  
 
1.2.2 Global trends in maternal mortality 
 In 2000, at the United Nations Millennium Summit, the Millennium 
Development Goal 5 (MDG 5) target was set to reduce the global maternal mortality 
ratio (MMR) by 75% from 1990 to 2015, and also to achieve universal access to 
reproductive healthcare.76 While the intentions were good in focusing global attention 
on the burden of maternal mortality and setting a target with a deadline, MDG 5 came 
under much criticism.77 The criticism centred on the MMR as a target for improving 
maternal health given the poor quality of data, and in many instances the complete 
lack of data, in the countries with the highest rates of maternal mortality.77 Questions 
were raised on how progress could be assessed when the baseline data on which 
progress would be measured were inaccurate.77 The original MDG 5 goal was also 
seen as reductionist, focusing on just one figure and ignoring all the complexities and 
drivers of maternal mortality.78 A secondary target of universal access to reproductive 
healthcare was later added in 2007, but the focus was again on numbers.78 Despite 
the shortcomings, MDG 5 targets were used worldwide up to 2015 to assess 
progress made in improving maternal health.             
Estimates of global trends in maternal mortality for the 25-year period, 1990 to 
2015, come from two sources, the United Nations Maternal Mortality Estimation Inter-
Agency Group (UN MMEIG) and the Institute of Health Metrics and Evaluation 
(IHME). The IHME data on maternal mortality estimates are published as part of the 
Global Burden of Disease Studies. The IHME is a multinational consortium that 
collects and analyses data on more than 300 diseases and injuries in 195 
countries.79 There have been debates about the differences in the UN MMEIG and 
IHME estimates for maternal mortality and how to interpret these differences in 
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monitoring trends.80,81 The differences in estimates are due to several factors and 
include different data sources used, differing methodologies used in processing the 
data, and also different modelling estimates used for incomplete maternal mortality 
data.80,82 Taking into account concerns raised about the varying estimates, and their 
value in monitoring maternal mortality trends, there has been a concerted effort by 
the UN MMEIG and the IHME to include country-level data in calculating the 
estimates.71,82 Reports from the UN MMEIG and the IHME will be discussed in turn to 
assess progress made in decreasing maternal mortality, and the merits of each will 
be discussed.  
The 2015 UN MMEIG estimates for 183 countries, for the 25-year period from 
1990, report a 44% decline in the global MMR.71 The decline is from an estimated 
385 maternal deaths per 100 000 live births in 1990 to 216 per 100 000 live births in 
2015, falling short of the MDG 5 target of a 75% reduction in the global MMR.71 For 
sub-Saharan Africa, which accounted for approximately 66% of the global maternal 
deaths in 2015, the decrease in MMR was 45%, from 987 in 1990 to 546 maternal 
deaths per 100 000 live births in 2015.71,82 Globally the UN MMEIG report estimates 
that nine countries globally achieved the target of decreasing their MMR by at least 
75%.71 The nine countries are Rwanda (the only country from sub-Saharan Africa), 
Maldives, Bhutan, Cambodia, Cabo Verde, the Islamic Republic of Iran, Timor-Leste, 
the Lao People’s Democratic Republic and Mongolia.71   
Results from the IHME, the other source of reports on trends in maternal 
mortality, suggest a lesser decrease in the global MMR.82 The reports are based on 
data from 195 countries and include late maternal deaths, up to 1 year 
postpartum.82,83 Reports from the IHME are published as Global Burden of Disease 
Studies. According to the Global Burden of Disease Study 2015, the global MMR 
decreased by 30% from 1990 to 2015, from a MMR of 282 in 1990 to 196 maternal 
deaths per 100 000 live births in 2015, reflecting lower estimates for the baseline and 
the 2015 MMR than the UN MMEIG figures.82 Estimates of the MMR in sub-Saharan 
Africa are also lower than those reported by the UN MMEIG, with the decrease in 
MMR for sub-Saharan Africa estimated to be from 495 in 1990 to 375 maternal 
deaths per 100 000 live births in 2015, with none of the countries achieving the MDG 
5 target.71,82 The authors of the Global Burden of Disease Study 2015 identified 
various strategies that could drive success in decreasing maternal mortality. These 
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are: addressing inequities in access to care; improving the quality of sexual, 
reproductive and maternal healthcare; strengthening of emergency obstetric care; 
increasing literacy rates among women and girls; and also conducting maternal 
death and near-miss audits.82   
In assessing the drivers of decreasing maternal mortality, the Global Burden of 
Disease Study 2015 used the sociodemographic index, a composite of income per 
capita, level of education and total fertility rate.82 While the sociodemographic index 
improved in all global regions from 1990 to 2015, trends in the MMR did not reflect 
improvements in the index universally, in any of the regions.82 In terms of 
reproductive healthcare, the study assessed coverage of the following interventions: 
one antenatal visit, four antenatal visits, delivery in a healthcare facility and 
availability of skilled birth attendants, and found that countries with the lowest MMR 
had more than 90% coverage of all four interventions.82   
The IHME report, published as the Global Burden of Disease Study 2015, 
appears robust as it is based on 599 data sources compared to 203 used for the UN 
MMEIG report, but the authors acknowledge that it also has limitations.82 No directly 
observed 2015 maternal mortality data were included in the final report, and all the 
2015 results were modelled on historical data.82 While the UN MMEIG and the IHME 
reports give different figures for the MMR estimates, they are in agreement that there 
has been a decrease in maternal deaths, albeit lower than the MDG 5 target.   
In addition to the MMR being the key indicator for monitoring progress in 
achieving the MDG 5 target, other indicators include key strategies for reducing 
maternal morbidity and mortality.84  These include the proportion of births attended by 
skilled healthcare workers, antenatal care coverage and addressing the unmet need 
for contraception.84 While globally there has been an increase in the proportion of 
births delivered with skilled attendance, from 59% in 1990 to 71% in 2014, the 
improvements in sub-Saharan Africa have been modest.85 For 2014, the MDG 2015 
report estimates that only 52% of births in sub-Saharan Africa were attended by a 
skilled birth attendant.85 In the same year, only 49% of pregnant women in sub-
Saharan Africa received the recommended four antenatal visits.85 There also remains 
a huge unmet need for contraception with only 28% of women in sub-Saharan Africa 
receiving contraception, and this reflects only married women and women in 
unions.85   
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With the deadline for MDG targets having ended in 2015, the Sustainable 
Development Goals (SDGs) came into effect in January 2016.86 The SDGs build on 
the successes of the MDGs, and targets have been set for the next 15 years.86 
Maternal mortality is addressed in SDG 3 and the target is to reduce the global MMR 
to less than 70 per 100 000 live births by 2030, with no country having more than 
double the global average.86,87 While the setting of a threshold for MMR, instead of a 
percentage decrease as was set out in MDG 5, has been welcomed, commentaries 
on the SDGs have given criticisms that health does not play a central role in the new 
goals.88,89 The criticism is that only one, SDG 3, of the 17 SDG goals addresses 
health, compared to the three health-related goals that were part of the eight MDG 
goals.88,89 Also, the agenda set out for health is too broad with the goal for SDG 3 
being ‘to ensure healthy lives and promote wellbeing for all at all ages’, and that this 
may result in less focused attention on the challenges prioritised in the MDGs.88 
Besides the MMR target, the only other target within SDG 3 that addresses maternal 
mortality directly is that of ensuring universal access to sexual and reproductive 
health by 2030, and this is not a new target as it was part of MDG 5.86    
As the global community works towards decreasing maternal mortality, the 
focus within countries and programmes needs to shift from chasing targets, to 
understanding the causes and drivers of maternal deaths.   
 
1.2.3 Causes of maternal deaths 
 The majority of maternal deaths are preventable, with the antenatal and 
peripartum healthcare interventions to prevent the deaths being well known.82,85 The 
key interventions are for all pregnant women to access antenatal care, with a 
minimum of four antenatal visits, and to have a skilled birth attendant at the time of 
delivery.85 Accessing antenatal care allows for timely identification and management 
of pre-existing conditions and their complications, and also identification of conditions 
that may arise for the first time during pregnancy. Having a skilled birth attendant 
decreases the risk of peripartum complications. Much of the information on causes of 
maternal deaths is based on modelled estimates due to the paucity of maternal 
mortality data, especially in low-resource settings where the majority of maternal 
deaths occur. According to the Global Burden of Disease Study 2015, 86% of all 
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global maternal deaths in 2015 were due to direct obstetric causes, with obstetric 
haemorrhage and hypertensive disorders of pregnancy the leading causes of 
maternal deaths.82 This proportion did not change compared to 1990, where 87% of 
all maternal deaths were attributed to direct obstetric causes.82 Regarding the role of 
HIV infection, estimates from the Global Burden of Disease Study 2015 are that HIV-
related indirect maternal deaths accounted for 0.84% of global maternal deaths, and 
1.6% of maternal deaths in sub-Saharan Africa, in 2015.82 In their modelling 
estimates, the Global Burden of Disease Study group disentangle the HIV-related 
indirect maternal deaths from the incidental HIV-related deaths as defined in the 
WHO ICD-10 classification.83 The authors of the 2015 Study state that a large 
number of HIV-infected women are dying incidentally during pregnancy or after 
delivery, and in the modelling of maternal deaths, they estimated the population 
attributable fraction of maternal mortality to HIV infection.82 In the modelling 
estimates for sub-Saharan Africa, there were 133 043 maternal deaths in 2015, and 
2 181 (1.6%) HIV-related maternal deaths.82 If incidental HIV-related deaths during 
pregnancy and postpartum are added to the HIV-related maternal deaths, the figure 
is much higher with an estimated 20 180 (15.2%) HIV-infected women in sub-
Saharan Africa dying during pregnancy or postpartum.82   
The UN MMEIG estimate for 2015 of 2% for HIV/AIDS-related indirect 
maternal deaths in sub-Saharan Africa is similar to the Global Burden of Disease 
Study 2015 estimate of 1.6%.71 No estimates of incidental HIV-related deaths are 
given in the UN MMEIG report. In countries with high HIV prevalence, the 
contribution of HIV-related indirect maternal deaths is higher, and South Africa is 
estimated to have had the highest proportion of maternal deaths due to indirect, HIV- 
related causes in 2015, at 32%.71 A detailed discussion of maternal mortality in South 
Africa is given below, in Section 1.2.4.       
The 2014 WHO systematic analysis on global causes of maternal deaths is 
another, but less comprehensive, source of data on leading causes of maternal 
mortality.90 The report is an analysis of maternal deaths from 2003 to 2009, and 
includes data from 115 countries. Sources used include vital registration data, 
studies published between 2003 and 2012, confidential enquiries, maternal mortality 
surveys and verbal autopsy data. The authors acknowledge that the datasets used in 
the report represent only 2.5% of global maternal deaths in the 7-year period.90 For 
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the large number of countries without any information on causes of maternal deaths, 
the authors used modelled estimates. According to the analysis, almost three-
quarters (73%) of global maternal deaths were due to direct obstetric causes, with 
obstetric haemorrhage the leading direct cause of maternal mortality, similar to the 
finding from the Global Burden of Disease Study 2015 report. Other leading direct 
causes of maternal mortality were complications related to hypertensive disorders, 
sepsis and unsafe abortions. Indirect causes were responsible for 27% of global 
maternal deaths, with 70% of these deaths from pre-existing disorders, including HIV 
infection. The pattern was the same for sub-Saharan Africa, with 28.6% of maternal 
deaths due to indirect causes, and 6.4% estimated to be HIV-related indirect 
maternal deaths.90 This figure is higher than that reported in the UN MMEIG report 
and the Global Burden of Disease Study 2015, and may be a result of the different 
time period that the WHO systematic analysis reports on, as well as different data 
sources and modelling estimates used.  
Despite the limitations of the data sources and modelling methods used in the 
different reports, direct maternal deaths dominate mortality worldwide, with obstetric 
haemorrhage and hypertensive disorders of pregnancy the leading causes. The three 
reports quoted above identified HIV infection as an important cause of indirect 
maternal deaths, especially in high HIV prevalence settings. All the reports have 
limitations as they are largely based on estimates because of lack of routinely 
collected maternal mortality data. As the global community works towards the SDG 3 
target of decreasing the global MMR to less than 70 per 100 000 live births by 2030, 
there is a need for routine collection of good quality maternal mortality data to 
facilitate implementation of targeted interventions and monitor progress.91,92 South 
Africa is one of the few countries in sub-Saharan Africa that has a functioning audit 
system for maternal deaths, and has tracked the causes of maternal deaths from 
early in the HIV epidemic.    
 
1.2.4 Maternal mortality trends in South Africa  
In 1997, the South African Department of Health established the National 
Committee on Confidential Enquiries into Maternal Deaths (NCCEMD). The 
committee is comprised of healthcare professionals experienced in obstetrics, 
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midwifery and anaesthetics, with representatives from all nine provinces in South 
Africa.93 The mandate of the committee is to recommend interventions to decrease 
maternal mortality, based on the analysis of maternal deaths. The committee 
releases annual interim reports on maternal deaths in South Africa, and publishes 
comprehensive reports on national trends in maternal mortality every three years. 
The enquiries into maternal deaths are facility-based, and hence report only on 
maternal deaths that occur in hospitals and community health centres. Provincial and 
national live births provide the denominator for reporting institutional maternal 
mortality ratios (iMMRs).93 While the enquiries do not report on maternal deaths that 
occur in the community, Moodley et al, writing on behalf of the NCCEMD, report that 
91% of pregnant women in South Africa give birth in a healthcare facility, hence the 
enquiry most likely covers the majority of maternal deaths in the country.93 According 
to the NCCEMD reports, few maternal deaths occur at home and these are reported 
in a ‘non-systematic and unstructured way’.94   
According to the UN MMEIG estimates, South Africa made no progress 
towards achieving the MDG5 target of decreasing the MMR, and actually saw an 
increase in the MMR, largely due to the HIV epidemic.71 The HIV prevalence among 
pregnant women in South Africa increased from less than 1% in 1990 to a peak of 
30.2% in 2005, and has plateaued at around 30% since 2006.95 The UN MMEIG 
estimate for the MMR, for South Africa in 1990 is 108 per 100 000 live births, while 
that for 2015 is 138 per 100 000 live births.71 In the Global Burden of Disease Study 
2015, the MMR estimates for South Africa are 154 and 158 per 100 000 live births for 
1990 and 2015 respectively.82 The NCCEMD figures on iMMR trends are only 
available from 2005, therefore   comparisons with other estimates of maternal 
mortality in South Africa can only be made from then.93   
There are several challenges with getting accurate estimates of the MMR 
trends in South Africa, with a reliance on local measurements and international 
modelling estimates, many of them point estimates.81,96 The baseline MMR figure 
used to assess trends in maternal mortality in South Africa is that of 150 per 100 000 
live births, and is based on data from the 1998 South Africa Demographic and Health 
Survey (DHS).96,97 According to the 2015 South African MDG report, ‘the last reliable 
survey-based estimate of maternal mortality in South Africa was made in the 1998 
DHS’.26 The 1998 Survey MMR estimate is for the period 1992 to 1998 and is based 
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on ‘reported survivorship of sisters’, the validated sisterhood method.98 Respondents 
in the survey who reported that their sisters had died were asked questions to 
determine whether the deaths could be classified as maternal deaths.97 The 
questions included whether the deaths occurred during pregnancy, delivery, or within 
two months postpartum or termination of a pregnancy, and whether the deaths were 
due to complications of pregnancy or childbirth.97 This method of obtaining maternal 
mortality data has its limitations in that it depends on accuracy of recall of information 
by relatives, and may be inaccurate, especially if the deaths occurred several years 
before the survey.      
Other sources for MMR estimates for South Africa include vital registration 
data analysed by Statistics South Africa, and the 2012 Rapid Mortality Surveillance 
report.26 MMR estimates from vital registration data are from 2002, hence the 1998 
DHS estimates from 1992 are closest to the MDG baseline year of 1990.26,97 Based 
on these data sources, the MMR in South Africa increased from a baseline of 150 per 
100 000 live births to a peak of 311 per 100 000 live births in 2009.26 From 2010, the 
MMR estimates show a progressive decline with the MMR estimated for 2013 at 141 
per 100 000 live births, which is the most recent available MMR estimate.26  
Figures from the NCCEMD reports, on facility-based maternal deaths, also 
show a peak in the iMMR in 2009 at 189 per 100 000 live births, a much lower figure 
than that of 311 per 100 000 live births reported from vital registration data.85,94 
Modelling estimates for the South African MMR are generally higher than those from 
the NCCEMD reports, which underestimate the MMR because they do not include 
maternal deaths that occur in the community, especially postpartum.99 As an 
illustration, the South African Health Data Advisory and Coordinating Committee 
(HDACC) used the 2008 MMR estimate from vital registration data, and adjusted it 
for incompleteness of adult death registration data and classification of causes of 
death.99 The figure after adjustment was also scaled up by 50% to account for under-
notification of maternal deaths, as suggested by international modelling groups.99 
The modelled estimate for MMR for 2008 was then reported as 310 per 100 000 live 
births, compared to the MMR of 167 per 100 000 estimated from the vital registration 
data and the NCCEMD report for 2008.99 It is difficult to determine whether the 
modelled estimates are a more accurate estimation of the MMR in South Africa than 
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the figures reported in the NCCEMD, as many assumptions are made in the 
modelling process.    
In their analysis of different data sources used to estimate the MMR for South 
Africa, Dorrington and Bradshaw (2016) highlight the challenges with getting an 
accurate estimate of maternal mortality figures, even in South Africa, which has a 
functioning maternal death auditing system and where 94% adult deaths are said to 
be registered.81,100 Figure 1.3 illustrates the different estimates for South Africa for 
the period 2000 to 2013.81 While the NCCEMD reports provide trends in iMMR, it 
may be an underestimation of maternal deaths especially deaths occurring early in 
pregnancy and also late maternal deaths beyond the first six weeks postpartum. The 
deaths may be occurring at home, or may be occurring in hospitals, but outside 
obstetric units.93   
 
 
Figure 1.3: Estimates of the maternal mortality ratio for South Africa from several 
data sources, 2000 to 2013. Source: Dorrington and Bradshaw (2016) 81   
 
It is accepted that the NCCEMD reports, being facility based, are likely to 
underestimate the true MMR for South Africa. Yet, because of consistent data 
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collection and reporting methods, they remain the best source for monitoring trends 
in maternal mortality and also causes of maternal deaths in South Africa.26,96 
According to the latest triennial NCCEMD report published in 2014, there has been a 
decline in the iMMR from 176 in the triennium 2008-2010 to 154 per 100 000 live 
births in 2011-2013.94,101 The finding of a reduction in the MMR is supported by vital 
registration data.85 The 2015 South African MDG report estimated that the MMR, 
based on vital registration data, decreased from 270 per 100 000 live births in 2010 
to 141 per 100 000 live births in 2013.26 While the MMR in South Africa is clearly on a 
downward trend, the number of maternal deaths remains high. According to the 
NCCEMD report, 4 452 women died during pregnancy and the puerperium in South 
African healthcare facilities in 2011-2013.94 Similar to assessing global trends, it is 
important to understand the causes of maternal deaths in South Africa, to be able to 
implement interventions to decrease the deaths. 
 
1.2.5 Causes of maternal deaths in South Africa  
The leading causes of maternal deaths in South African health institutions 
have remained the same since the first published report for the triennium 1999-2001, 
with non-pregnancy related infections, the majority HIV-related, being the leading 
cause of maternal mortality – Figure 1.4.94,101–104 In the classification of indirect 
maternal deaths in HIV-infected women, in the triennial reports, no distinction is 
made on whether the deaths are aggravated by pregnancy or are incidental. All HIV-
related deaths in pregnant or postpartum women (not including direct maternal 
deaths in HIV infected women) are considered as indirect maternal deaths.  
Among the non-pregnancy related infections, TB and respiratory infections 
have been identified as the most common causes of death.94 The other leading 
causes of maternal deaths in South Africa are complications related to hypertensive 
disorders, obstetric haemorrhage, pregnancy-related sepsis and medical and surgical 
disorders, and together these five leading causes were responsible for 86% of 
maternal deaths in the period 2011-2013.94  
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                            % of all maternal deaths 
Figure 1.4: Leading causes of maternal deaths in South Africa, 1999-2013 94,101–104     
Source: Author’s own design 
 
The decrease in the iMMR in South Africa is due to a decrease in maternal 
deaths due to non-pregnancy related infections and complications of hypertensive 
disorders.94 The proportion of deaths due to non-pregnancy related infections peaked 
in 2005-2007 at 43.7% of all maternal deaths, with a subsequent steady decline to 
34.7% in 2011-2013 (Figure 1.4). Among the women who died from non-pregnancy 
related infections, 90% were HIV-infected.94 The authors of the 2014 report suggest 
that the decrease in deaths due to these infections is likely to be related to routine 
HIV testing during pregnancy, and expansion of the ART programme.94 Of the HIV-
infected women who died from non-pregnancy related infections in 2011-2013, 55% 
were on ART at the time of death, falling to 36% in the 2008-2010.94 No data are 
available in the 2014 NCCEMD report on what the unmet need for ART was. CD4 
counts were also not available for most cases, but 80% of HIV-infected women who 
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died of non-pregnancy related infections were classified as having AIDS on clinical 
assessment.94     
Similar to global reports, obstetric haemorrhage is one of the leading causes 
of maternal deaths in South Africa.94 The last decade has seen an increase in the 
number of maternal deaths due to obstetric haemorrhage, the majority related to 
caesarean section.105 According to the 2001-2013 NCCEMD, 71% of the obstetric 
haemorrhage-related deaths had avoidable factors.105 Obstetric haemorrhage-related 
maternal deaths, together with deaths due to non-pregnancy related infections and 
complications of hypertensive disorders were the three biggest contributors to 
preventable maternal deaths, accounting for 65% of avoidable deaths.94   
Factors identified as contributing to avoidable maternal deaths are: not 
adhering to standard protocols; sub-standard care related to poor clinical assessment 
and inappropriate response to abnormalities detected; delays in referral to higher 
levels of care; and also delays in patients accessing care, including presenting late 
for antenatal care.94 While maternal deaths due to non-pregnancy related infections 
are decreasing in South Africa, they remain an increasingly important cause of 
avoidable maternal deaths. Of all the maternal deaths due to non-pregnancy related 
infections in the triennium 2011-2013, 43.3% were considered avoidable.94 In 
assessment of medical management of the cases, there were many cases where 
there was failure to recognise the severity of the illness, with substandard care and 
failure to make a diagnosis.94 Some women with HIV-related complications were 
assessed as having a poor prognosis and management was not aggressive, despite 
the fact that HIV infection is no longer a terminal illness.94   
In South Africa and in other high HIV prevalence settings, it is important to 
understand the patterns of maternal mortality in HIV-infected women, and also to 
understand the role of ART in reducing HIV-related maternal mortality. 
 
1.2.6 Maternal mortality in HIV-infected women 
The HIV epidemic has had an enormous impact on maternal mortality in sub-
Saharan Africa, and the 2015 UN MMEIG estimates are that 85% of global HIV-
related maternal deaths occurred in sub-Saharan Africa.71 In 2015, there were five 
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countries where more than 10% of maternal deaths were estimated to be HIV-
related, with the highest figure in South Africa at 32.0%, a figure similar to the 34.7% 
reported in the 2011-2013 NCCEMD report.71,94 Other countries with a high 
percentage of HIV-related maternal deaths reported for 2015 are Swaziland (19%), 
Botswana (18%), Lesotho (13%) and Mozambique (11%).71 The 2016 UNAIDS report 
estimates that there has been a 43% decline in HIV-related deaths in women of 
reproductive age in the 21 priority countries in sub-Saharan Africa between 2009 and 
2015, and the decrease is said to be related to ART scale-up.2     
There are challenges in determining the impact of HIV infection on maternal 
mortality because of paucity of data, different data sources used to estimate number 
of deaths, and misclassification of causes of death in HIV-infected pregnant and 
postpartum women.92 Paucity of data and different data sources used has been 
discussed earlier. Blencowe et al argue that misclassification of causes of maternal 
deaths may be a result of difficulties with the definitions used for reporting, or may be 
deliberate for reasons related to blame or stigma, all important factors when 
determining HIV-related maternal deaths.92 With misclassification of causes of death, 
it is likely that the proportion of HIV-related maternal deaths may be 
underestimated.75,92   
In their systematic review and meta-analysis of studies from Africa, the United 
States, Europe, India, and South America, Calvert et al found a 7.74 risk ratio (95% 
CI: 5.37–11.16) of pregnancy-related deaths in HIV-infected compared to HIV-
uninfected women.75 They estimate that in regions where HIV prevalence among 
pregnant women is at least 15%, half of all deaths during pregnancy and up to 1 year 
postpartum are attributable to HIV infection.   
 
1.2.7 Mortality risk among HIV-infected women  
Despite the abovementioned challenges with data, several studies from sub-
Saharan Africa have consistently shown an excess risk of maternal mortality among 
HIV-infected women.106–113 In my literature search of studies on maternal deaths 
among HIV-infected women in the 21 priority countries in sub-Saharan Africa, I 
identified 25 publications from 1990, the baseline year for the MDGs, to 2016 where 
the primary outcome was maternal mortality in HIV-infected women – Table 1.3. Of 
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the 25 studies, six compared the risk of maternal mortality among HIV-infected 
women versus HIV-uninfected women, and the risk of mortality was increased from 
2- to 7-fold among HIV-infected women.106–110,112,113 Seventeen of the studies 
reported on maternal deaths up to 42 days postpartum, while five included late 
maternal deaths up to one year postpartum.106–127 Three studies also included deaths 
beyond the first year postpartum.128–130  
Twenty-four of the 25 studies were hospital-based or cohort studies within HIV 
programmes, and one study, done in Mozambique, was a secondary data analysis of 
two national cross-sectional surveys. Data from the national surveys in Mozambique, 
representing community-based data, can however not be used to assess trends in 
maternal deaths in HIV-infected women, as different categorizations for causes of 
death were used in the two time periods.123 This again highlights the point made 
already about the inconsistencies in classification of maternal deaths. Other 
community-based data are from a secondary analysis of pooled data from six studies 
in Eastern and Southern Africa by Zaba et al.131 The studies were designed for HIV 
surveillance, and data were collected on demographics and pregnancy reports, with 
analyses done to determine the contribution of HIV infection on mortality. The 
authors reported on pregnancy-related mortality during pregnancy and in the 42 days 
postpartum, and did not exclude deaths that were coincidental or incidental. Verbal-
autopsy reporting was used to determine circumstances surrounding the death, 
including information on whether the woman was pregnant or postpartum at the time 
of death, and whether she was known to be HIV-infected. Based on the analyses, the 
authors estimate that HIV-infected pregnant and postpartum women have an eight 
times higher risk of mortality than HIV-uninfected women. With this finding, the 
estimation is that in sub-Saharan Africa, about 24% of deaths in pregnant or 
postpartum women are attributable to HIV infection. The limitation of this study is that 
only half of the pregnant and postpartum women had a known HIV status, and that 
61% of the pregnancy-related deaths were determined on verbal autopsy reports 
alone.131   
While hospital-based, cohort and community-based studies all have limitations 
– the first two miss deaths that occur outside of healthcare facilities, while the later 
rely on verbal autopsy reports that may lead to misclassification of causes of death – 
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studies consistently show that there is higher risk of maternal mortality among HIV-
infected women.    
 
1.2.8 Causes of maternal mortality in HIV-infected women 
Infectious causes are said to be the predominant cause of death in HIV-
infected women in low-resource settings.132 In the 25 studies I identified through my 
literature search (Table 1.3), a significant proportion of women died with an unknown 
HIV status, and this proportion was higher in the earlier years when universal testing 
for pregnant and postpartum women was not standard. It is possible that there was 
an underestimation of indirect, HIV-related causes of maternal deaths.  
 
Indirect maternal deaths 
Fourteen of the 25 studies reported on the causes of maternal deaths and the 
leading causes of indirect death in HIV-infected women were non-pregnancy related 
infections, mainly TB, pulmonary and extrapulmonary, respiratory infections, and 
malaria.107,109–118,121,123,129 TB has long been recognised as one of the leading causes 
of indirect maternal deaths in high HIV prevalence settings, with a two to three times 
increased risk of dying in TB/HIV co-infected pregnant women than those with TB 
alone.107,114,133–135 Pregnant women have an increased incidence and risk of 
complications associated with respiratory infections, and these are related to 
immunologic and physiologic changes associated with pregnancy.136 These changes 
include alterations in cell-mediated immunity and decrease in functional residual 
capacity of the lung. HIV infection, which alters immune function, further increases 
the incidence and risk of complications from respiratory infections.136 With malaria, 
pregnant women have increased susceptibility to infection, and have also been 
shown to have a three times increased risk of severe infection compared to non-
pregnant women.137 Similar to respiratory infections, by altering immune function, HIV 
infection increases susceptibility to malaria during pregnancy.138 In summary, 
infectious causes of maternal deaths in HIV-infected women have an underlying 
factor of immune suppression associated with HIV infection. Hence it follows that the 
risk of mortality from infectious diseases will be higher in HIV-infected pregnant and 
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postpartum women with advanced immune suppression. As expected, several of the 
studies reviewed (Table 1.3) reported that in the HIV-infected women who died and 
were assessed for level of immune suppression, the majority had advanced disease, 
based on either a CD4 count of <200 cells/µL, or WHO stage 4 
disease.109,111,113,115,117–121,129,127 Anaemia has also been identified as an important 
underlying risk factor for maternal deaths in HIV-infected women.111,112,117,119,123,127 
The cause of the anaemia is multi-factorial and includes pregnancy itself, HIV 
infection, malaria and parasitic infections.  
In all but one of the 14 studies, the causes of death were determined from 
patient records. This has obvious limitations in terms of quality and completeness of 
clinical information. In the one autopsy study, Menendez et al reported on 139 cases 
of maternal deaths who had autopsies, and 123 were tested for HIV and 65/123 
(53%) were found to be HIV-infected.118 Out of the 139 autopsies, the cause of death 
could be determined in 131 women and 60% (78/131) of the deaths were due to 
indirect causes. Among the leading causes of indirect maternal deaths were 
HIV/AIDS-related diseases, respiratory infections and severe malaria, similar to 
findings from studies where the cause of death was determined from patient records. 
The authors used the Centre for Disease Control (CDC) criteria to define the 
HIV/AIDS-related diseases and these included opportunistic infections and other 
AIDS-defining conditions, including malignancies. There was no significant difference 
in the non-HIV related causes of indirect maternal deaths between HIV-infected and 
–uninfected women. This finding highlights the importance of indirect causes of 
maternal deaths even for HIV-uninfected women.  
 
Direct maternal deaths  
Similar to HIV-uninfected women, puerperal sepsis, complications of 
hypertensive disorders, and obstetric haemorrhage are the leading causes of direct 
maternal deaths in HIV-infected women.107,109,112,115,116,118,123 Data on whether HIV 
infection increases the risk of these obstetric complications are inconsistent, with the 
only consensus being on the increased risk of postpartum infectious morbidity with 
HIV infection.110,139–143 Studies on infectious morbidity with HIV infection are not 
limited to puerperal sepsis, but also include fever beyond 24 hours postpartum, 
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respiratory infections, peritonitis, generalised sepsis, and abdominal and vaginal 
wound infections.139–143   
The highest risk of postpartum infectious morbidity in HIV-infected women has 
been found after emergency caesarean sections, but the risk is also increased with 
elective (non-emergency) caesarean sections and vaginal deliveries in comparison 
with HIV-uninfected women.139–141,143 In a study on puerperal sepsis after caesarean 
section, done at a tertiary hospital in South Africa, the majority of women that were 
readmitted with sepsis were HIV-infected and all had had emergency caesarean 
sections.144 The numbers in the study were however small and the study was not 
powered to detect association between risk factors, including HIV infection, and 
puerperal sepsis. Livingston et al, in a study done in the United States and Puerto 
Rico with over 2 000 HIV-infected women, assessed complications associated with 
mode of delivery.141 They found that the highest rate of all postpartum morbidities – 
infectious, haemorrhagic, gastrointestinal and thromboembolic events – were in 
women who had emergency caesarean sections.      
While earlier studies, done before the widespread availability of ART, report a 
higher risk of infections and subsequent complications in women with advanced 
immune suppression, recent studies report that the rate of complications remains 
higher in HIV-infected women who have had caesarean sections despite ART 
use.141–143,145 In their study, which was done in the US and had a nationwide sample 
of over a million HIV-infected and –uninfected women, Kourtis et al found that the 
rate of infectious complications and hospitalization after caesarean section remained 
higher in HIV-infected women despite use of combination ART.143 In the study done 
in the United States and Puerto Rico discussed above, 89% of the women were on 
combination ART and 84% were virally suppressed.141 Hence available data suggest 
that even with widespread availability of ART, the incidence of postpartum infectious 
morbidity, largely related to caesarean deliveries, remains higher in HIV-infected 
women.  
Routine antibiotic prophylaxis is well established at caesarean section 
irrespective of HIV infection status. A Cochrane review of 95 studies comparing the 
use of prophylactic antibiotics at caesarean section vs placebo or no treatment found 
a 60% to 70% reduction in the incidence of wound infection, endometritis and serious 
infectious complications.146 With regard to prophylactic antibiotics at vaginal delivery, 
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a South African randomized controlled trial found no significant difference in overall 
sepsis rate in HIV-infected women who delivered vaginally and received a single, 
intrapartum dose of prophylactic antibiotics and those who did not.147 The majority of 
cases of infectious morbidity occurred in the first week postpartum, and there was no 
difference in the mean CD4 count in women who developed sepsis and those who 
did not.  
Data on the risk of complications of hypertensive disorders in pregnancy, one 
of the leading direct causes of maternal mortality in HIV-infected women, are 
inconsistent. The pathophysiology of hypertensive disorders in pregnancy is complex 
and is thought to have an immunologic basis, and it has been postulated that HIV 
infection and the use of ART may modify the risk of the disorders through the effect 
on immune function. Wimalasundera et al found that HIV-infected pregnant women 
on no antiretroviral therapy and those on zidovudine monotherapy, or zidovudine and 
lamivudine dual therapy, had a significantly lower incidence of preeclampsia 
compared to women on triple therapy, odds ratio 15.3 (95% CI 0·9–270), 
p=0.0087.148 The authors suggested that the immunosuppressive effect of untreated 
HIV infection decreases the risk of hypertensive disorders and their complications, 
and that with triple therapy use and immune reconstitution, the risk increases. 
Contrary to this suggestion, it has also been postulated that untreated HIV infection 
could increase the risk of hypertensive disorders of pregnancy due to inflammatory 
changes associated with HIV infection, and that ART use reverses these changes 
and thereby decreasing the risk. In their systematic review and meta-analysis, 
Browne et al found no clear association between hypertensive disorders in 
pregnancy and their complications, and HIV infection.149 There was also no 
difference found in studies done before and after widespread availability of ART. The 
authors considered that in the 28 studies they reviewed, there was a high risk of 
bias.149   
Studies done in South Africa also show inconsistent results.150–152 In a study 
done in South Africa, in the pre-ART era, Frank et al found no difference in the rate of 
pre-eclampsia and eclampsia among HIV-infected women compared to HIV-
uninfected women.150 No details were available on the level of immune suppression 
in the population as only 0.5% of the HIV-infected women had a known CD4 cell 
count. In another South African study, done when ART was widely available in public 
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health facilities, there was a significantly decreased incidence of gestational 
hypertension and preeclampsia among HIV-infected women compared to –
uninfected women, odds ratio 0.59 (95% CI: 0.42, 0.84), p=0.003.152 CD4 counts 
were known for 95% of the women, and there was no difference found in women with 
CD4 counts <350 cells/µl and those with CD4 counts ≥350 cells/µl. There was also 
no difference between women on triple therapy (ART) and those on zidovudine 
monotherapy. Contrary to these findings, Tooke et al, in another South African study, 
found a significant increase in the risk of early onset preeclampsia in women who 
had more than four weeks of antiretrovirals – triple therapy or zidovudine 
monotherapy.151 There was no association between CD4 count levels and the risk of 
preeclampsia. 
The available literature on the association between HIV infection and 
hypertensive disorders of pregnancy and their complications remain inconsistent. 
While hypertensive disorders remain one of the leading direct causes of maternal 
mortality in HIV-infected women, similar to HIV-uninfected women, no clear 
association is evident between the disorders and HIV infection. It is likely that, apart 
from bias related to study designs, the inconsistencies may relate to studying 
different populations with differing HIV and treatment exposures, and baseline risk 
factors for preeclampsia.   
Turning to obstetric haemorrhage as a cause of maternal deaths in HIV-
infected women, findings on the association between HIV infection and obstetric 
haemorrhage are also inconsistent.153–156 Among participants in a cluster-randomized 
controlled trial of a non-pneumatic anti-shock garment in Zambia, HIV-infected 
women who presented with hypovolaemic shock, secondary to obstetric 
haemorrhage, had increased odds of severe haemorrhage compared to HIV-
uninfected women, OR 1.92 (95% CI: 1.05, 3.50), p= 0.03.153 The study however has 
limitations as it was not designed to assess an association between HIV infection and 
obstetric haemorrhage.153 Despite this limitation, a prospective cohort study done in 
Uganda, on prevention of postpartum haemorrhage using misoprostol, found similar 
results to the Zambian study.154 In the Ugandan study involving 1 188 women, HIV 
infection was associated with almost double the odds of postpartum haemorrhage – 
aOR 1.93 (95 % CI: 1.06, 3.50), p=0.004.154 In both studies, there were no details on 
the level of immune suppression or whether the women were on ART. Contrary to 
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the findings from the Ghanaian and Ugandan studies, a cross-sectional study 
involving four referral hospitals in South Africa, with over 15 000 study participants, 
found no association between HIV infection and obstetric haemorrhage, OR 0.95 
(95% C: 0.72, 1.25).155 The study did however find that HIV-infected women were 
more likely to receive blood and blood products than HIV-uninfected women, aOR 
1.52 (95% CI, 1.14, 2.03). Half, 50.9%, of the HIV-infected women had CD4 counts 
<350 cells/µl and 81.2% were on ART.155 The authors suggest that the higher 
incidence of blood transfusion among HIV-infected women could be related to higher 
rates of untreated anaemia, making them less able to tolerate peripartum blood 
loss.155   
Hence available data on whether HIV infection increases the risk of 
hypertensive disorders of pregnancy and obstetric haemorrhage remain inconsistent. 
While the majority of studies on maternal mortality in HIV-infected women, in sub-
Saharan Africa, were done in the pre-ART era, the question is what impact has the 
widespread availability of ART had on maternal deaths in this group of women. 
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Table 1.3: Studies on HIV-related maternal mortality in the 21 Global Plan priority countries, 1999-2016 
Author and year 
 
Country  Methods  Key findings  
 
Key findings  Comments  
Ahmed et al.  
1999 114 
 
 
Zambia Retrospective record 
review of maternal deaths 
in a teaching hospital. 
 
Study period: 1996-1997 
 
 
251 maternal deaths:  
106 (42%) were due to 
direct obstetric causes 
145 (58%) were due to 
indirect causes. 
 
Malaria (30%), TB (25%) 
and ‘unspecified’ chronic 
respiratory tract illnesses 
(22%) were the top three 
causes of indirect deaths. 
 
Diagnosis of AIDS, based on 
clinical criteria, was 
associated with 92% of 
cases with TB, and 97% of 
cases with ‘unspecified’ 
chronic respiratory tract 
illnesses. 
 
Overall MMR 921. 
 
Hospital-based data. 
 
No details on the 
unspecified chronic 
respiratory illnesses. 
 
No details on what % were 
HIV+. Diagnosis of AIDS 
clinical.  
 
Pre-ART. 
 
 
 
Sewankambo et al. 
2000 106 
 
 
Uganda 
 
Prospective cohort to 
assess mortality impact of 
HIV in adults 15-59 years. 
Study period: 1994-1997. 
 
HIV-associated maternal 
mortality estimated in 
2997 women who were 
pregnant during the study 
period. 
Highest attributable 
risk of HIV-associated 
deaths were observed in 
persons aged 20-39 years 
and in women. 
 
7 maternal deaths in 415 
HIV-positive 
mothers; 
8 maternal deaths in 2582 
HIV-negative mothers 
MMR: 
HIV+ 1687  
HIV- 310  
RR: 5.44 (95% CI: 1.98, 
14.93) 
 
Population HIV prevalence 
16%. 
 
No details on cause of 
maternal deaths. Small 
number of maternal deaths 
overall. 
 
Data from community-
based studies.  
 
Pre-ART. 
 
HIV+ = HIV-infected; MMR=maternal mortality ratio, maternal deaths per 100 000 live births; OR=odds ration; CI=confidence interval   
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Author and year  
 
Country  Methods  Key findings  
 
Key findings  Comments  
Khan et al. 
2001 107 
 
 
South Africa  Retrospective and 
prospective study to 
determine impact of TB 
and HIV on maternal 
mortality at a tertiary 
hospital. 
 
Imputations from 
seroprevalence rates for 
those with unknown HIV 
status.   
Study period: 1996-1998  
101 maternal deaths 
Overall MMR 200 
 
40/101 tested for HIV 
30/40 (75%) HIV+ 
 
Calculated MMR (with 
imputations): 
HIV+ 323 
HIV- 149  
 
RR of death due to HIV 2.2  
Leading causes of maternal 
deaths: 
puerperal sepsis (34%); 
hypertensive disorders 
(25%); TB (15%) – 15 cases 
of TB – 14 HIV+ 
 
HIV+ - 43% of deaths due 
to direct obstetric causes 
HIV+ more likely to be 
anaemic and unbooked 
60% had an unknown HIV 
status at time of death. 
 
Included late maternal 
deaths up to 1 year 
postpartum. 
 
Pre-ART. 
Kruger et al.  
2003 115 
 
 
South Africa  Retrospective review of 
maternal deaths at a 
tertiary hospital. 
 
Study periods: 1995-1996 
(20 deaths) and 2000-2001 
(35 deaths). 
 
iMMR: 183 for 1995-1996; 
354 for 2000-2001. 
 
1995-1996: 4 (20%) HIV+, 
10 HIV unknown. Causes of 
death: hypertensive 
disorders (10); 
haemorrhage (4); 
pneumonia (1). 
 
2000-2001: 16 HIV+ 
(42.7%), 17 HIV unknown. 
Causes of death: 
pneumonia (13 – 10 cases 
in HIV+); hypertension (6); 
haemorrhage (5)  
2000-2001: 
HIV/AIDS-associated 
disease was the leading 
cause of mortality at 
42.7%.  
 
Pneumonia the leading 
cause of death. 5/13 cases 
had TB.  
 
11/16 had CD4 counts – 
median 34/µL. 
High number with 
unknown HIV status.  
 
According to the authors, 
no evidence in the records 
that HIV unknown died 
from HIV-related diseases. 
 
Pre-ART. 
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Author and year  
 
Country  Methods  Key findings  
 
Key findings  Comments  
Le Coeur et al.  
2005 108 
Congo  Prospective study on 
cause of death in women 
15-44 yrs. 
 
Post-mortem examination 
(HIV status and pregnancy), 
interview of relatives, and 
record reviews. 
 
Study period: 2001  
 
368 deaths analysed – 34 
maternal deaths, 7 (20%) 
HIV+.  
 
Antenatal HIV prevalence – 
6%. 
 
HIV prevalence among non-
pregnant women who died 
– 78%. 
MMR: 
1842 for HIV+ 
478 for HIV- 
RR: 3.9; 95% CI: 1.7, 8.8. 
 
Death rate lower in HIV+ 
pregnant vs. non-pregnant 
women, RR, 0.2; 95% CI: 
0.1, 0.5. 
 
Good birth and death 
registration system. 
 
‘Healthy pregnant woman 
effect’ – women in early 
stages of HIV infection 
likely to be pregnant. 
 
No details on causes of 
death, or level of immune 
suppression. 
Pre-ART. 
Mbizvo et al. 
2005 128 
 
 
Uganda and Zimbabwe  Prospective case-control 
study – antenatal to two 
years postpartum. 
 
Compared birth outcomes, 
hospital admissions and 
mortality in (400) HIV+ and 
(400) HIV- women. 
One death in the antenatal 
period in a HIV- woman.  
 
6/8 deaths in the 6 weeks 
postpartum in HIV+ 
women. 
 
6 weeks to 2 years after 
delivery: 51/53 deaths in 
HIV+ women. 
RR of death in HIV+ vs. 
HIV-: 
Uganda: RR = 17.7; 95% 
CI: 4.3, 73.2; 
 
Zimbabwe: RR = 10.0; 95% 
CI:2.3, 43.1 
Looked at deaths up to two 
years postpartum. 
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Author and year  
 
Country  Methods  Key findings  
 
Key findings  Comments  
Ramogale et al.  
2007 116 
 
 
South Africa  Retrospective review of 
maternal deaths at a 
tertiary hospital. 
 
Study period: 1998-2004 
  
378 maternal deaths 
HIV+: 146 
HIV-: 50 
HIV unknown: 182 
 
Leading causes of death in 
HIV+: 
WHO stage 4 disease 
(21%); pneumonia (20%); 
pregnancy-related sepsis 
(19%); pulmonary TB (15%) 
 
Peak HIV-associated MMR 
in 2003 at 553, 164 in 1998 
 
Causes of death in HIV- 
women: 
Pregnancy-related sepsis 
(32%); hypertension (22%)  
 
No maternal deaths in HIV- 
women related to 
pneumonia or pulmonary 
TB. 
 
 
48% of maternal deaths 
with an unknown HIV 
status – more than 50% 
died of pregnancy-related 
sepsis.  
 
Pre-ART.  
 
 
Chilongozi et al. 
2008 117 
 
Malawi, Tanzania, and 
Zambia   
Part of an antibiotic trial to 
decrease chorioamnionitis-
related MTCT (HIVNET 
024). 
  
Study period: 2001-2003 
2292 HIV+ and 367 HIV- 
women enrolled in the 2nd 
trimester until 1 year 
postpartum.   
42 maternal deaths, all in 
HIV+ women – 7 antenatal 
and 35 postpartum. 
 
Anaemia, sepsis, TB and 
malaria leading (53%) 
causes of deaths. 
Other significant causes: 
pneumonia, meningitis, 
AIDS-related complex and 
Kaposi’s. 
CD4 <200 and VL ≥50 000 
associated with an 
increased risk of mortality. 
Pre-ART.  
 
Postpartum deaths not 
divided into early and late. 
 
No maternal deaths in HIV- 
women. 
 
Anaemia – role of malaria, 
intestinal parasites and 
HIV. 
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Author and year 
 
Country  Methods  Key findings  
 
Key findings  Comments  
Menendez et al. 
2008 118 
Mozambique   Prospective study at a 
tertiary hospital. 
 
Study period: 2002-2004 
 
179 maternal deaths   
MMR 847 
 
139 had autopsies and 
formed the basis of the 
analysis. 
123/139 had an HIV test, 
and 65 (53%) were HIV+ 
 
131/139 cause of death 
known: 
53 (40%) due to obstetric 
complications with 
haemorrhage the 
commonest cause of 
death. 
 
 
78 (60%) due to non-
obstetric causes – 
HIV/AIDS-related 
complications the 
commonest cause. 
67/78 died of infectious 
diseases. 
 
Pneumonia, meningitis and 
severe malaria leading 
indirect causes of maternal 
deaths in HIV+ women.  
 
Strength – autopsy 
diagnosis of cause of 
death. 
 
Pre-ART. 
Black et al. 
2009 109 
 
South Africa  Record review of maternal 
deaths at a tertiary 
hospital. 
Study period: 2003-2007 
 
106 maternal deaths  
HIV+: 59 
HIV-: 17 
HIV unknown: 30  
 
 
70% of deaths in HIV+ 
women considered to be 
HIV-related 
 
Leading causes of death in 
HIV+: TB 36%; pneumonia 
20% 
 
MMR: 
HIV+: 776 
HIV-: 124 
HIV unknown: 195 
MMR in HIV+ 6.2-fold 
higher (95% CI 3.6 –11.4) 
than in 
HIV- 
 
Leading causes of death in 
HIV- and HIV unknown: 
Hypertension – 34% 
Pregnancy-related sepsis: 
15% 
Cardiac disease: 17% 
 
 
28% had an unknown HIV 
status.  
 
Only 2/59 on ART despite 
availability for 4 years 
during the study period 
 
53/59 HIV+ had a CD4 
count; median 72 µ/L 
(IQR: 29, 194) 
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Author and year 
 
Country  Methods  Key findings  
 
Key findings  Comments  
Marazzi et al. 
2011 119 
 
Mozambique and Malawi Retrospective 
observational cohort study 
– mother–infant pairs 
enrolled in a public health 
PMTCT programme. 
3273 pregnant women 
 
Study period: 2005-2009 
 
MMR was 10-fold lower in 
women with >90 days of 
antenatal ART, compared 
with no ART prior to 
delivery, p<0.001. 
 
Decrease in MMR directly 
proportional to duration of 
ART and present at all CD4 
count levels. 
Survival benefit of ART 
seen even at CD4 >350 µ/L. 
 
Independent association 
between baseline CD4, 
anaemia, BMI, and pre-
delivery length of maternal 
ART with maternal 
mortality. 
 
No details on the causes of 
maternal deaths. 
 
No adherence data. 
 
 
van den Akker et al. 
2011 110 
 
Malawi 
 
Facility-based prospective 
cohort study. 
Assessed association 
between mortality 
and non-obstetric 
infection, HIV prevalence, 
and ART uptake. 
 
Study period: 2007-2009 
  
23 infection-related 
maternal deaths, 15/23 
(65%) non-obstetric; 
classified as indirect. 
15 of the 23 maternal 
deaths were HIV+. 
 
Pneumonia the most 
common non-obstetric 
infection. All TB cases in 
HIV+. 
 
HIV+ 3X likely to die 
compared to HIV-.  
OR 3.1, 95% CI: 1.1, 9.2; 
p=0.03 
 
Independent association 
between mortality and 
HIV+ and  
not on ART – aOR 3.0, 95% 
CI: 1.1, 8.6  
HIV+ on ART aOR 0.5 95% 
CI: 0.1, 2.7 
ART introduced in 2003 – 
approx. 80% coverage in 
2007. 
Eligibility then: CD4 <200 
µ/L, WHO stage 3 or 4 
disease  
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Author and year   
 
Publication date 
Country  
Methods  Key findings  
 
Key findings  Comments  
Liotta et al. 
2013 120 
 
Malawi and Mozambique  Retrospective 
observational cohort in 
established PMTCT 
programmes. 
 
Median CD4 count at 
baseline 392 µ/L 
 
Study period: 2002 -2010 
101 maternal deaths – 87 
in women initiating ART 
for PMTCT, 14 in women 
initiated on ART pre-
pregnancy 
 
Higher risk of death with 
shorter duration of 
antenatal ART (<30 days 
OR =2.6 (CI: 1.6, 4.2) 
p<0.001), and baseline CD4 
counts <350 µ/L, OR: 1.9 
(CI: 1.3, 2.9) p= 0.001  
Long-term mortality – 43 
days to 4 years postpartum 
– 2-fold higher with <30 
days of antenatal ART 
compared to ≥90 days, 
p<0.0001. 
 
Shorter duration of 
antenatal ART; baseline 
CD4; Hb and BMI 
associated with long-term 
mortality.  
 
Pre-pregnancy ART – 
mortality not increased 
despite low CD4 counts 
 
No details on causes of 
deaths. 
 
Long-term deaths 
determined from home 
visits. 
High rate of LTFU – 56 
women who died in within 
42 days postpartum were 
LTFU. 
Matthews et al. 
2013 125 
 
Uganda  
 
Assessed pregnancy-
related mortality (up to 1 
year postpartum) in a 
cohort of women initiating 
ART. 
 
Study period: 2005-2011 
 
109 self-reported 
pregnancies out of 354 
women. 
 
 
4 pregnant at ART 
initiation. 
 
5 pregnancy-related 
deaths – 1 during 
pregnancy and 4 
postpartum. 
 
Death determined through 
interviews with relatives 
and review of clinic 
records.     
Cause of death unknown in 
3 cases. 
 
1 had pulmonary TB. 
 
1 probably died from 
cryptococcal meningitis. 
Very small number of 
deaths to make any 
conclusions on pregnancy-
related deaths in the 1st 
year of ART. 
 
Definitive cause of death 
unknown in 4/5 cases. 
 
Pregnancy self-reported. 
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Author and year 
 
Country  Methods  Key findings  
 
Key findings  Comments  
Ngene et al.  
2013 126  
 
South Africa   Prospective study. 
Maternal and fetal 
outcomes of HIV+ and HIV- 
women admitted in ICU 
during pregnancy or up to 
42 days postpartum. 
Followed up to 7 days post 
ICU discharge or discharge 
from hospital.  
Study period: 2010-2011 
84 admissions: 31 (37%) 
HIV+; 42 (50%) HIV-; 11 
(13%) HIV unknown 
 
HIV+: 8 (26%) on ART; 
 
25% with CD4 ≤200 µ/L on 
co-trimoxazole  
 
18 maternal deaths: 
11 (61%) HIV+; 4 (22%) 
HIV-; 3 (17%) HIV unknown  
Leading indications for ICU 
admission: 
HIV+: respiratory failure 
(26%); obstetric 
haemorrhage (26%); sepsis 
(19%) 
 
HIV-: respiratory failure 
(2%); obstetric 
haemorrhage (29%); sepsis 
(2%); seizures (10%) 
 
Majority of maternal 
deaths in HIV+ women, not 
statistically significant – 
small numbers.  
 
Small number on ART. 
 
 
No details on causes of 
death. 
 
 
Ray et al. 
2013 121  
 
Botswana Record review of maternal 
deaths up to 42 days 
postpartum. 
 
Study period: 2010 
 
80 deaths notified, MMR – 
163  
 
56 case records available 
for review.  
Cause of death identified 
in 55 cases. 
36/56 (64%) HIV+; 20/36 
(55.6%) on ART 
 
11 (20%) HIV- 
9 (16%) HIV unknown. 
 
Direct causes of death– 
23/55 (42%): haemorrhage 
(43%), hypertension (22%), 
pregnancy-related sepsis 
(13%).  
 
Indirect causes of death – 
32/55 (58%):  
19/32 (59%) attributable 
to HIV;  
13/32 due to medical and 
surgical disorders. 
 
Of the 19 deaths 
attributable to HIV, 12 had 
AIDS.  
 
 
 
58% of maternal deaths 
due to indirect causes. 
 
No data on duration of 
ART. 
 
High number (24) of 
missing case records – 
could have influenced 
study findings. 
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Author and year  
 
Country  Methods  Key findings  
 
Key findings  Comments  
Shapiro et al. 
2013 129 
 
 
Botswana RCT of maternal ART for 
PMTCT. 
CD4 ≥200 – ART initiated 
antenatally through 
weaning or 6 months 
postpartum.  
 
Observational arm: CD4 
<200 or AIDS-defining 
condition – lifelong ART.  
Study period: 2006 – 2008.  
14 women died up to 24 
months postpartum  
1 antenatally, 3 from 
delivery though 6 months 
postpartum, and 10 from 
6–24 months postpartum. 
 
5 deaths were in the 
observational arm – all had 
CD4 counts <250 µ/L  
 
9 deaths were in the 
interventional arms and 
occurred – 5 deaths in 
women with CD4 >350.  
 
8/9 deaths occurred after 
stopping ART for PMTCT.   
 Some of the causes of 
death – extrapulmonary 
TB, pulmonary TB, 
diarrhoea, hepatic/renal 
failure, PJP, toxoplasmosis, 
nevirapine toxicity.  
 
Small number of maternal 
deaths. 
Westreich et al. 
2013 122 
 
 
South Africa   Observational cohort – 
retrospective analysis of an 
electronic patient 
database, N=7 534 women. 
 
Main exposure – incident 
pregnancy after ART 
initiation. Main outcome – 
death.  
 
Study period: 2004-2011 
918 (12%) women were 
ever pregnant, median of 
14 months (IQR: 7, 26) 
after ART initiation. 
 
21/918 (2.3%) women 
died, median time between 
start of pregnancy and 
death was 15 months (IQR: 
8, 24). 
 
Incident pregnancy was 
not associated with an 
increased hazard and risk 
of death in women on 
ART, HR 0.67 
(95% CI: 0.43, 1.05). 
 
Incident pregnancy 
associated with decreased 
risk of LTFU, HR= 0.62 (95% 
CI: 0.51, 0.75). 
No details on causes of 
death in the women who 
died. 
 
Cohort – high retention 
rates in care. 
 
Adherence to treatment 
assessed as good. 
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Author and year 
 
Country  Methods  Key findings  
 
Key findings  Comments  
Buchmann et al. 
2014 111  
 
 
South Africa  Record review of maternal 
deaths in a referral hospital 
obstetrics unit. 
 
Study period: 1997-2012  
Top 3 leading causes of 
death:  
1. Non-pregnancy related 
infections (40%) (92% 
HIV+, >50% respiratory 
infections, 68% had 
anaemia at baseline) 
2. Hypertensive disorders 
(17%) 
3. Obstetric haemorrhage 
(13%) 
46% of maternal deaths 
due to indirect causes. 
 
Decrease in MMR with 
introduction of ART; 23% 
on ART. 
 
Peak MMR of 139 in 2004 
and a decline to 86 in 2011. 
 
CD4 counts – majority <200 
µ/L. 
Record review – possible 
misdiagnosis 
and misclassification of 
causes of death. 
 
Increase in HIV prevalence 
in women who died with 
increased testing. 
Li et al. 
2014 127 
 
 
 
Tanzania  Prospective cohort study – 
64 296 HIV+ women 
enrolled in a HIV/AIDS care 
and treatment programme.  
 
Study period: 2004-2011 
20 996 live births 
363 maternal deaths, 
MMR – 1729  
 
27% on ART overall – 16% 
started pre-pregnancy. 
 
Advanced immune 
suppression and anaemia 
were significantly 
associated with an 
increased risk of maternal 
mortality   
Pre-pregnancy ART 
associated with 55% 
decrease in risk of 
mortality, (OR 0.45, 95% CI 
0.29–0.70). 
 
34% decrease in risk of 
death in those on ART at 
delivery, (OR: 0.66, 95% CI: 
0.51, 0.87) risk decreased 
by 8% with each additional 
month on ART during 
pregnancy. 
 
Death information from 
clinic records and home 
visits. 
 
No information on causes 
of death. 
 
82% decrease in MMR 
from 2007 to 2011 
 
MMR for HIV+ women 
estimated to be 5X higher 
than for HIV- women 
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Author and year 
 
Country  Methods  Key findings  
 
Key findings  Comments  
Bailey et al. 
2015 123  
 
 
Mozambique  Secondary data analysis 
from two national cross-
sectional surveys done in 
2007 and 2012. 
 
Evaluated changes in 
iMMR, causes of death, 
and contribution of HIV, 
malaria and anaemia to 
maternal mortality. 
Obstetric haemorrhage the 
leading cause of death in 
direct causes. 
 
2007 – 10% of deaths due 
to HIV/AIDS; 9% due to 
malaria. 
 
2012 – different 
categorization allowed 
multiple conditions – 
comparisons not possible.   
With indirect causes of 
death, HIV infection, 
malaria and anaemia were 
more prevalent.  
Also present in women 
dying of direct causes. 
 
Appears to be an increase 
in deaths due to indirect 
causes. 
 
In 2007, large number of 
maternal deaths that 
appear as “other” direct 
and indirect causes. 
 
2007 – 12 months of data; 
3 months for 2012 
 
No information on ART 
use. 
Nganira et al.  
2015 130 
 
Tanzania  Sub-cohort in a PMTCT 
study – 84 women with 
CD4 ≤200 at enrolment, 
continued on ART for life 
and followed up for 24 
months after delivery. 
Median CD4 139 cells/µ/L. 
 
Enrolment 2004-2006 
Increase in proportion of 
women who had a 
detectable viral load 
(≥400) at 12 months – 
61%, 86% at 24 months 
postpartum – p=0.000. 
 
Increase in proportion with 
immunologic failure 
postpartum: 
25% at 12 months 
(p = 0.032) and 41% (p = 
0.035) at 24 months. 
 
High rate of treatment 
failure and drug resistance 
– 56% at 12 months 
postpartum – despite close 
monitoring and follow-up, 
including home visits. 
5 deaths postpartum: 1 at 
1 week; the other four died 
at months 2,5,14 and 24 – 
all died of HIV-related 
complications. 
Probability of virologic and 
immunologic failure 
associated with self-
reported non-adherence – 
wide CI. 
 
Adherence was taken as 
not having missed a single 
dose. 
 
 Small number of maternal 
deaths. 
 
 
 
LTFU= lost to follow-up – ≥60 days late for scheduled follow-up 
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Author and year  
 
Country  Methods  Key findings  
 
Key findings  Comments  
Auld et al. 
2016 124 
 
 
Mozambique  Observational cohort 
study. Analysed database 
of patient-level data. 
Adults ≥15 years initiated 
on ART. 
 
Study period: 2004-2013; 
Option B+ introduced in 
2013  
 
Primary outcomes – 
mortality and LTFU 
6-month mortality lowest 
among Option B+ 
pregnant women with CD4 
>350 cells/µ/L and WHO 
stage 1 or 2 disease (0.1%), 
vs. other pregnant ART 
enrolees (1%), non-
pregnant females (3%), and 
males (5%). 
6-month LTFU highest for 
Option B+ group (38%), 
compared with other 
pregnant ART enrolees 
(26%), non-pregnant 
females (18%), and males 
(23%). 
 
LTFU for pregnant women: 
aHR: 1.11, CI:  1.00 to 1.22, 
p=0.049 
High rates of LTFU. 
 
No details on causes of 
death in pregnant women. 
 
Mortality risk for pregnant 
women: aHR: 0.81, CI: 0.69 
to 0.94, p= 0.007. 
Ngonzi et al.  
2016 112 
 
 
Uganda  Retrospective unmatched 
case control study in a 
referral hospital. Cases – 
maternal deaths (139), 
controls – women 
admitted to the obstetric 
ward and survived (417). 
 
Study period: 2010-2014 
Causes of mortality 
 
Direct causes 78%: 
puerperal sepsis (31%), 
PPH (22%), hypertensive 
disorders (14%), abortion 
complications (11%).  
 
Indirect causes 22%: 
malaria (40%), anaemia 
(4%), others (9%). 
 
 
Some of the factors 
associated with mortality: 
HIV infection – aOR 3.6 (CI: 
1.9–7.0) p<0.001; lack of 
antenatal care – aOR 3.6 
(CI: 1.9–6.9), p<0.001. 
Hospital-based data. 
Record review. 
 
HIV prevalence: cases 
(35%); controls (16%) 
 
Causes of death not 
disaggregated into HIV+ 
and HIV-; no details on ART 
use. 
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Author and year  
 
Country  Methods  Key findings  
 
Key findings  Comments  
Black et al. 
2016 113 
 
 
South Africa  Audit at a tertiary hospital. 
Compared causes of death 
and MMR over 3 periods 
corresponding to changes 
in ART policy.   
 
Study period: 2003 to 2012 
MMR in HIV+ vs. HIV- 
women decreased from 
being 7.1X higher in the 
pre-ART era to 3.2X higher 
with expanded ART 
programme.  
 
Even with expanded ART 
(period 3), 33.3% of 
maternal deaths attributed 
to HIV. 
In period 3, 28.6% of 
women who died were on 
ART. 
 
Decrease in maternal 
deaths due to TB, among 
HIV+ women, over time. 
Higher coverage of HIV 
testing and ART reduced 
MMR among HIV+ women. 
 
MMR among HIV- 
remained unchanged. 
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1.2.9 The role of ART in HIV-related maternal mortality  
  ART for maternal health was not available in state health institutions in sub-
Saharan Africa, before 2003. In the early years of the ART roll-out, treatment was 
usually offered within donor-funded HIV programmes, and much of the published 
literature on maternal mortality in HIV-infected women from this period is from 
cohorts within these programmes.109,110,119,120,122,124,125,129,130,127 In the 25 studies on 
maternal mortality in HIV-infected women (Table 1.3), where ART was available as 
part of routine care, the proportion of women that were on treatment at the time of 
death ranged from 3% to 29%.109,111,113,121,127,126 In only one study, done in Botswana, 
was the proportion of women on ART higher at 56%.121 This illustrates that even 
when ART programmes had been scaled up, women who died were likely not to 
have been on treatment, despite advanced immune suppression as mentioned 
above. Botswana is one of the countries in sub-Saharan Africa that had a rapid 
evolution of its PMTCT programme, and according to a UNAIDS 2010 report, when 
the maternal mortality study was done, the estimated that ART coverage among 
pregnant women was 94%.157   
 Data from five of the 25 studies show a survival benefit of ART for both 
pregnant and postpartum women, even for those without advanced immune 
suppression.110,119,120,124,127 The studies suggest that the effect of ART in decreasing 
HIV-related maternal mortality is modified by the duration of treatment and also the 
level of immune suppression at ART initiation.119,120,127 In a retrospective cohort study 
of women enrolled in PMTCT programmes in Mozambique and Malawi, Marazzi et al 
found that maternal mortality up to 42 days postpartum, was 10-fold higher in women 
who had no ART prior to delivery, compared to those who had 90 days or more of 
prenatal ART (p<0.001).119 In the same study, even a short duration of prenatal ART 
was associated with a significant decrease in risk of maternal deaths – there was a 
70% decrease in risk of death in women who had more than 30 days of prenatal ART 
compared with no ART.119 The benefits of prenatal ART in decreasing the risk of 
maternal deaths was seen at all CD4 count strata, even at CD4 counts greater than 
350 cells/µl. While the results of the study are important, no details were given on the 
causes of maternal deaths. The study cohort was also in relatively good health, with 
a median CD4 count of 357 cells/ µL, IQR: 234-518, and the women were enrolled in 
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a donor-funded HIV programme where they were followed up antenatally and 
postpartum.119  
Additional evidence on the benefits of ART initiation in pregnancy at higher 
CD4 counts comes from another study done in Mozambique.124 The aim of the study 
was to assess scale-up of an ART programme in Mozambique from 2004 to 2013, a 
period that saw several guideline changes with introduction of Option B+ in 2013.124 
There was evidence of a decline in mortality among pregnant women initiated on 
ART within an Option B+ programme and with CD4 counts above 350 cells/µl, 
compared to pregnant women initiated on ART outside of an Option B+ programme, 
non-pregnant women and men.124 There was however a high rate of loss to follow-
up, with 38% of women lost by six months after ART initiation.124 It is difficult to 
appreciate the decrease in mortality with such a high rate of loss to follow-up as it is 
estimated that up to 60% of patients lost to follow-up are likely to have died.158  
 A study by Liotta et al, done in the same PMTCT programmes in Mozambique 
and Malawi as the study by Marazzi et al discussed above, showed a lower risk of 
maternal mortality in women initiated on ART pre-pregnancy.120 In women on pre-
pregnancy ART, the mortality rate was 0.7%, while that in women initiated on ART 
during pregnancy and had a higher baseline CD4 count was 1.1%; the difference 
was however not statistically significant. There are limitations to this study in that 
there were no details on the causes of maternal deaths. The authors report that “41 
women died in the process of giving birth, presumably of obstetrical complications, 
while 4 others died due to complications leading to concurrent fetal demise during the 
labour process”, a statement that does not give insight into the causes of death.120 
There was also a high rate of loss to follow-up, with 56 women who died in the six 
weeks postpartum period not returning for care in the programmes, and deaths 
ascertained through home visits.120   
With ART started before pregnancy, Li et al from Tanzania also found a 
reduction in risk of maternal mortality compared to pregnant women not on any 
treatment.127 In a prospective cohort study done within a large HIV care and 
treatment programme, pre-pregnancy ART was associated with a 55% reduction in 
risk of maternal mortality compared to women who were not started on ART. While 
the study was large, with 363 maternal deaths reported in seven years, no details 
were given on the duration of pre-pregnancy ART and no details were given on the 
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causes of death, making it difficult to compare the findings with those from other 
studies.  
ART has also been shown to be associated with a decrease in deaths due to 
TB in HIV-infected individuals, one of the leading HIV-related causes of maternal 
mortality.159 In their audit of maternal deaths in a referral hospital in South Africa, 
Black et al showed a more than 50% decline in odds of death from TB with 
expansion of the ART programme.113  
While available data show a beneficial effect of ART started before pregnancy, 
or early in pregnancy, questions have been raised about the impact of incident 
pregnancy on maternal mortality in HIV-infected women on ART.122,125 This is an 
important concern because as ART programmes are scaled up, more HIV-infected 
women will become pregnant already on ART. A South African study looking at the 
impact of incident pregnancy on maternal mortality, in women already on ART, 
showed no increased risk of death in women who became pregnant compared to 
those who did not.122 In a cohort of 7 534 women, there were 21 deaths (2.3%) in 
918 women who had a recognised pregnancy compared to 614 deaths (9.3%) in 
6 616 women who did not have a pregnancy. The median time between the start of 
the pregnancy and death was 15 months (IQR 8, 24). The authors argue that the 
results do not show a protective effect of pregnancy, but rather illustrate that incident 
pregnancy is not associated with an increased risk of death in women already on 
ART.122 At the time of pregnancy, the median time on ART was 14 months (IQR: 7; 
26), and women ≤25 years and those with higher CD4 counts were more likely to be 
pregnant than older women and those with lower CD4 counts.122 At follow-up, the 
majority of women in the cohort (this is not quantified in the paper) were likely to be 
virally suppressed and also have a CD4 count greater than 200 cells/µl. Hence the 
women who became pregnant were a young and healthy cohort, who intuitively 
would have a decreased risk of maternal mortality. One of the limitations of the study 
is that there were no details on the causes of death.  
Some studies have suggested that there is a ‘healthy pregnant women effect’, 
i.e. HIV-infected women who become pregnant are likely to be in early stages of HIV 
infection, and hence have a lower risk of death.108,160 In a study done in the Republic 
of Congo, in the pre-ART era, Le Coeur et al found the risk of death in HIV-infected 
pregnant women to be five times lower compared to HIV-infected women that were 
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not pregnant, RR: 0.2, 95% CI: 0.1, 0.5.108 No details were given on the causes of 
death, or the level of immune suppression. In another study, a large community-
based study done in rural South Africa, HIV-related mortality in women during the 
maternal risk period (pregnancy, delivery and puerperium) was lower compared to 
HIV-infected women of reproductive age that were not pregnant, RR = 0.75; 95% CI 
= 0.63, 0.89.160 The authors postulate that HIV-infected women who become 
pregnant are less likely to have advanced disease and therefore at lesser risk for 
death, but no details are given in the paper on the level of immune suppression and 
ART use in the study cohort.160   
While HIV-infected women who become pregnant are likely to be in the early 
stages of HIV infection, and there appears to be no increased risk of death 
associated with incident pregnancy in women on established ART, there is limited 
information on the impact of incident pregnancy on maternal mortality in the early 
stages of ART initiation, in women with advanced immune suppression. In their 
cohort study of women initiating ART in Uganda and assessing pregnancy-related 
mortality up to one year postpartum, Matthews et al report that there is increased 
mortality within the first year of ART initiation among pregnant and postpartum 
women with advanced HIV disease.125 The authors postulate that this could be an 
effect of persisting immune suppression, or related to an increased risk of immune 
reconstitution inflammatory syndromes at ART initiation. While this is a plausible 
explanation, the numbers in the study are too small, at only five deaths reported 
during pregnancy and postpartum, to make any definitive conclusions.125 Data from 
non-pregnant populations, including women and men, show an increased risk of 
mortality in the first year of starting ART, in patients with advanced immune 
suppression, and it is likely that the same effect will be seen in pregnant 
women.161,162   
To be able to see substantial and sustained decreases in HIV-related maternal 
mortality, there needs to be an increase in HIV screening and ART initiation outside 
of pregnancy, especially for women with advanced immune suppression. Universal 
access to ART for all pregnant and postpartum women, through either Option B+ or 
through the Universal Test and Treat strategy, will be the key driver in further 
decreasing HIV-related maternal mortality. With many sub-Saharan African countries 
adopting Option B+, a significant proportion of HIV-infected pregnant women will be 
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started on ART at higher CD4 counts, and the expectation is that this will offset the 
risk of maternal mortality associated with advanced immune suppression. However, 
retention in care and adherence to ART remain a major challenge, with high rates of 
postpartum loss to follow-up reported in established Option B+ programmes.65,64,163 
Retention in care within Option B+ programmes has been discussed in the PMTCT 
literature review.  
Reducing maternal mortality remains a global priority. Monitoring trends in 
maternal mortality in sub-Saharan Africa, where two-thirds of maternal deaths occur, 
has been hampered by the lack of comprehensive data on maternal deaths.71 As a 
result, there has been a reliance on modelled estimates, which have yielded varied 
results. Despite this, there appears to be a downward trend in maternal mortality in 
sub-Saharan Africa. From this literature review, it is evident that HIV-infected 
pregnant and postpartum women have an excess risk of mortality compared to those 
who are HIV-uninfected. While the leading cause of indirect maternal death in HIV-
infected women is HIV-related disease, the causes of direct maternal deaths remain 
important targets for intervention. Although the data are inconsistent, some of the 
leading causes of direct maternal deaths have risk factors directly related to HIV 
infection. Expansion of ART programmes will undoubtedly have an important impact 
on decreasing direct and indirect maternal mortality in HIV-infected women. 
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CHAPTER 2: RATIONALE FOR THE RESEARCH, OVERALL AIM AND 
OBJECTIVES 
This chapter outlines the rationale, overall aim and objectives of my PhD. 
2.1 Rationale for the research 
There are many lessons to be learnt from programmatic experience in 
implementation of PMTCT programmes. This PhD makes an important contribution to 
the existing PMTCT literature as it chronicles the evolution of one of the oldest and 
largest PMTCT programmes in South Africa, starting in the period when only single-
dose nevirapine was available for PMTCT, to adoption of Option B+ in 2015. It 
provides information on the successful implementation of the Soweto PMTCT 
programme through evaluation of 14 years of routinely collected data and original 
research conducted in facilities that form part of the programme. Results from the 
different studies also highlight challenges that still exist within PMTCT programmes.   
While studies have reported on maternal mortality in HIV-infected women, the 
quality of the evidence is limited by small sample sizes and short review periods.  
Hence the findings from the study on maternal deaths in HIV-infected women, which 
is part of this PhD, make an important contribution to current literature. The review of 
maternal deaths in HIV-infected women covers a 19-year period, much longer than in 
any of the published studies, and chronicles changes in HIV diagnosis and treatment 
in pregnant women, and causes of maternal deaths in HIV-infected women. The 
review reflects on evolving HIV management guidelines, starting prior to availability 
of ART, through different eligibility criteria, culminating with availability of triple 
therapy for all HIV-infected pregnant women.    
 
2.2 Research aim 
The aim of this PhD was to evaluate the impact, on maternal and child health, 
of a large PMTCT and ART programme in the Johannesburg Health District, South 
Africa, and how therapeutic interventions have had an impact on MTCT and maternal 
mortality. Successes achieved in the programme were evaluated based on progress 
made in implementation of evolving PMTCT and ART interventions. The evaluation 
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was also based on progressive reduction in the MTCT risk and changing patterns in 
maternal deaths in HIV-infected women.  
The research projects that contribute to this PhD are unique in that they were 
conducted in one of the largest and most established PMTCT and ART programmes 
in South Africa, and provide an opportunity to chronicle the evolution of the South 
African PMTCT and ART guidelines.  
 
2.3 Research objectives  
The conceptual framework, Figure 2.1, illustrates how the research objectives 
address elimination of MTCT and reduction of maternal mortality.  
 
                                                           
Figure 2.1: Conceptual framework for elimination of MTCT and reducing HIV-related 
maternal deaths. Source: Author’s own design 
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Objective 2 
The second objective was to identify patient-related risk factors for MTCT, and 
also to evaluate infant feeding practices among HIV-infected women, an important 
factor in MTCT. 
Objective 3 
The third objective was to assess the impact of evolving HIV management 
guidelines and increased availability of ART on maternal mortality in HIV-infected 
women.     
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CHAPTER 3: METHODS 
Chapter 3 gives a summary of the methodologies of the six studies that 
contributed to this PhD. Details of the methodologies for the individual studies are 
contained in the appended Papers 1-6.    
 
3.1 Study setting 
All the studies were conducted in regions D and G of the Johannesburg Health 
District, in Johannesburg, Gauteng Province, South Africa. The Johannesburg Health 
District is divided into six regions, A to G – Figure 3.1. The estimated population for 
the City of Johannesburg, for 2016, is just under five million people at 4 949 347.164   
 
 
Figure 3.1: A map of the six regions that make up the Johannesburg Health District  
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Region D is the Greater Soweto, and is the most populous of the six regions 
and constitutes approximately 26% of the population in the City of 
Johannesburg.164,165 Region G is made up of Ennerdale and Orange Farm, and is 
home to approximately 14% of the population in the City of Johannesburg. Both 
regions D and G are areas of mixed urban and informal settlements, and the official 
overall unemployment rate for the City of Johannesburg was 25% in 2011, while that 
for individuals aged 15-34 years was 32% for the same year.164     
The HIV prevalence among pregnant women accessing antenatal care in the 
Gauteng province increased rapidly from less than 1% in 1990 to 23% by 1998, and 
has plateaued around 30% for the past decade – figures similar to the national 
prevalence,  Figure 3.2.95,166 The rapid increase in prevalence coincides with a dark 
period in the South African history marked by denialism about the aetiology of HIV 
infection and related deaths, and also refusal of the government to provide 
antiretrovirals.  
  
Figure 3.2: HIV prevalence among pregnant women attending antenatal clinics in 
South Africa and in the Gauteng Province, 1990-2015  95,166   
These results are from the South African national antenatal HIV prevalence 
surveys that have been conducted since 1990. From 2006, antenatal HIV prevalence 
figures have been reported for individual districts within the provinces and the figures 
for the City of Johannesburg Health District are also presented in Figure 3.2. 95,166     
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History of the Soweto PMTCT programme 
The Soweto PMTCT programme was established in 2000 as the 
Demonstration of Antiretroviral Treatment (DART) programme initiated by the 
Perinatal HIV Research Unit (PHRU).167 The programme was initially funded by the 
Elizabeth Glazer Paediatric AIDS Foundation (EGPAF), and the Gauteng 
Department of Health, and later fully funded by the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) via the US Agency for International 
Development (USAID).167 As part of the DART programme, pregnant women were 
offered voluntary counselling and testing (VCT) for HIV, and if found to be HIV-
infected, maternal and infant single-dose nevirapine was given. A six-months supply 
of infant formula, from the Gauteng department of Health, was also available for HIV-
infected women who elected not to breastfeed.167 
As part of the collaboration between PHRU and the Gauteng Department of 
Health to establish the Soweto PMTCT programme, PHRU provided dedicated staff, 
professional nurses and lay counsellors with a focus on service provision. At the start 
of the programme, Chris Hani Baragwanath Academic Hospital (CHBAH) and 12 
primary healthcare facilities were supported and approximately 30 000 pregnant 
women were seen in the programme annually. From 2009, the Soweto PMTCT 
programme has been supported by the Anova Health Institute (Anova), and from 
2012 there was a shift from service provision to technical support, with a focus on 
training and mentoring of government employees to take over running of the 
programme.  
Details on the evolution of the South African PMTCT and ART guidelines are 
given in Chapter 1, in the PMTCT literature review section, and changes in the 
Soweto PMTCT programme mirror these guideline changes. Prior to the introduction 
of NIMART within antenatal clinics in the Soweto programme, in 2010, antenatal 
clinics only provided PMTCT prophylaxis and pregnant women who were eligible for 
ART were referred to separate ART sites for treatment initiation and follow-up. 
Routine testing of HIV-exposed infants became widely available from 2007, and was 
done around six weeks of life, six weeks post cessation of breastfeeding, and again 
at 18 months if the initial tests were negative. 
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Up until May 2014, when Bheki Mlangeni District Hospital was opened in 
Soweto, CHBAH was the only referral hospital for regions D and G, and surrounding 
areas.  The obstetrics unit at CHBAH is a high-volume unit with over 20 000 live 
births per annum reported in the past decade (Figure 3.3).  
 
 
Figure 3.3: Live births at Chris Hani Baragwanath Academic Hospital: 1997-2015 
Source: DHIS data 
 
Two-thirds of the total number of live births in regions D and G occur at 
CHBAH, and the rest in the midwife obstetric units, in primary healthcare clinics in the 
two regions.111    
 
3.2 Study design 
Overall, the studies were quantitative, and details of the individual study 
methodologies are given in the manuscripts (Appendices 1 – 6). Below is a summary 
of the individual study methodologies and Table 3.1 gives an overview of the study 
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3.2.1 Implementation of evolving PMTCT and ART interventions 
In the first study (Paper 1), trends in HIV diagnosis and management in 
pregnancy, routine testing of HIV-exposed infants and rate of MTCT were analysed 
over a 14-year period of evolving PMTCT and ART guidelines. This was secondary 
data analysis of routinely collected PMTCT data in 13 facilities. Standard PMTCT 
indicators, adapted from the district health and information system (DHIS) indicators 
used for routine reporting in PMTCT programmes, were selected to describe the 
implementation of increasingly efficacious ARV interventions in line with changing 
guidelines.  
3.2.2 Timing of antenatal care and ART initiation in HIV-infected pregnant 
women  
This study (Paper 2) was a secondary analysis of routinely collected PMTCT 
data to assess the timing of antenatal care and ART initiation in HIV-infected 
pregnant women before and after introduction of NIMART within antenatal clinics.  
3.2.3 Quality of care in PMTCT programmes  
The third study (Paper 3) was a cross-sectional survey conducted in ten 
antenatal clinics in Greater Soweto. Pregnant HIV-infected women, and healthcare 
workers involved in PMTCT services, were interviewed, using structured 
questionnaires, to assess their knowledge of PMTCT guidelines and their 
experiences of the PMTCT programme.     
3.2.4 Patient-related risk factors for mother-to-child transmission of HIV 
This was a case control study (Paper 4) of HIV-infected women, with HIV-
infected (cases) and HIV-uninfected (controls) infants diagnosed around six weeks of 
age as part of routine, early infant diagnosis.  Structured interviews were conducted 
with a focus on history of HIV infection, and antenatal, intrapartum and immediate 
postpartum management of the mother-infant pairs. Patient-related risk factors for 
MTCT were identified.  
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3.2.5 Infant feeding intentions, practices, knowledge and perceptions  
This study was a cross-sectional survey (Paper 5) conducted in ten public 
healthcare facilities in the Johannesburg Health District. Pregnant and postpartum 
HIV-infected and HIV-uninfected women were interviewed using a structured 
questionnaire. Infant feeding intentions and practices were determined among 
pregnant and postpartum women with infants up to 12 months old, respectively. 
Knowledge and perceptions of safe infant practices were also evaluated in both 
groups.   
3.2.6 Maternal mortality in HIV-infected women 
This was a retrospective record review (Paper 6) of maternal deaths in HIV-
infected women, at CHBAH, over a 19-year period. Trends in HIV diagnosis and 
management in pregnancy and causes of maternal deaths were analysed over four 
time periods coinciding with the changes in PMTCT and ART guidelines (Figure 3.4).  
 
 
Figure 3.4: Analysis time periods and changes in South African PMTCT and ART 
guidelines  
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Table 3.1: An overview of the study populations and methodologies for the six studies that contributed to this PhD 
 Study 1 Study 2 Study 3  Study 4 Study 5  Study 6 
 
Focus of study 
 
Implementation of 
evolving PMTCT 
interventions  
 
Timing of antenatal 
care and ART 
initiation  
Quality of care in 
PMTCT 
programmes  
Patient-related risk 
factors for MTCT 
Infant feeding 
intentions, practices, 
knowledge and 
perceptions 
 
Maternal mortality in 
HIV-infected women  
Data collection period  
 
January 2002 to 
December 2015 
October 2010 to 
March 2012 
November to 
December 2009 
November 2010 to 
May 2012 
April 2014 to March 
2015 
January 1997 to 
December 2015 
Methodology 
 
Secondary data 
analysis 
 
Secondary data 
analysis 
Cross-sectional 
study 
Case-control study Cross-sectional 
survey 
Record review  
Data source and 
study population 
 
Routinely collected 
PMTCT programme 
and DHIS data 
 
Routinely collected 
PMTCT programme 
data 
Structured 
interviews with 
HIV-infected 
pregnant women 
and healthcare 
workers 
Structured interviews 
with HIV-infected 
postpartum women 
with HIV-infected and 
uninfected infants 
 
Structured interviews 
with HIV-infected 
pregnant and 
postpartum women 
 
Record review of 
maternal death cases 
Sample size 
 
 
___ 
1 436 ART-eligible, 
pregnant HIV-
infected women  
201 HIV-infected 
women  
 
80 healthcare 
workers 
154 HIV-infected 
women with HIV-
uninfected infants, 
and 77 with HIV-
infected infants 
190 pregnant women, 
and 180 postpartum 
women 
692 maternal death 
cases 
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CHAPTER 4: SUMMARY OF KEY FINDINGS  
This chapter summarises the key findings from the six studies that contribute 
to this PhD. Table 4.1 outlines how each of the six manuscripts addresses the 
research objectives.  
 
Table 4.1: A list of the thesis manuscripts and the research objectives they address 
Objectives  Manuscripts  
 
Objective 1  1: Evolution of a successful PMTCT programme in a high HIV prevalence 
setting, in Johannesburg, South Africa: 2002-2015.  
(To be submitted for publication) 
 
2: Timing of antenatal care and ART initiation in HIV-infected pregnant 
women before and after introduction of NIMART. S Afr J HIV Med 
2014;15(2):55-56. 
 
3: Challenges to delivering quality of care in prevention of mother-to-child 
transmission of HIV programme in Soweto. S Afr J HIV Med 2013;14(2):64-69. 
  
Objective 2 4: Patient factors to target for elimination of mother-to-child transmission of 
HIV. Global Health 2014;10:36. 
 
5: Infant feeding intentions, practices, knowledge and perceptions among 
HIV-infected and HIV-uninfected women in Johannesburg, South Africa. Int 
Breastfeed J 2017;12:17. 
 
Objective 3 6: Trends in maternal deaths in HIV-infected women, on a background of 
changing HIV management guidelines in South Africa: 1997 to 2015. J Int 
AIDS Soc 2017;20:e25022. 
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Detailed results and findings from each study are presented in the individual 
papers – Appendices 1 – 6. Paper 1 describes progress made in implementation of 
efficacious PMTCT interventions and ART coverage in HIV-infected pregnant 
women. The paper also documents the progressive decline in the MTCT rate and 
advances made towards eMTCT. The second paper describes the timing of antenatal 
care and ART initiation in HIV-infected women before and after the introduction of 
NIMART within antenatal clinics. Paper 3 discusses the challenges in delivering 
quality of care in PMTCT programmes. Paper 4 identifies patient-related risk factors 
to target for eMTCT, while Paper 5 presents data comparing infant feeding intentions, 
practices, knowledge and perceptions among HIV-infected and HIV-uninfected 
pregnant and postpartum women. The last paper, Paper 6, presents findings of a 19-
year review of trends in HIV management and causes of maternal deaths in HIV-
infected women, on a background of changing PMTCT and ART guidelines.  
The detail on the key findings for each study will reflect the depth of data 
collected and analysis done for each study. There were three overarching themes 
that emerged from the studies, and these will be discussed in depth in the discussion 
section. The three themes are: delayed or lack of access to antenatal care among 
HIV-infected pregnant women and the impact on MTCT risk and maternal mortality; 
timing of HIV diagnosis and ART initiation in pregnant women; and knowledge of 
PMTCT interventions among healthcare workers and women accessing care.  
 
KEY FINDINGS     
4.1 Successful implementation of evolving PMTCT and ART guidelines and 
significant decrease in MTCT rate 
 
4.1.1 Successful implementation of evolving PMTCT and ART guidelines
 Since inception of the Soweto PMTCT programme in 2002, the HIV testing 
rate among pregnant women has remained high, with more than 95% of pregnant 
women presenting to the 13 facilities reviewed tested for HIV – Paper 1. Of the 
pregnant women identified as HIV-infected, the proportion presenting for antenatal 
care with an already known HIV status increased from 14.3% in 2009 to 45% in 
2015, p=0.0000. Starting in 2010, the indicator on pregnant women accessing 
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antenatal care before 20 weeks was collected and the figure increased from 40.8% in 
2010 to 51.3% in 2015, p=0.0000. CD4 count testing for ART eligibility became 
standard in 2006 and the proportion of ART-eligible pregnant women, based on a 
CD4 count of ≤200 cells/µl, was approximately 16% from 2006 to 2009. From 2010, 
with the increase in CD4 count threshold for ART initiation to ≤350 cells/µl, the 
proportion of pregnant women eligible for ART increased to around 40%. Prior to 
2010, when ART services became decentralised and NIMART was introduced within 
antenatal clinics, ART initiation in pregnant women was low, increasing from 6.5% in 
2006 to 37.3% in 2009. Consequent to the decentralisation of services and 
introduction of NIMART, the proportion of HIV-infected women initiated on ART 
increased significantly, with universal coverage of ART (≥80% coverage) achieved in 
2011 (Figure 4.1).  
 
  
Figure 4.1: Number of ART-eligible pregnant women initiated on ART, 2006-2015 
 
4.1.2 Significant decrease in the rate of mother-to-child transmission of HIV at 
early infant diagnosis   
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significantly to levels less than 2% by 2011 (Figures 4.2 and 4.3) – Paper 1. The 
MTCT rate decreased from 7.0% in 2007 to less than 1% in 2015, p=0.0000.  
 
      
Figure 4.2: The rate of mother-to-child transmission of HIV at early infant diagnosis, 
2007-2015.  
 
4.2 Timing of antenatal care and ART initiation in pregnant women 
In the secondary data analysis assessing timing of antenatal care and 
initiation of ART (Paper 2), HIV-infected pregnant women accessed antenatal care at 
a mean gestational age of 19.2±6.6 weeks, while the mean gestational age at ART 
initiation was 24.6±6.2 weeks. There were indications that ART initiation in pregnant 
women was prioritised, even prior to the introduction on NIMART within antenatal 
clinics. The median time to ART initiation prior to the introduction of NIMART was 3.4 
weeks (IQR 2.0 - 5.9) while after the introduction of NIMART it was 3.0 weeks (IQR 
1.4 - 5.4). Overall, the MTCT rate among 874 infants tested for HIV around six weeks 
of age was 0.2%.  
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Figure 4.3: Proportion of ART-eligible pregnant women initiated on antiretroviral 
therapy and the rate of mother-to-child transmission of HIV at early infant diagnosis.  
 
4.3 Challenges to delivering quality care in the Soweto prevention of mother-to-
child transmission of HIV programme  
 In the study on challenges in delivering quality of care in the Soweto PMTCT 
programme (Paper 3), there were important gaps in knowledge of PMTCT 
interventions among both healthcare workers and pregnant HIV-infected women 
accessing the services. The gaps in knowledge among pregnant women were 
despite almost all of them (97.5%) receiving counselling, and the majority (67.7%) 
having had more than one counselling session at the time of the interview. Among 
healthcare workers, the level of knowledge was similar with a mean score of 5.4±1.6 
for professional nurses and 5.2±1.9 for lay counsellors (p=0.586), in an 8-item 
questionnaire. The gaps in knowledge among healthcare workers were despite the 
fact that the majority (96.3%) felt confident about managing HIV-infected pregnant 
women. There were several negative opinions expressed by healthcare workers, 
about HIV-infected women having children, including some who thought that HIV-
infected individuals should not have children and that social grants were an incentive 
to have more children.  
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4.4 Patient-related risk factors for mother-to-child transmission of HIV 
 In the case-control study (Paper 4) of HIV-infected women with HIV-infected 
infants (cases) and HIV-uninfected infants (controls), important patient-related risk 
factors for MTCT were identified. In a multivariate analysis, unknown HIV status prior 
to index pregnancy, first antenatal visit after 20 weeks of gestation, 11 years and less 
of formal education and unplanned pregnancies were associated with increased odds 
of MTCT – Table 4.2. Although the majority of cases and controls were diagnosed as 
HIV-infected during pregnancy, significantly more women with HIV-uninfected infants 
knew that they were HIV-infected prior to the index pregnancy – 43.5% (67/154), 
compared to 13% (10/77) of women with HIV-infected infants, p<0.001. Women with 
HIV-infected infants were more likely to access antenatal care at a later gestation 
with a median gestational age at first antenatal visit of 24.0 weeks (IQR 16 – 26), 
compared to a median gestational age of 16.0 weeks (IQR 12 – 20) for women with 
HIV-uninfected infants. They were also more likely not to access any antenatal care, 
despite some of them knowing that they were HIV-infected prior to the pregnancy. 
The most common reason given for not accessing antenatal care was fear of 
stigmatisation either by healthcare workers or their families.  
 
Table 4.2: Multivariate analysis of risk factors for mother-to-child transmission of HIV 
at early infant diagnosis 
Factors  Adjusted odds ratio 
AOR (95% CI) 
P-value 
Unplanned pregnancy 2.7 (1.2 – 6.3) 0.022 
≤ 11 years of formal education 3.4 (1.6 – 7.5) 0.002 
First antenatal visit after 20 weeks 4.3 (2.0 – 9.3) <0.001 
Unknown HIV status prior to index 
pregnancy 
6.6 (2.4 – 18.4) <0.001 
AOR (95% CI) = adjusted odds ratio, 95% confidence intervals  
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A greater proportion of women with HIV-infected infants had unplanned 
pregnancies compared to women with uninfected infants – 83.1% (64/77) vs. 56.5%, 
(p<0.001). Early infant diagnosis was according to the guidelines, and once 
diagnosed as HIV-infected, there were no delays in ART initiation. The mean age at 
HIV diagnosis was 9.0±4.2 weeks, while the mean age at ART initiation was 10.8±4.4 
weeks.        
 
4.5 Infant feeding knowledge, perceptions and practices among HIV-infected 
and HIV-uninfected women  
In Paper 5, which assessed infant feeding knowledge, perceptions and 
perceptions among HIV-infected and HIV-uninfected pregnant and postpartum 
women, there was evidence of changing infant feeding patterns among HIV-infected 
women. Compared to findings from the secondary analysis of routinely collected data 
(Paper 1), a greater proportion of HIV-infected women elected to breastfeed. HIV 
infection was however still an important determining factor in infant feeding intentions 
with significantly more HIV-uninfected pregnant women intending to breastfeed than 
HIV-infected women – 80.9% (93/115) compared to 64.9% (48/74) of HIV-infected 
pregnant women, p=0.014. Fear of infecting their infants with HIV was the main 
reason given by pregnant women who intended to formula feed or breastfeed for a 
shorter duration. In a multivariable logistic regression analysis of factors associated 
with an intention to exclusively breastfeed, the adjusted odds ratio for HIV infection 
was 0.278 (95% CI 0.116 – 0.665), p=0.004. Although not significant HIV infection 
was associated with greater odds of exclusive breastfeeding, adjusted odds ratio 
2.604 (95% CI 0.571 – 11.872), p=0.216.  
Similar to findings in Paper 2, there were knowledge gaps among both 
pregnant and postpartum women, but HIV-infected women had significantly better 
knowledge of safe infant feeding practices than HIV-uninfected women. There were 
strong perceptions in all groups of women in the study that although enough 
information was given in healthcare facilities to encourage women to exclusively 
breastfeed, it was difficult to exclusively breastfeed. Cultural factors and influence 
from elders were perceived to be detrimental to exclusive breastfeeding.   
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4.6 Trends in maternal mortality in HIV-infected women 
Findings from Paper 6, the 19-year review of maternal deaths at CHBAH, 
highlight the challenges that still remain in decreasing maternal mortality, especially 
in HIV-infected women. While the majority (75.7%) of the 692 maternal deaths 
occurred postpartum, the events that led up to the deaths occurred in the antenatal 
and intrapartum periods. Almost a quarter of the women who died and had antenatal 
details had not accessed any antenatal care and throughout the review period, the 
majority of these unbooked women had an unknown HIV status. Of the women with a 
known HIV status, 83.8% were diagnosed as HIV-infected during pregnancy. Despite 
a low median antepartum CD4 count of 136 cells/µl (IQR 45 – 301), only 23.3% 
(78/335) of the HIV-infected women who died were on ART at the time of death. 
Even in the last three years of the review period, 2013-2015, where there was 
widespread availability of ART within antenatal clinics, 38.8% (19/49) of women who 
died were not on treatment. Among the women who died on non-pregnancy related 
infections, only 22.3% (46/206) were on ART at the time of death, despite a CD4 
count ≤200 cells/µl in the majority of patients who had a CD4 count done. 
Overall, non-pregnancy related infections, the majority respiratory infections, 
were the leading cause of death among HIV-infected women throughout the review 
period, accounting for 61.5% (206/335) of deaths. There was however a progressive 
decline in the proportion of women who died of non-pregnancy related infections, 
starting in the period 2010-2012 and coinciding with scale-up of ART availability and 
changes in PMTCT and HIV management guidelines. Of the women who died of 
direct causes of death, obstetric haemorrhage, pregnancy-related sepsis, and 
hypertensive disorders were the leading causes of death. In the women who died of 
obstetric haemorrhage and pregnancy-related sepsis, the majority were secondary to 
complications related to caesarean sections. The iMMR in HIV-infected women was 
three to eight-fold higher compared to the iMMR in HIV-uninfected women – Figure 
4.4. 
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Figure 4.4: Trends in the institutional maternal mortality ratio in HIV-infected women 
at Chris Hani Baragwanath Academic Hospital, 1997 – 2015  
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CHAPTER 5: DISCUSSION AND CONCLUSION  
This PhD thesis has shown the successful implementation of evolving PMTCT 
and ART guidelines and the impact this has had on MTCT rates and HIV-related 
maternal mortality, in a large PMTCT programme in Soweto, Johannesburg. With 
PMTCT data spanning a 14-year period, 2002-2015, antiretroviral interventions for 
PMTCT evolved from provision of only single-dose nevirapine to triple therapy for all 
HIV-infected pregnant and postpartum women (Paper 1). The period 2008-2015 saw 
a rapid evolution of interventions starting with the introduction of more efficacious 
PMTCT interventions, increase in the CD4 threshold for ART initiation in pregnant 
women and the integration of PMTCT and ART services within antenatal clinics. The 
integration of services and increased availability of efficacious antiretroviral regimens 
led to a decrease in the MTCT rate to levels below 2% at early infant diagnosis by 
2011. There is evidence of a decrease in the MMR among HIV-infected women 
(Paper 6), coinciding with expansion of the South African ART programme, but the 
MMR remains unacceptably high. While there have been great achievements in the 
past decade, the denialism and lack of political will by the South African government 
in the 1990s and early 2000s led to countless lives being lost.  
Despite the great achievements, this thesis, through evaluating various 
aspects of the continuum of care along the PMTCT cascade, highlights the 
challenges that still remain within PMTCT programmes. The majority of women still 
present for antenatal care late in pregnancy, beyond the first trimester, with a high 
reported rate of unplanned pregnancies (Papers 1-3). Also, the majority of women 
are diagnosed as HIV-infected during pregnancy and this has implications for the 
timing of initiation of antiretrovirals, whether for prophylaxis or treatment (Paper 1, 3-
6). The delay in accessing antenatal care and diagnosis of HIV infection during 
pregnancy were identified as some of the significant risk factors associated with 
MTCT (Paper 4). The other risk factors were unplanned pregnancies and incomplete 
schooling. The importance of antenatal care was also highlighted in the 19-year 
review of maternal deaths (Paper 6). The majority of women who died were 
diagnosed as HIV-infected during pregnancy, and in those who died with an unknown 
HIV status, the majority did not access antenatal care. Timing of access to antenatal 
care and initiation of antiretrovirals highlight challenges with provision and uptake of 
services. The other challenge identified in the thesis relate to the quality of care 
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provided in PMTCT and ART programmes, as reflected in gaps in knowledge of 
PMTCT interventions among both healthcare workers and patients accessing care 
(paper 3 and 5). Findings from the research that make up this thesis make an 
important contribution to existing literature, highlighting achievements made and 
challenges that still remain. The discussion will reflect on the research findings in 
relation to existing literature. No data from a HIV programme the same magnitude as 
the Soweto PMTCT, spanning a period of almost two decades, has yet been 
published.   
Three overarching themes emerged from the six studies that make up this 
thesis and Figure 5.1 illustrates how these (highlighted in pink) interact in the PMTCT 
continuum of care on the risk of MTCT and maternal mortality among HIV-infected 
women.  
The overarching themes are: 
• Delayed or lack of access to antenatal care  
• Timing of HIV diagnosis and ART initiation among pregnant women 
• Quality of care in PMTCT and ART programmes as reflected in the 
knowledge of PMTCT interventions 
The next three sections will discuss each theme in turn. 
 
5.1 Delayed or lack of access to antenatal care  
Findings from the secondary analysis of routinely collected PMTCT data 
(Paper 1) indicate that from 2010 (when the indicator for timing of first antenatal visit 
was initially collected) to 2014, less than 50% of pregnant women accessed 
antenatal care before 20 weeks gestation, with the average at 42% for the five years. 
For 2015, the figure was just over 50%, at 51.3%. Our findings are similar to the 
DHIS data from South Africa which up until 2015 also show a low proportion of 
pregnant women accessing antenatal care early. For the period 2010-2011 only 38% 
of pregnant women presented for antenatal care before 20 weeks despite 
recommendations that women should present as early as the first missed menstrual 
period.168–171 With data-driven quality improvement interventions, the proportion  
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of pregnant women accessing care before 20 weeks increased progressively to 50% 
in 2013 and to 54% in the financial year 2014/2015.170–172 The increase has been 
more substantial in 2015/2016 and 2016/2017 with 61% and 65% of women 
presenting for antenatal care before 20 weeks, respectively.172 The interventions 
implemented to increase the proportion of pregnant women presenting early include 
provision of daily antenatal services at health facilities; community mobilisation to 
increase awareness of the importance of early antenatal care and encouraging male 
partner involvement.170 With positive results achieved, there is a need for sustained 
efforts to improve on these figures. 
Accessing antenatal care late has an impact on the number of antenatal visits 
attended. From 2008 until the beginning of 2017, the recommendation in South Africa 
was for pregnant women to attend at least four antenatal visits and this was adapted 
from the WHO model for basic antenatal care.168,173 The WHO basic or focused 
antenatal care model consists of goal-orientated visits at four critical times during 
pregnancy and is based on results from a randomized trial which showed that 
focused visits do not compromise maternal and perinatal outcomes.173,174 However, 
global data show that in the period 2007-2014 only 64% of pregnant women attended 
the minimum four visits.175 In South Africa the figures are better with data from the 
2016 South African Demographic and Health Survey showing that in 2011-2015 76% 
of women had the minimum four visits.24,168,176 In April 2017 South Africa increased 
the recommended number of antenatal visits to eight following revised WHO 
guidelines published in 2016.175,176 The rationale behind the revision are data 
showing that the four-visit focused antenatal model does not offer pregnant women 
adequate contact with healthcare practitioners and is associated with an increased 
risk of stillbirths which peak in the third trimester.175 Hence the revised antenatal 
schedule includes an additional visit late in the second trimester and three additional 
visits in the third trimester. 
Cultural beliefs, financial considerations, and poor quality of services at 
antenatal clinics all contribute to women not accessing or delaying accessing 
antenatal care.33 Even when women reach healthcare facilities they may not receive 
the appropriate care. In a cross-sectional survey to assess women’s experiences of 
public antenatal care services and reasons for late antenatal care attendance in 
Johannesburg, South Africa, one of the reasons women who presented late for care 
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reported was that they knew that they would be turned away from clinics if they 
presented early.177 Some of the women who reported being turned away from clinics 
ended up accessing no antenatal care.  
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Antenatal services that do not meet the needs and expectations of women 
may also be a barrier to uptake of care. While service providers view antenatal care 
as for the identification of risk factors and prevention of morbidity and mortality, for 
women and their families it is about a positive pregnancy experience.178 In their 
systematic review of women’s expectations of antenatal care services, Downe et al 
identified expectations that were universal, In addition to investigations and 
therapeutic interventions; women need relevant and timely information, and social 
and psychological support.178 They also reported on the importance of healthcare 
providers’ attitudes and behaviours. Hence in addressing barriers to lack of or 
delayed access to antenatal care, interventions need to address not just the 
availability of services but also the quality of care provided in these services, taking 
into account the social and cultural context.   
Access and timing of antenatal care are critical for both elimination of MTCT 
and decreasing HIV-related maternal mortality. In the study on patient-related risk 
factors to target for elimination of MTCT (Paper 4), accessing antenatal care after 20 
weeks gestation was associated with a 4.3-fold increased risk for MTCT. There were 
also women who accessed no antenatal care despite knowing that they were HIV-
infected because of fears of being stigmatised by either healthcare workers or their 
families. While disclosure rates were high, similar to findings from Papers 3 and 5, 
stigma remains a reality for people living with HIV.   
With regard to decreasing maternal mortality in HIV-infected women, in our 
setting and in many resource-limited settings, antenatal care remains the cornerstone 
for diagnosis and management of HIV infection. In HIV-infected women who die 
without accessing antenatal care there are often delays in seeking care and there 
may also be delays in diagnosis and inappropriate management of conditions.179 
Lack of antenatal care was identified in almost a fifth (19.1%) of HIV-infected women 
who died in the 19-year review of maternal deaths (Paper 6). Black et al, in their 
review of maternal deaths in the early period of ART roll-out (2003-2007), reported a 
higher figure with 40% of HIV-infected women who died accessing no antenatal 
care.109 The lack of antenatal care in HIV-infected women who die is higher than that 
reported in South African national data for the pregnant population. In 2011-2015, 
94% of women had at least one antenatal visit.24 Access to antenatal care has a 
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bearing on timing of HIV diagnosis and initiation of antiretroviral therapy especially in 
settings where routine testing outside of pregnancy is not the norm. 
 
5.2 Timing of HIV diagnosis and initiation of antiretroviral therapy among HIV-
infected pregnant women  
Findings from five of the six studies (Papers 1, and 3-6) indicate that the 
majority of pregnant women were diagnosed as HIV-infected during pregnancy, also 
reported in other studies conducted in sub-Saharan Africa.64,180–182 This has 
implications on the timing of initiation of ART, and prophylaxis. While the routine 
PMTCT data (Paper 1) show that there has been an increase in the proportion of 
pregnant women presenting with a known HIV status – an increase from 14.3% in 
2009, when the indicator was first collected, to 45.0% in 2015. HIV diagnosis outside 
of pregnancy will allow for early linkage to care and initiation of ART. Preconception 
ART is associated with the lowest risk of MTCT as it increases the likelihood of being 
virally suppressed at the time of delivery, the most important factor in determining the 
risk of MTCT.183,184   
Notwithstanding the majority of pregnant women presenting in the second 
trimester and being diagnosed as HIV-infected during pregnancy, the proportion of 
ART-eligible pregnant women initiated on treatment has increased progressively as 
PMTCT and ART guidelines evolved. In the Soweto PMTCT programme, the 
percentage of pregnant women initiated on ART increased from less than 10% in 
2006 to 88% in 2011 (Paper 1). The increase in the CD4 count threshold for ART 
eligibility among pregnant women and the introduction of NIMART within antenatal 
clinics had the greatest impact in increasing treatment initiation in the programme. 
South African national figures show that in 2010 only 30% of women received ART 
before or during pregnancy, increasing to 55% in 2012.24 The rate of ART initiation 
among pregnant women in South Africa increased rapidly after 2012 with 76% 
started on ART in the financial year 2013/2014 and 94% in 2016/2017.172,185 South 
Africa is one of a few countries in sub-Saharan African where more than 90% of 
pregnant women receive antiretrovirals during pregnancy.2 The diagnosis of HIV 
infection in pregnancy, and consequently ART initiation only in pregnancy determines 
the duration of antenatal treatment. The duration of antenatal ART is directly related 
to the maternal viral load at the time of delivery, and consequently the risk of 
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MTCT.183 The diagnosis and management of HIV infection in pregnancy also has an 
impact on maternal mortality. In the review of maternal deaths (Paper 6), the majority 
of women who died were diagnosed as HIV-infected during pregnancy. Published 
data show a significant survival benefit of pre-pregnancy ART.120   
Timing of HIV diagnosis also has an impact on initiation of prophylaxis – co-
trimoxazole and isoniazid – in HIV-infected individuals. The 2016 WHO ART 
guidelines acknowledge the benefits of co-trimoxazole prophylaxis even with 
expanded access to ART, and that these benefits extend beyond the prevention of 
AIDS-associated opportunistic infections to prevention of severe bacterial infections 
and malaria.10 Isoniazid prophylaxis is also important in reducing morbidity and 
mortality in HIV-infected individuals, and in South Africa, a country with one of the 
world’s worst TB epidemics driven by HIV, TB prevention has been a neglected part 
of TB control.186     
Comprehensive data from the Saving Mothers reports have consistently 
shown non-pregnancy related infections as the leading cause of death and TB to be 
the most common cause of maternal deaths from non-pregnancy related infections.94 
Data from our review of maternal deaths (Paper 5) are consistent with these findings. 
While significant progress has been made in decreasing MTCT rates with availability 
of efficacious ARV regimens, the same level of success has not been seen in 
decreasing mortality in HIV-infected women. An important shortcoming of PMTCT 
programmes is that the focus has been on preventing HIV transmission to the infant, 
not on keeping mothers alive. Both patient-related and health system factors need to 
be addressed if we are to see a significant decrease in HIV-related maternal 
mortality. In our review the majority of maternal deaths occurred in postpartum 
period, but in most cases the conditions that led to the deaths occurred in the 
antenatal and intrapartum periods. This highlights several missed opportunities 
where HIV-infected women are in contact with health services during the antenatal 
and intrapartum periods.  
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5.3 Quality of care in PMTCT and ART programmes as reflected in the 
knowledge of PMTCT interventions 
In Papers 3 and 5, important gaps in knowledge of PMTCT and ART 
interventions were identified among both healthcare workers and women accessing 
the services. These gaps exist despite staff being trained and women receiving 
counselling, and this reflects on aspects of quality of care provided in the 
programmes. While interventions have been simplified with the same antiretrovirals 
given for PMTCT and maternal health, knowledge of how the interventions work, 
including the importance of adherence to treatment, and practices that may impact 
on the risk of MTCT and maternal health remain important. This is especially 
important for safe infant feeding practices to prevent MTCT. As the MTCT rates at 
early infant diagnosis (reflecting intrauterine and intrapartum HIV transmission) have 
decreased significantly, breastfeeding transmission has become important.2,59 
UNAIDS estimates that in sub-Saharan Africa, the transmission rate after cessation 
of breastfeeding is almost double that at early infant diagnosis.2 Data from a South 
African cohort also showed higher rates of MTCT beyond eight weeks, with 81% of 
cases of MTCT having occurred by six months postpartum.59 These results highlight 
the ongoing risk of MTCT associated with breastfeeding, and hence the importance 
of safe infant feeding practices. 
In the study assessing knowledge of safe infant practices (Paper 5), there 
were gaps in knowledge among both HIV-infected and -uninfected pregnant and 
postpartum women, but HIV-infected women had consistently better knowledge. 
Healthcare facilities were the main source of information for the majority of women 
overall, and this finding is consistent with reports from other studies.187–190 The 
rapidly evolving guidelines on safe infant feeding practices in the context of HIV 
infection, in low-resource settings, have created confusion for both healthcare 
workers and women accessing care.187,188 In counselling on safe infant feeding 
practises, the emphasis has been on HIV-infected women and an impression has 
been created that safe practices are only relevant for PMTCT.190 There is a need for 
standardisation of messaging on safe infant feeding practices targeting both HIV-
infected and -uninfected women. The information given to pregnant and postpartum 
women also needs to be accurate and consistent throughout the continuum of care. 
104 
 
Patient information should be simplified and reinforced at every opportunity. 
Understanding and adherence to treatment need not depend on level of education, 
although a low level of formal education was one of the risk factors for MTCT 
identified (Paper 4).  
 
5.4 Limitations of the research  
 Limitations specific to each study have been discussed in Papers 1-6. An 
overall limitation was the use of routine, aggregate data, related to the quality and 
completeness of the data. In public healthcare facilities, paper-based registers are 
used to record patients’ details and health information and these data are then 
captured and reported electronically. Discrepancies have been reported between the 
registers and the monthly facility reports and highlight problems with validation of 
data.191 In the Soweto PMTCT programme, monitoring and evaluation officers and 
managers have always been available and are involved in the validation of data.  
Accuracy and completeness of data extracted from patients’ records relies on notes 
made by clinicians, and also storage of the records. In the case of maternal death 
records, because maternal deaths are notifiable, there was meticulous storage of 
records.  
The use of quantitative methods in the studies meant that while a large 
number of participants could be reached and precise estimates could be calculated, 
the depth and nuances of responses may have been missed. With any clinical 
research there are reporting biases, with social desirability one of the most important 
– participants may give responses that they think are expected of them. While all the 
studies that make up this PhD were conducted in one setting, the results may not be 
generalisable to other settings in South Africa and in sub-Saharan Africa. Soweto is 
unique in that it is combination of formal and informal settlements, and is a relatively 
mobile community with people moving from provinces in South Africa and from 
neighbouring countries. Due to often poor resources in rural areas, it is common 
practice that pregnant women move from rural to urban areas during pregnancy and 
move back home after delivery. The same reason is what drives pregnant women 
from neighbouring countries to South Africa, and Johannesburg, because of its 
location, is the most accessible city in South Africa. The Soweto PMTCT programme 
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is also not typical of public healthcare programmes in South Africa in that since its 
inception it has had strong partner support from non-governmental organisations, 
and had better resources in terms of staff and infrastructure. 
 
5.5 Conclusion  
The findings of this PhD provide valuable information on how the PMTCT and 
ART programmes evolved in Soweto, South Africa, as an example of high HIV-
prevalence urban setting. With data spanning almost two decades, in one of the 
largest programmes in South Africa, these show how a successful collaboration can 
be achieved between the Department of Health and donor-funded organisations. For 
the future, the priority is to ensure that the gains made in decreasing the MTCT rate 
in the early postnatal period are sustained well into the postnatal period, beyond the 
cessation of breastfeeding. Strategies need to be in place to ensure long-term 
retention in care during pregnancy and postpartum. In women on ART, high rates of 
postpartum loss to follow-up is one of the greatest challenges identified.66-68 Large-
scale viral suppression during pregnancy, postpartum and long-term will require 
innovative interventions such as point-of-care viral load testing. 
Factors and practices that increase the risk of MTCT also need to be 
addressed as availability of efficacious antiretrovirals alone is not enough. There is a 
need for research to investigate why there are still important gaps in the knowledge 
of PMTCT interventions. Also, research to determine why the rate of unplanned 
pregnancies and undiagnosed maternal HIV infection prior to conception remain 
high, and why there are still delays in accessing antenatal care. Interventions are 
also needed to address these challenges that still remain in PMTCT programmes. 
While progress has also been made in decreasing HIV-related maternal mortality, 
there are still many avoidable deaths in HIV-infected women. As we work towards the 
SDG targets on maternal mortality, there is an urgent need to address drivers of 
mortality in HIV-infected women.      
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Questionnaire for healthcare workers in the study on assessment of the new PMTCT programme in 
Soweto, Johannesburg 
 
This questionnaire is part of a study to assess healthcare workers’ and clients’ experiences with the 
new PMTCT programme in Soweto, Johannesburg. The programme was rolled out in March 2008, 
and most facilities have had at least 6 months experience with the new programme. The aim of this 
study is to assess these experiences, and identify any challenges and shortcomings in the 
programme. 
 
Any information you give will be treated with confidence, and you may refuse to answer any 
questions you are not comfortable with.     
 
Questions about self 
 
1. Gender 
 Female 
 Male 
 
2. What is your position in the clinic? 
 Midwife 
 PMTCT coordinator 
 PCR sister 
 Lay counselor 
 Other, specify____________ 
 
3. How long have you been in the current position? 
 Less than 6 months 
 6 months to 1 year 
 2 to 5 years 
 6 to 10 years 
 More than 10 years 
 
Questions about the job 
 
4. How many patients do you see everyday? 
 Indicate number 
 
5. Are you coping with the number? 
 Yes 
 No 
 
6. If you are not coping, have you spoken to anyone about it? 
 Yes 
 No 
 Coping 
 
7. If you are not coping, and have spoken to someone, has anything been done to make the situation   
better? 
 Yes 
 No  
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8. How satisfied are you with these aspects of your job? 
     
    1 = not satisfied  
    2 = only slightly satisfied  
    3 = satisfied 
    4 = very satisfied 
    5 = extremely satisfied 
 
 Working hours 
 Working conditions 
 Cooperation of coworkers 
 Support from your supervisor 
 Attitude of your supervisor 
 Technical ‘know-how’ of your supervisor 
 The amount of pay for the work that you do  
 Personal knowledge on PMTCT 
 Personal knowledge on HIV/AIDS 
 The number of clients you see everyday  
 Knowledge of clients about the new PMTCT programme 
 Attitude of clients 
 Ability to manage clients who are HIV-infected  
 Chance to be of service to others 
 Interaction with the community you are working in 
 
 
Questions on the new PMTCT programme 
 
9. Were you informed about the new programme before it started? 
 Yes 
 No 
 Don’t know 
 
10. Do you feel that the information you were given was enough? 
 Yes 
 No 
 Don’t know 
 
11. Did you receive any training before the new programme was started? 
 Yes 
 No 
 
12. Do you feel that the training you received was sufficient? 
 Yes 
 No 
 Don’t know  
 
13. Except for the training you received, have you had any other opportunities to learn about the 
new programme? 
 Yes 
 No  
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14. If you had other opportunities to learn, where were they from? 
 Government guidelines 
 Further training on the programme 
 Media 
 Co-workers 
 Other, specify________________ 
 
15. Do you feel confident to manage pregnant women who are HIV-infected? 
 Yes 
 No  
 
16. Is there somebody you can ask if there is an issue you are not sure about in the management of 
your clients? 
 Yes 
 No  
 
Questions on people’s perception about pregnant women with HIV/AIDS. 
Please answer strongly agree (SA), agree (A), disagree (D), strongly disagree (SD), don’t know (DK)  
 
17. Pregnant women with HIV/AIDS deserve special care 
  
 
18. Disclosure is still a big issue in pregnant women who are HIV-infected 
  
 
19. HIV-infected pregnant women face neglect from their partners 
 . 
 
20. HIV-infected pregnant women face violence from their partners 
  
 
21. People with HIV/AIDS should not have children 
  
 
22. HIV-infected women are not compliant on their ART 
  
 
23. Healthcare facilities are not doing enough to support HIV-infected pregnant women 
 . 
 
24. The government is not doing enough to support HIV-infected pregnant women 
 . 
 
25. Women with HIV/AIDS are having too many children 
 . 
 
26. HIV-infected women are getting pregnant to get grant money 
  
 
27. Men are involved in the PMTCT programme 
 . 
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28. Men should be tested for HIV if their partner is positive 
  
 
I am going to ask you a few questions about PMTCT 
 
29. Someone who has taken nevirapine in a previous pregnancy cannot take it again in the next 
pregnancy 
 Yes 
 No  
 
30. If she takes Nevirapine a second time, it does not work 
 Yes 
 No 
 
31. Nevirapine can be taken more than once in the same pregnancy 
 Yes 
 No  
 
32. Taking AZT alone can lead to the development of resistance 
 Yes 
 No 
 
33. AZT alone is used to treat HIV even if one is not pregnant 
 Yes 
 No  
 
34. All pregnant women should be given HAART regardless of their CD4 count 
 Yes 
 No  
 
35. If a pregnant woman gets HIV for the 1st time during pregnancy, chances of infecting the baby are 
small 
 Yes 
 No  
 
36. It is important to know the pregnant woman’s partner’s HIV status 
 Yes 
 No 
 
37. If a woman exclusively breastfeeds, the baby cannot get HIV 
 Yes 
 No 
 
38. When a child is more than a year old and the mother is still breastfeeding, chances of the baby 
getting HIV are smaller than when the child is less than 6 months old 
 Yes 
 No  
 
39. Women who are HIV-infected should not use the loop (IUCD) for contraception 
 Yes 
 No  
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Questions on attitudes towards the new PMTCT programme 
 
40. Has the new programme increased your workload? 
 Yes 
 No 
 
41. Do you think you were prepared for the new programme when it started? 
 Yes 
 No 
 
42. Do you think the new programme is helping HIV-infected pregnant women and their children? 
 Yes 
 No  
 
43. Do you think it is a good thing that the programme was started? 
 Yes 
 No  
 
44. Do you think you need more staff to deal with the new programme? 
 Yes 
 No 
 
Questions about the clients’ knowledge and attitudes towards the new programme 
 
45. Where you work, do you have a lot of clients, who refuse to take AZT? 
 Yes 
 No 
 
46. Do you think your clients are compliant on AZT? 
 Yes 
 No 
 
47. Do your clients know enough about the new programme? 
 Yes 
 No 
 
48. Do your clients ask a lot of questions? 
 Yes 
 No 
 
49. Do you think most of your clients disclose their status to their partners? 
 Yes 
 No 
 
50. Do you think your clients understand all the information given to them about the PMTCT 
programme? 
 Yes 
 No  
 
Is there anything that could have been done differently about the new programme? 
 Yes 
 No 
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If yes, what could have been done differently? 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
____________________________________________________________________________ 
 
Is there anything that can be done to improve the programme? 
 Yes 
 No 
 
If yes, what do you think can be done? 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
______________ 
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Questionnaire for clients in the study on assessment of the new PMTCT programme in Soweto, 
Johannesburg 
 
This questionnaire is part of a study to assess clients’ and healthcare workers’ experiences with the 
new PMTCT programme that was started in March 2008. Clients who will be interviewed are those 
who are HIV-infected, pregnant and attending antenatal clinics in healthcare facilities in Soweto, 
Johannesburg.   
 
 History of previous pregnancies: 
 
1. Age                                                                                                               
 
2. Parity                                                                                                           
 
3. Gravidity                                                                                                     
 
4. Gestational age                                                                 weeks/       months 
 
5. Number of live children                                                                           
 
6. When did you discover that you are HIV positive? 
 Current pregnancy 
 Previous pregnancy 
 Other time outside of pregnancy 
 
7. If diagnosed in previous pregnancy, did you take nevirapine then? 
 Yes 
 No  
 Don’t know 
 
8. If nevirapine was taken, what year was it?                                       
 
9. Has the baby from that pregnancy been tested for HIV? 
 Yes 
 No  
 
10. If tested, what is the baby’s HIV status? 
 Negative 
 Positive 
 Don’t know 
 
Questions on disclosure of HIV status: 
 
11. Have you disclosed your HIV status? 
 Yes 
 No 
 
12. If yes, to whom? 
 Partner 
 Parent 
 Sibling 
 Friend 
 Other, specify_____________ 
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13. If you have not disclosed to partner, why? (Can choose more than 1 option) 
 Partner will leave me 
 Scared that partner will be violent 
 Partner will accuse me of being unfaithful 
 Partner will accuse me of infecting him with HIV 
 Other, specify ___________________________ 
 
14. Have you discussed HIV/AIDS with your partner? 
 Yes 
 No  
 
15. Do you know your partner’s HIV status? 
 Yes 
 No  
 
16. If known, what is it? 
 Negative 
 Positive 
 Don’t know 
 
Questions about current pregnancy and PMTCT: 
 
17. How far was your pregnancy when you booked?                                     weeks 
 
18. What is your latest CD4 count?                                                                
 
19. Have you started using AZT yet? 
 Yes 
 No  
 
20. If yes, how long have you been using AZT for?                                          weeks 
 
21. Why are you using AZT/ why do you need to use AZT if you are HIV-infected and pregnant? 
 For my own health 
 To prevent my partner getting HIV 
 To decrease the chance of the baby getting HIV 
 All of the above 
 
22. What is the ideal time to start AZT? 
 3 months 
 5 months 
 7 months 
 9 months 
 
23. Is AZT taken throughout pregnancy? 
 Yes  
 No 
 Don’t know 
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24. What do you need to take during labour? 
 Nothing 
 Nevirapine only 
 AZT only 
 Nevirapine and AZT 
 Don’t know 
 
25. Does the baby get any treatment after being born? 
 Yes  
 No 
 Don’t know 
 
26. If yes, what does the baby get? 
 Nevirapine only 
 AZT only 
 Nevirapine and AZT 
 Don’t know 
 
27. If the mother took AZT for 2 months in pregnancy, and the baby is given AZT, how much does it 
get?  
 1 day 
 7 days 
 10 days 
 28 days 
 Don’t know 
 
Questions on infant feeding and testing: 
 
28. What have you decided to give your baby after delivery? 
 Breast milk only 
 Formula only 
 Breast milk and formula 
 Have not decided yet 
 
29. If you have chosen to exclusively breast feed, how long should it be for? 
 1 month 
 3 months 
 6 months 
 9 months 
 
30. If you have chosen to exclusively formula feed, how long should it be for? 
 1 month 
 3 months 
 6 months 
 9 months 
 
31. If exclusive breast feeding is the preferred option, what else can be given to the baby? 
 Water 
 Formula 
 Porridge  
 Nothing 
 Don’t know 
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32. If exclusive formula feeding is option chosen, what else can be given to the baby? 
 Water 
 Breast milk 
 Porridge 
 Nothing 
 Don’t know 
 
33. Do you think that if you choose to use formula, people will know that you are HIV-infected? 
 Yes 
 No  
 
34. At what age is the baby usually tested for HIV for the 1st time? 
 At birth 
 At 4 or 6 weeks 
 At 3 months 
 At 6 months 
 At 1 year 
 
Questions on counseling: 
 
35. Do you think that the information you are given by sisters and counselors is enough? 
 Yes 
 No 
 
36. How many counseling sessions have you received? 
 None 
 1 session  
 2 sessions 
 3 sessions 
 More than 3 sessions 
 
37. Do you think that the time the counselors/health care workers spend talking to you is enough? 
 Yes 
 No 
 
38. Do you think the counselors/health care workers treat you differently because you are HIV 
positive? 
 Yes 
 No  
 
39. Are the counselors/health care workers impatient with you? 
 Sometimes 
 All the time 
 Never 
 
 
40. Do you belong to a support group? 
 Yes 
 No  
 
 
 
 
190 
 
41. If you belong to a support group, does it help you in any way? 
 Yes 
 No  
 Don’t know 
 
42. Is there anything else you would like to say about being HIV positive and pregnant? 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
________________________________________________________________ 
 
43. Is there anything that can be done differently in the antenatal clinics? 
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
____________________________________ 
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Questionnaire for audit study  Study number:  
 
Date of interview: __/ __/ __ (dd/mm/yy)  
 
Clinic: ________________________            
 
Clinic number:  
 
 
A. Demographics: 
 
1. Age:            
 
2. Place of birth:  South Africa 
 Mozambique 
    Zimbabwe 
 Other, specify_________ 
 
 
3. Parity:   4. Gravidity:  
 
5. Marital status:    single and not living with partner 
        unmarried, but living with partner 
        married 
      divorced 
      widowed 
     other, specify________________ 
 
6. Highest level of education:  no formal schooling 
     junior school (grade 1-7) 
     senior school (grade 8-11) 
     matric (grade 12) 
     tertiary education 
 
7. Employed:      yes  no 
 
8. Source of income:    self only 
              partner only 
                   self and partner 
              parents  
              other, specify______________ 
 
9. Dwelling:      house with electricity and water 
              informal settlement 
 
B. History of positive HIV status: 
 
10. Known HIV positive before last pregnancy:  yes  no 
 
11. If known, for how long?  month(s) or  
           year(s) 
 
12. On ART prior to last pregnancy:  yes  no 
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13. If yes, for how long?  month(s) or 
     year(s) 
 
14. Any regimen change since start of ART:  yes  no 
 
15. If yes, reason for regimen change:     side effects 
      non-adherence 
      pregnancy 
      other, specify _______________ 
 
16. Has a CD4 count ever been done?  yes  no  
       
17. If yes, what is the latest CD4 count?  
 
18. Partner’s HIV status:  negative 
  positive 
                                            unknown 
 
19. If partner HIV-infected, on ART:  yes  no  don’t know 
 
C. History of previous pregnancies:  
 
20. Previous PMTCT (excluding last pregnancy):  yes  no 
 
21. If yes, how many pregnancies where PMTCT was taken:  
 
22. If previous PMTCT, how long ago was it:  months  year(s) 
 
23. Please give details about previous pregnancies with known positive HIV status: 
 
Year  Type of 
PMTCT 
taken 
Child’s HIV 
status 
If child HIV+, 
on ART? 
 
  
 
  
  
 
  
  
 
  
  
 
  
 
D. History of last pregnancy: 
 
24. Planned pregnancy:  yes  no  
 
25. Booked:  yes  no 
 
26. If unbooked, what was the reason:   clinic far 
      turned away from the clinic 
         did not know she was pregnant until very late 
      other, specify ______________________ 
Type of PMTCT taken: 1=sdNVP, 
2=AZT only, 3=sdNVP and AZT, 
4=ART, 5=other, specify 
Child’s HIV status: 1=negative, 
2=positive  
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27. If booked, facility where antenatal clinic attended: _______________________ 
 
28. Province where antenatal clinic attended:    Gauteng 
        Western Cape 
        Eastern Cape 
        KwaZulu-Natal 
        Limpopo 
        Mpumalanga 
        North West 
        Northern Cape 
        Free State 
 
29. Antenatal clinic attended in another country:  Zimbabwe 
         Mozambique 
         Other, specify ______________ 
 
30. Gestational age at booking:  weeks  
 
31. Total number of antenatal clinic visits:  
 
32. HIV test done antenatally:  yes  no 
 
33. HIV test only done after delivery:  yes  no 
 
34. If HIV test only done after delivery, reason(s) why only done after delivery:    
      unbooked 
      not offered HIV test during pregnancy 
      declined HIV test during pregnancy 
      other, specify ________________________ 
 
If HIV test done antenatally, 
 
35. Gestational age when HIV test done:  
 
36. CD4 cell count done at same visit:  yes  no  
 
37. Was CD4 count result given:  yes  no 
       
If given, how long after HIV test were CD4 cell count results collected:  day(s) 
          week(s) 
 
38. If CD4 cell count not done at same visit as HIV test, at what gestation was it done:   
           weeks 
 
39. Booking CD4 cell count result:  
 
40. Prophylaxis or ART received during last pregnancy:   AZT only 
        AZT 1st, then ART 
        ART   
 nothing 
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41. If AZT received, gestational age at which started:  weeks 
      Total duration of AZT before delivery:  weeks  
 
42. If ART started in last pregnancy, gestational age at which started:  weeks 
      Total duration of ART before delivery:  weeks 
 
43. If ART started before last pregnancy, total duration of ART before delivery: 
  weeks 
  year(s) 
 
44. Self-reported adherence to AZT or ART during pregnancy:   very good 
                  good 
                  fair 
                  poor 
                  very poor 
 
E. History of labour and delivery:  
 
45. Date of delivery: __/ __/ __ (dd/mm/yy) 
 
46. Place of delivery:   Chris Hani Baragwanath Hospital 
               Lenasia South 
               Lillian Ngoyi 
              Zola 
              Itereleng 
               Stretford 
              Mofolo 
              Home 
               Other, specify ________________ 
 
 
47. Gestational age at delivery:  weeks 
      Based on   dates 
            ultrasound  
 
48. Mode of delivery:   normal vaginal delivery 
    elective caesarean section, indication _______________  
    emergency caesarean section, indication _______________ 
    vacuum 
    forceps 
 
49. Episiotomy:   yes  no 
 
50. Birth weight:  g 
    
51. Intrapartum and postpartum complications during labour:  
    none 
    rupture of membranes more than 4 hours before delivery 
    labour more than 12 hours 
    labour augmented 
                                     antepartum haemorrhage 
    baby admitted to neonatal ICU  days               
                other, specify ______________________________ 
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52. Prophylaxis or treatment taken during labour and delivery:   NVP only 
         AZT only 
         NVP and AZT 
         Truvada 
         ART  nothing 
 
53. If no prophylaxis or treatment taken, what were the reasons: 
       forgot to take tablets 
       tablets left at home 
       declined treatment 
       other, specify __________________ 
F. Infant prophylaxis given: 
 
54. Infant prophylaxis given after delivery:   sdNVP only 
                 AZT syrup for 7 days 
               AZT syrup for 28 days 
                 AZT syrup for 6 weeks 
                NVP syrup for 6 weeks 
                 extended NVP syrup prophylaxis 
                 nothing 
 
55. If infant prophylaxis given, how soon after delivery was the prophylaxis given? 
                 immediately after delivery 
           days after delivery 
            weeks after delivery 
            months after delivery 
 
56. If no infant prophylaxis given, reasons why not given: 
                
                        not offered 
                 declined infant prophylaxis 
                 other, specify ____________________ 
 
G. Infant feeding option: 
 
57. Counselling given on infant feeding:  yes  no  
 
58. Infant feeding option chosen after delivery:   exclusive breastfeeding 
             exclusive formula feeding 
             mixed feeding 
 
59. If exclusive breastfeeding, duration:  week(s)   month(s) 
           
60. If exclusive formula feeding, duration:  week(s)   month(s) 
               
61. Source of formula if formula feeding:  local clinic 
        buys own formula   
        other, specify _______________________ 
 
62. Has the supply of formula been:   uninterrupted 
             interrupted 
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63. Current infant feeding option:  exclusive breastfeeding 
     exclusive formula feeding 
     mixed feeding 
 
64. Duration of current feeding option:   days 
 weeks 
 months 
 
H. Infant testing and treatment: 
 
65. Age at which baby first tested for HIV:  week(s)   month(s) 
 
66. Previous admission to hospital:  yes  no 
 
67. If admitted, reason for admission:  gastroenteritis 
       chest infection 
       other, specify ______________________ 
 
68. Duration of admission:  days   weeks 
 
69. Is the baby currently on any of the following:   none 
 cotrimoxazole 
                 antibiotics 
                TB treatment 
               multivitamins 
                other, specify ________________ 
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Infant feeding survey interview guide – antenatal component   
 
The interview guide is for both HIV-infected and –uninfected women  
 
Date of interview: ___/ ___/___          Interviewer: _______________ 
        dd   mm   yy 
 
 Study number:      Clinic number:  _____________ 
 
 
     Number of clinic visits for this pregnancy – 1st, 2nd, 3rd, 4th, other________  
(Circle the one that applies, and include current visit)  
 
A. Demographics: 
 
1. Age: _____ 2. Weeks pregnant _____ (Get duration of pregnancy from the antenatal card) 
 
3. Number of previous pregnancies: _____  
    (Include all pregnancies whether the child/children are alive or not)  
     
4. Marital status:   Single and not living with partner  Single, but living with partner 
 Married  Divorced  Widowed     
 Other, specify________________ 
 
5. Highest level of education:    Junior school (grade 1-7)   Senior school (grade 8-11) 
 Matric (grade 12)   Tertiary education  No formal schooling 
 
6. Employed:  Yes  No 
 
7. Source of income:    Self only  Partner only   Self and partner 
     Parents Other, specify______________ 
 
8. Dwelling:     House with electricity and water 
     Informal settlement, if yes,  
A. does it have water?  (inside)  Yes  No  
    B. does it have electricity?  Yes  No    
 
9. Total number of people in household: _____ 
 
10. Number of children younger than 18 years in household: _____ 
      (Include also those that are not the client’s own) 
 
11. Currently living with parents or parent in-laws in household:  Yes  No 
 
B. Details on HIV status 
 
12. HIV status:  Negative  Positive  Unknown  
 
13. Timing of HIV diagnosis:  Before current pregnancy    During pregnancy      Not done 
                  (Current pregnancy) 
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14. If HIV positive, latest CD4 count: _____ 
       (From the antenatal card)     
15. What tablets are you currently taking?  FDC/ART started before current pregnancy 
                                                                                        AZT        FDC/ART started during pregnancy 
       Nothing  Other, specify ____________ 
16. Have you disclosed your HIV status?   Yes   No 
      (Whether HIV-infected or –uninfected) 
 
If no, why? 
_____________________________________________________________________________ 
 
17. If you’ve disclosed, who have you disclosed to?     Partner   Parent  Sibling 
 Friend   Other, specify________ 
(Can choose more than one answer) 
 
C. Infant feeding choices: 
 
18. Have you ever breastfed before?   Yes  No 
 
19. If you’ve breastfed before, what is the longest time you breastfed for? _________________ 
(Weeks, months, years. If there’s more than one child that was breastfed, choose one that was         
breastfed the longest, and give that answer) 
 
20. What are you planning to feed the baby?  Breast milk only  Formula only 
   Breast milk and formula  Other, specify ______________________ 
 
21. Did you receive counselling in the clinic on infant feeding?    Yes  No  
 
22. If planning to breastfeed, how long do you plan to breastfeed for? 
 _____ weeks or  _____months or  _____years  
 
23. If planning to formula feed, how long do you plan to formula feed for 
_____ weeks or  _____months or  _____years  
 
24. If planning to give breast milk and formula, how long do you plan to give this for? 
_____ weeks or  _____months or  _____years  
 
25. If planning to formula feed, where will you get the money to buy formula from? 
 Own money   Money from partner   Money from your family 
 Money from partner’s family  Social grant   Other, specify_______________ 
(Can choose more than one) 
26. Why have you decided the above?       
 Information from the clinic    Information from the media, e.g. radio  
 Decision made with partner     Influence from the family                               
 Information from friends    Other, specify ____________________________ 
(Can choose more than one) 
 
27. Have you discussed your decision with anyone?   Yes   No 
       (Infant feeding choice) 
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28. If yes, who have you discussed it with?   Partner  My family  Partner’s family 
       Friend  Other, specify_______________ 
       (Can choose more than one; exclude healthcare workers) 
 
29. If HIV-infected, has your HIV status influenced your infant feeding choice?   Yes   No  
Explain, 
______________________________________________________________________________ 
(Only ask if the woman is HIV-infected) 
 
30. If employed, are you returning to work after delivery?   Yes  No 
If returning to work, when? In  6 weeks  3 months  4 months  5 months 
 6 months  other, specify ____________________________ 
 
How has this affected your infant feeding choice? 
__________________________________________________________________________________ 
 
__________________________________________________________________________________ 
 
 
D. Infant Feeding knowledge 
 
Please do not lead clients when asking questions, and don’t comment if they give wrong answers. 
Be careful of your body language also when asking the questions   
 
31. If one chooses to exclusively breast feed, how long should it be for? 
 1 month  3 months   6 months   9 months  other, specify ________  
 
32. If one chooses to exclusively formula feed, how long should it be for? 
 1 month  3 months   6 months   9 months  other, specify ________  
 
33. If exclusive breast feeding is the option chosen, what else can be given to the baby? 
 Water  Formula milk  Porridge  Other food   Nothing  Don’t know 
(Can choose more than one) 
 
34. If exclusive formula feeding is the option chosen, what else can be given to the baby? 
 Water  Breast milk  Porridge  Other food   Nothing  Don’t know 
(Can choose more than one) 
 
35. Do you think that if you choose to use formula, people will think that you are HIV-infected? 
 True   False 
36. Do you think most mothers exclusively breastfeed for 6 months?   
 True     False    Don’t know 
 
37. Do you think it is easy for mothers to exclusively breastfeed for 6 months? 
 True     False    Don’t know 
 
38. Enough information is given in the clinics to encourage mothers to exclusively breastfeed 
 True     False    Don’t know 
 
39. Working mothers can easily exclusively breastfeed for 6 months    
 True     False    don’t know   
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40. When an infant cries it always means that it’s hungry           
 True     False    don’t know    
 
41. Breast milk is better than formula milk             
 True     False    don’t know      
 
42. Formula milk is almost as good as breast milk            
 True     False    don’t know     
 
43. Infants who are breastfed are less likely to get infections           
 True     False    don’t know 
 
44. All mothers should breastfeed for up to 2 years            
 True     False    don’t know 
 
Questions 45 to 52 must be answered by both HIV+ and HIV- women 
 
45. Does the HIV-infected mother who is breastfeeding need to take any medication?  
Yes        No        Don’t know 
 
46. If she needs to take medication, what does she need to take? 
____________________________________________________________________________  
 
47. If she takes medication, how long does she need to take it for? 
 For life     Until 1 week after stopping breastfeeding      It depends on the CD4 count      
 Don’t know       other, specify ____________  
 
48. Does the baby need to take medication during breastfeeding?    
 Yes        No        don’t know 
 
49. If the baby needs to take medication, what does it need to take? __________________________  
 
50. If the baby takes medication, how long does it need to take it for? 
 6 weeks      12 weeks    6 months      9 months      It depends on whether the mother is on 
ART or the FDC and when she started treatment   
 Don’t know       other, specify ____________  
51. If the mother is HIV-infected, when is the infant first tested for HIV?    
At  ______ weeks or _____months 
 
52. With the HIV-infected mother, when is the infant tested again after stopping breastfeeding? 
 
After:    1 month        6 weeks        3 months        6 months        9 months        
              Other, specify ________        don’t know  
 
E. Breastfeeding support 
 
53. Not enough information is given in the clinics on exclusively breastfeeding 
 True    False    don’t know  
 
54. Breastfeeding support groups in the clinics would encourage mothers to exclusively breastfeed 
         True    False    Don’t know 
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55. Breastfeeding support groups in the community would encourage mothers to exclusively 
breastfeed         True    False    Don’t know 
 
56. Cultural factors prevent most mothers from exclusively breastfeeding 
        True   False      Don’t know 
 
57. Influence from elders in the family prevent most mothers from exclusively breastfeeding 
        True   False      Don’t know 
 
Comments: ________________________________________________________________________ 
__________________________________________________________________________________
__________________________________________________________________________________ 
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Infant feeding survey interview guide – postnatal component  
 
Date of interview: ___/ ___/___     Interviewer: _______________ 
 
 Study number:        Clinic number: _____________ 
 
 
A. Demographics: 
 
1. Age: _____        2. Number of previous pregnancies: _____ 
  (Include all pregnancies whether the child/children are alive or not-include the recent pregnancy) 
 
3. Marital status:   Single and not living with partner Single, but living with partner 
 Married  Divorced Widowed  Other, 
specify____________ 
4. Highest level of education:  Junior school (grade 1-7)      Senior school (grade 8-11) 
 Matric (grade 12)      Tertiary education      No formal 
schooling 
5. Employed:  Yes  No 
 
6. Source of income:    Self only      Partner only      Self and partner 
     Parents        Other, specify______________ 
7. Dwelling:     House with electricity and water 
     Informal settlement, if yes, does it have water?  Yes  No ;  
                                                                                                            Does it have electricity? Yes  No    
8. Total number of people in household: _____ 
 
9. Number of children younger than 18 years in household: _____ 
      (Include also those that are not the client’s own) 
 
10. Currently living with parents or parent in-laws in household:  Yes  No 
 
 
B. Details on HIV status: 
 
11. HIV status:  Negative  Positive  Unknown  
 
12. Timing of HIV diagnosis:  Before pregnancy  During pregnancy  Not done 
    (Recent pregnancy) 
 
13. If HIV positive, latest CD4 count: _____ (If available) 
 
14. What tablets are you currently taking?  FDC/ART started before pregnancy 
       FDC/ART started during pregnancy 
       Nothing  Other, specify _____________ 
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15. Have you disclosed your HIV status?   Yes   No 
      (Whether HIV-infected or –uninfected) 
 
16. If you’ve disclosed, who have you disclosed to?    Partner   Parent  Sibling 
 Friend   Other, 
specify____________ 
(Can choose more than one answer) 
C. Infant feeding choice: 
 
17. How old is the infant? _____ weeks/months 
 
18. Place of delivery:   Chris Hani Baragwaneth Hospital  Lenasia South 
 Lillian Ngoyi   Zola   Itereleng Stretford  Mofolo  Home 
 Other, specify ________________ 
19. Date of delivery: ___/___/___  
          dd/mm/yy 
 
20. What are you currently feeding the infant?  Breast milk only  Formula only 
 Breast milk and formula  Breast milk and solids  Formula and solids 
 Other, specify ______________________ 
 
21. If breastfeeding, how long have you been breastfeeding for?   
_____ weeks or ______ months 
 
22. Have you ever breastfed before?   Yes   No 
 
23. If you’ve breastfed before, what is the longest time you breastfed for? _________________ 
(Weeks, months, years. If there’s more than one child that was breastfed, choose one that was         
breastfed the longest, and give that answer) 
 
24. If formula feeding, how long have you been formula feeding for?   
_____ weeks or   _____ months 
 
25. If giving breast milk and formula, how long have you been giving this for?  
_____ weeks or   _____ months 
 
26. If giving breast milk and solids, how long has she been giving this for? 
_____ weeks or   _____ months 
 
27. If giving formula and solids, how long have you been giving this for? 
_____ weeks or   _____ months 
 
28. Have you given any of the following: gripe water, traditional medicines, tea, water, juice or any 
other drinks? (Circle the ones that apply)- (Can choose more than one) 
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29. If using formula, where do you get the money to buy formula from? 
 Own money   Money from partner   Money from my family 
Money from partner’s family  Social grant   Other, specify 
_________________ 
(Can choose more than one) 
 
30. What is your current infant feeding decision based on?   
 Information from the clinic   Information from the media, e.g. radio or TV 
 Decision made with partner    Influence from the family 
 Information from friends  Other, specify ____________________________ 
(Can choose more than one) 
 
31. Have you discussed your decision with anyone?  Yes  No 
(infant feeding choice) 
 
32. If yes, who have you discussed it with?   Partner  Her family  Partner’s family 
 Friend  Other, specify ____________________________ 
 (Can choose more than one; exclude healthcare workers) 
33. If HIV-infected, has your HIV status influenced your infant feeding choice?   Yes   
No  
 
Explain____________________________________________________________________________ 
(Only ask if the woman is HIV-infected) 
 
34. Are you returning to work?     Yes   No     
 
35. If you are returning, when are you returning?  Have returned already 
Returning in:   6 Weeks  3 Months  4 Months  5 Months  6 Months 
 Other, specify ____________________________ 
36. How has this affected your infant feeding choice? 
_________________________________________ 
 
__________________________________________________________________________________ 
 
37. If you have chosen to exclusively breastfeed, what have the challenges been? 
_________________________________________________________________________________ 
 
__________________________________________________________________________________ 
 
D. Infant feeding knowledge: 
 
Please do not lead clients when asking questions, and don’t comment if they give wrong answers. 
Be careful of your body language also when asking the questions  
 
38. If one chooses to exclusively breast feed, how long should it be for? 
 1 month  3 months   6 months   9 months  Other, specify ________  
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39. If one chooses to exclusively formula feed, how long should it be for? 
 1 month  3 months   6 months   9 months  Other, specify ________  
40. If exclusive breast feeding is the option chosen, what else can be given to the baby? 
 Water  Breast milk  Porridge  Other food     Nothing   Don’t know 
(Can choose more than one) 
41. If exclusive formula feeding is the option chosen, what else can be given to the baby? 
 Water  Breast milk  Porridge  Other food     Nothing   Don’t know 
(Can choose more than one) 
42. Do you think that if you choose to use formula, people will think that you are HIV-infected? 
 Yes   No 
43. Do you think most mothers exclusively breastfeed for 6 months?   Yes  No     Don’t 
know 
44. Do you think it is easy for mothers to exclusively breastfeed for 6 months?  
  Yes       No       Don’t know 
45. Enough information is given in the clinics to encourage mothers to exclusively breastfeed 
  True      False   Don’t know 
46. Working mothers can easily exclusively breastfeed for 6 months 
  True      False   Don’t know  
47. When an infant cries it always means that it’s hungry 
  True       False   Don’t know 
48. Breast milk is better than formula milk 
  True       False   Don’t know  
49. Formula milk is almost as good as breast milk 
  True       False   Don’t know  
50. Infants who are breastfed are less likely to get infections 
  True       False   Don’t know 
51. All mothers should breastfeed for up to 2 years 
  True       False  Don’t know 
Questions 52 to 59 must be answered by both HIV+ and HIV- women 
 
52. Does the HIV-infected mother who is breastfeeding need to take any medication?   
  Yes   No    Don’t know 
53. If she needs to take medication, what does she need to take? 
_______________________________  
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54. If she takes medication, how long does she need to take it for? 
 1 month  3 months   6 months  9 months  It depends on the CD4 count  
 Don’t know   other, specify _______________________________________________  
55. Does the baby need to take medication during breastfeeding? 
 Yes         No   Don’t know 
56. If the baby needs to take medication, what does it need to take? 
_____________________________  
57. If the baby takes treatment, how long does it need to take it for? 
 1 month  3 months   6 months  9 months  It depends on whether the 
mother is on FDC/ART and when it was started     Don’t know   Other, specify 
_________________________  
58. If the mother is HIV-infected, when is the infant first tested for HIV?   At _______ weeks/months 
59. With the HIV-infected mother, when is the infant tested again after stopping breastfeeding? 
After:  1 month    6 weeks   3 months     6 months     9 months    Don’t know 
 
D. Breastfeeding support: 
 
60. Not enough information is given in the clinics on exclusively breastfeeding  
True      False      Don’t know  
61. Breastfeeding support groups in the clinics would encourage mothers to exclusively breastfeed  
True     False      Don’t know 
62. Breastfeeding support groups in the community would encourage mothers to exclusively 
breastfeed           
 True     False      Don’t know  
63. Cultural factors prevent most mothers from exclusively breastfeeding 
True      False      don’t know 
64. Influence from elders in the family prevent most mothers from exclusively breastfeeding 
 True     False      don’t know 
 
Comments: ________________________________________________________________________ 
__________________________________________________________________________________
_________________________________________________________________________________ 
 
 
 
 
 
207 
 
Maternal mortality study data collection tool 
 
File number: _______________   Study number:  
 
Background information 
 
Area of residence: ___________________________________________________________________  
 
Age at time of death: ____ years Parity: ____ Gravidity: ____   
 
Booked: Y/N  Booking date: ___/___/___ Gestational age at booking: ____ weeks  
 
Gestational age determined by: LNMP/palpation/ultrasound  
 
Singleton/twins/other, specify ________________________ 
 
 ectopic pregnancy     abdominal pregnancy gestational age: ____ weeks      
 
  other, specify____________________  
 
Booking haemoglobin: _____ 
 
At the time of death, was the woman still pregnant?              Y/N 
 
If not pregnant, when did she die?  during labour and delivery   postpartum  
  
Details on HIV testing 
 
Timing of HIV test: prepregnancy/antenatal/intrapartum/postpartum/not done  
 
HIV status: negative/positive/unknown   
 
If HIV positive, baseline CD4 count done: Y/N        Date of baseline CD4 count: ___/___/___  
 
Baseline CD4 count result: _______ 
 
Antenatal AZT initiated: Y/N           Date AZT initiated: ___/___/___  
 
Duration of AZT before delivery or death: ____ days/weeks 
 
Preconception ART: Y/N  If yes, duration: ____ months/years 
 
ART regimen:     d4T     TDF     3TC     AZT     NVP     EFV     Aluvia     
 
   unknown          other, specify ______________________ 
 
Referred for ART antenatally: Y/N   If referred, date referred: __/ __/ __ 
 
ART initiated during pregnancy: Y/N If yes, duration of ART before death: ____ weeks/months 
 
ART regimen:     d4T     TDF     3TC     AZT     NVP     EFV     Aluvia     
   
 other, specify ______________________ 
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Comments: _______________________________________________________________________ 
 
__________________________________________________________________________________ 
 
__________________________________________________________________________________ 
 
 
 
Admission details 
 
Date of admission: ___/ ___/___  Time of admission: ___ h ___   
 
Self-referral: Y/N     Referred by:   clinic or  hospital    
 
If referred, referring clinic or hospital: __________________________________________________ 
 
Was the woman still pregnant on admission? Y/N 
 
Gestational age on admission: ____ weeks  If still pregnant, was she in labour? Y/N  
 
If in labour, was she in latent/active phase?   latent phase    active phase 
 
Postpartum on admission: Y/N  If postpartum, days postpartum: ____ days  
 
Reason(s) for admission : (can choose more than one)  
 
 LAP    in labour    rupture of membranes   antepartum haemorrhage    BBA       
 postpartum haemorrhage    abdominal wound sepsis    offensive vaginal discharge 
 headache    blurred vision    convulsions    collapsed      
 elevated blood pressure (BP) Admission BP: ____     proteinuria        
 pyrexia    cough    shortness of breath    chest pains       
 abdominal pain    diarrhoea    vomiting   other, specify _________________________  
 
Comments: _________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
Underlying medical condition 
 
 neurological ______________   respiratory ______________   cardiac _______________ 
 
 renal ____________________   abdominal ______________    other ________________  
 
On chronic medication: Y/N        If yes, specify: ____________________________________ 
 
___________________________________________________________________________  
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Special investigations 
 
Blood results on admission: 
 
WCC _______           Hb _______           Platelets _______           Urea _______          Creatinine _______ 
 
Total protein _______          Albumin _______          ALT _______           AST _______ 
 
LDH _______          INR _______          PTT _______ 
 
 
Worst blood results:             Date of blood results: ___/___/___  
 
Hb _______           Platelets _______           Urea _______          Creatinine _______  
 
CD4 count _______  
  
 
Other: ____________________________________________________________________________ 
 
 
Admission foetal ultrasound done: Y/N  
 
If done, findings on ultrasound:  placenta praevia  abruption placentae  
 
 ectopic pregnancy  abdominal pregnancy  RPOC  IUFD 
 
 other, specify: _________________________  
 
Chest X-ray: done/not done  Chest X-ray findings:  normal    parenchymal infiltrates    
 
 pleural effusion  unilobar pneumonia         multilobar pneumonia   
 
 military pattern  ground glass pattern        cardiomegaly    pulmonary oedema 
 
 hilar lymph nodes  other, specify _______________________________________________ 
Sputum results:  AFB positive    AFB negative   TB culture positive    
 
 other, specify ________________________________  not done 
 
 
 
Lumbar puncture (LP): done/not done  Findings:  normal  bacterial meningitis 
 
 TB meningitis  cryptococcal meningitis  other, specify _____________________   
 
 
CT brain: Y/N     If done, findings:  
 
 intracerebral bleed   infarct  space-occupying lesion  oedema 
 
 coning  other, specify: _____________________________________________________ 
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Other special investigations and findings: ________________________________________________ 
 
__________________________________________________________________________________ 
 
__________________________________________________________________________________ 
 
 
Delivery details  
 
Date of delivery: __/ __/ __   Place of delivery: clinic/hospital/home/BBA 
  
Name of delivery clinic/hospital: ____________________ 
 
GA at delivery: ____ weeks    Birth weight: ____ g 
 
Mode of delivery:  NVD    vacuum    forceps  elective C/S     emergency C/S  
 
       peri-mortem C/S 
 
Indication for C/S: ____________________      
 
Pregnancy outcome:  live birth    FSB    MSB    neonatal death     miscarriage    
 
  ectopic pregnancy 
     
Comments: _________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
 
 
Medical management 
 
 oral antibiotics    IVI antibiotics    TB treatment    antihypertensives    
 
 oral steroids         IVI steroids   tocolytic  
 
 misoprostol          route of administration  PR  oral         sublingual  
 
 total misoprostol dose administered  other, _________________________________    
 
 
Blood transfusion: Y/N  
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Surgical interventions 
 
 evacuation of the uterus    hysterectomy    laparotomy    other __________________ 
 
Comments: _______________________________________________________________________ 
 
__________________________________________________________________________________ 
 
 
Details about the death 
 
Date of death: ___/_ __/___    Time of death: ___ h ___   
  
 undelivered  delivered  If delivered, hours/days postpartum: ____  hours/days 
 
If undelivered, gestational age at death: ______ weeks 
 
 
Cause of death: please circle one or more causes under each category 
 
 Coincidental cause:  
MVA, other accidents, assault, rape, herbal medicine, other (specify) __________________________ 
 
 Medical and Surgical disorders:  
Cardiac disease, endocrine, GIT, CNS, respiratory, haematological, genito-urinary, auto-immune, 
skeletal, psychiatric, neoplasm, other (specify) ____________________________________________ 
 
 Non-pregnancy-related infections: 
 PCP pneumonia, other pneumonia, TB, endocarditis, UTI, appendicitis, malaria, cryptococcal 
meningitis, other meningitis, Kaposi’s sarcoma, toxoplasmosis, cholera, hepatitis, gastroenteritis, 
wasting syndrome, complications of anti-retroviral therapy, other (specify) _____________________ 
 
 Ectopic pregnancy:  
<20 weeks, >20 weeks 
 
 Miscarriage:  
Septic miscarriage, haemorrhage (non- traumatic), uterine trauma, GTD, following legal TOP 
 
 Pregnancy-related sepsis:  
Chorioamnionitis with ruptured membranes, chorioamnionitis without ruptured membranes, 
puerperal sepsis after NVD, puerperal sepsis after c/s, bowel trauma at c/s 
 
 Obstetric haemorrhage: 
Abruption with/without h/t, praevia, other APH not specified, ruptured uterus with/without previous 
c/s, retained placenta, morbidly adherent placenta, uterine atony, vaginal/cervical trauma, inverted 
uterus, bleeding during c/s, bleeding after c/s, other PPH not specified _________________ 
 
 Hyperemesis gravidarum 
 
 Hypertension:  
Chronic hypertension, proteinuric hypertension, eclampsia, HELLP, liver rupture, acute fatty liver 
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Final cause of death:  respiratory failure    cardiac failure (pulmonary oedema, cardiac arrest)  
 
 renal failure    liver failure    cerebral complications (intracranial haemorrhage, cerebral 
oedema, brain death following hypoxic event)   haematological (disseminated intravascular 
coagulation, severe anaemia)          multi-organ failure        
 
 Anaesthetic complications:  
General / epidural / spinal anaesthetic 
 
 Embolism:  
Pulmonary embolus, amniotic fluid embolus 
 
 Acute collapse – cause unknown 
 
 Unknown:  
Death at home or outside health services, no primary cause found, lack information 
 
 other, specify ___________________________________________________________________ 
 
 
Comments: _________________________________________________________________ 
 
___________________________________________________________________________ 
 
Post-mortem done: Y/N  If done, result: _____________________________________ 
 
__________________________________________________________________________________ 
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